var title_f27_62_28640="Resection of omentum from transverse colon";
var content_f27_62_28640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Resection of omentum from transverse colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 476px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The omentum is resected from the colon in a relatively avascular plane using electrocautery. If a cancer in the transverse colon involves the omentum, it is resected en bloc with the colectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28640=[""].join("\n");
var outline_f27_62_28640=null;
var title_f27_62_28641="Oral chronic graft-versus-host disease";
var content_f27_62_28641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prominent reticular oral chronic graft-versus-host disease of the left buccal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nathaniel Treister, DMD, DMSc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28641=[""].join("\n");
var outline_f27_62_28641=null;
var title_f27_62_28642="Diet and health";
var content_f27_62_28642=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Diet and health (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/62/28642/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28642/contributors\" id=\"au4356\">",
"       Graham A Colditz, MD, DrPh",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/62/28642/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28642/contributors\" id=\"se5582\">",
"       Timothy O Lipman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/62/28642/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28642/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?27/62/28642?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HEALTHY DIET OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The food choices we make can have an important impact on our health. However, expert opinions continue to change about which and how much of these foods is optimal.",
"    </p>",
"    <p>",
"     This topic summarizes the relationships between various foods or supplements and specific health conditions, and concludes with general recommendations for following a healthy diet. A separate topic review is available about diets for weight loss. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link&amp;anchor=H10#H10\">",
"      \"Patient information: Weight loss treatments (Beyond the Basics)\", section on 'Choosing a diet or new eating plan'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      FRUITS AND VEGETABLES",
"     </span>",
"    </p>",
"    <p>",
"     A number of studies have demonstrated important health benefits of eating fruits and vegetables.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Increased intake of fruits and vegetables is linked to a lower risk of premature death.",
"      </li>",
"      <li>",
"       Fruits and vegetables decrease the risk of cardiovascular diseases including coronary heart disease (CHD) and stroke, including death from CHD [",
"       <a class=\"abstract\" href=\"UTD.htm?27/62/28642/abstract/1\">",
"        1",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       High intake of fruits and vegetables also reduces the risk of developing certain kinds of cancer (including lung cancer and cancer of the gastrointestinal system). Tomato and tomato-based foods may be beneficial at lowering the risk of prostate cancer.",
"      </li>",
"      <li>",
"       At least five servings of fruits",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       vegetables should be eaten daily.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      FIBER",
"     </span>",
"    </p>",
"    <p>",
"     Eating a diet that is high in fiber can decrease the risk of coronary heart disease, stroke, colon cancer, and death [",
"     <a class=\"abstract\" href=\"UTD.htm?27/62/28642/abstract/2,3\">",
"      2,3",
"     </a>",
"     ]. Eating fiber also protects against type 2 diabetes, and eating soluble fiber (such as that found in vegetables, fruits, and especially legumes) may help control blood sugar in people who already have diabetes. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      \"Patient information: High-fiber diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The recommended amount of dietary fiber is 25 grams per day for women and 38 grams per day for men. Many breakfast cereals, fruits, and vegetables are excellent sources of dietary fiber. By reading the product information panel on the side of the package, it is possible to determine the number of grams of fiber per serving (",
"     <a class=\"graphic graphic_figure graphicRef51585 \" href=\"UTD.htm?38/31/39413\">",
"      figure 1",
"     </a>",
"     ). A list of the fiber content of a number of foods can be found in the table (",
"     <a class=\"graphic graphic_table graphicRef52349 \" href=\"UTD.htm?28/61/29661\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      FAT",
"     </span>",
"    </p>",
"    <p>",
"     Eating foods higher in healthy fats and lower in unhealthy fats can reduce the risk of coronary heart disease.",
"    </p>",
"    <p>",
"     The type of fat consumed appears to be more important than the amount of total fat. Saturated fats and trans fats should be avoided in favor of monounsaturated and polyunsaturated fats (eg, in fish, olive oil, peanut oil, nuts).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Trans fats are those that are solid at room temperature, and are found in many margarines and in other fats labeled \"partially hydrogenated.\" Another major source is oils that are maintained at high temperature for a long period, such as in fast food restaurants.",
"      </li>",
"      <li>",
"       Saturated fats come mainly from animal products, such as cheese, butter, and red meat.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     It is important not to replace fat with refined carbohydrates (eg, white bread, white rice, most sweets). Increases in refined carbohydrate intake may lower levels of high density lipoprotein (HDL) cholesterol (good cholesterol), which actually increases the risk of coronary heart disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      FOLATE",
"     </span>",
"    </p>",
"    <p>",
"     Folate is a type of B vitamin that is important in the production of red blood cells. Low levels of folate in pregnant women have been linked to a group of birth defects called neural tube defects, which includes spina bifida and anencephaly. Vitamins containing folate and breakfast cereal fortified with folate are recommended as the best ways to ensure adequate folate intake.",
"    </p>",
"    <p>",
"     However, supplements containing folate (called folic acid) are no longer recommended to reduce the risk of heart disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      ANTIOXIDANTS",
"     </span>",
"    </p>",
"    <p>",
"     The antioxidant vitamins include vitamins A, C, E, and beta-carotene. Many other foods, especially fruits and vegetables, also have antioxidant properties. Studies have not clearly shown that antioxidant vitamins prevent cancer, and some studies show they may actually cause harm. There is no evidence to support antioxidant vitamin supplementation for individuals who do not have specific vitamin deficiencies.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      CALCIUM AND VITAMIN D",
"     </span>",
"    </p>",
"    <p>",
"     Adequate calcium and vitamin D intake are important, particularly in women, to reduce the risk of osteoporosis. A healthcare provider can help to decide if supplements are needed, depending upon a person's dietary intake of calcium and vitamin D (",
"     <a class=\"graphic graphic_table graphicRef67824 \" href=\"UTD.htm?28/58/29611\">",
"      table 2",
"     </a>",
"     ). Although the optimal level has not been clearly established, experts recommend that premenopausal women and men consume at least 1000 mg per day and postmenopausal women should consume 1200 mg per day. No more than 2000 mg of calcium should be consumed per day. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The current recommendation is that postmenopausal women with or at risk for osteoporosis consume at least 800 International Units of vitamin D per day. Lower levels of vitamin D are not as effective while high doses can be toxic, especially if taken for long periods of time. Although the optimal intake has not been clearly established in premenopausal women or in men with osteoporosis, 400 to 600 International units of vitamin D daily is generally suggested.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ALCOHOL",
"     </span>",
"    </p>",
"    <p>",
"     Moderate alcohol intake may reduce the risk of heart disease. However, it is not clear what amount of alcohol is best. There are some risks associated with alcohol use, including breast cancer in women; cancers of the mouth, esophagus, throat, larynx, and liver; other illnesses such as cirrhosis and alcoholism; and injuries and other trauma-related problems, particularly in men. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/23/4468?source=see_link\">",
"      \"Patient information: Risks and benefits of alcohol (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Based on the trade-off between these risks and benefits, the United States Dietary Guidelines recommend alcohol intake in moderation, if at all. This means no more than one drink per day for women, and up to 2 drinks per day for men. Those who do not drink alcohol do not need to start.",
"    </p>",
"    <p>",
"     Drinking is discouraged for those under 40 years who are at low risk of cardiovascular disease because the risks are likely to outweigh the benefits in this group.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      CALORIC INTAKE",
"     </span>",
"    </p>",
"    <p>",
"     Calories count. Too many calories lead to weight gain and obesity. It is linked with premature death as well as an increased risk of cardiovascular disease, diabetes, hypertension, cancer, and other important diseases [",
"     <a class=\"abstract\" href=\"UTD.htm?27/62/28642/abstract/4-8\">",
"      4-8",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     The total number of calories a person needs depends upon the following factors:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Weight",
"      </li>",
"      <li>",
"       Age",
"      </li>",
"      <li>",
"       Gender",
"      </li>",
"      <li>",
"       Height",
"      </li>",
"      <li>",
"       Activity level",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      GENERAL RECOMMENDATIONS FOR A HEALTHY DIET",
"     </span>",
"    </p>",
"    <p>",
"     Eat lots of vegetables, fruits, and whole grains and a limited amount of red meat. Get at least five servings of fruits and vegetables every day. Tips for achieving this goal include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Make fruits and vegetables part of every meal. Eat a variety of fruits and vegetables. Frozen or canned can be used when fresh isn't convenient.",
"      </li>",
"      <li>",
"       Eat vegetables as snacks.",
"      </li>",
"      <li>",
"       Have a bowl of fruit out all the time for kids to take snacks from.",
"      </li>",
"      <li>",
"       Put fruit on your cereal.",
"      </li>",
"      <li>",
"       Consume at least half of all grains as whole grains (like whole wheat bread, brown rice, whole grain cereal), replacing refined grains (like white bread, white rice, refined or sweetened cereals).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Cut down on unhealthy fats (trans fats and saturated fats) and consume healthy fats (polyunsaturated and monounsaturated fat). Tips for achieving this goal include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Choose chicken, fish, and beans instead of red meat and cheese.",
"      </li>",
"      <li>",
"       Cook with oils that contain polyunsaturated and monounsaturated fats, like olive and peanut oil.",
"      </li>",
"      <li>",
"       Choose margarines that do not have partially hydrogenated oils. Soft margarines (especially squeeze margarines) have less trans fatty acids than stick margarines.",
"      </li>",
"      <li>",
"       Eat fewer baked goods that are store-made and contain partially hydrogenated fats (like many types of crackers, cookies, and cupcakes).",
"      </li>",
"      <li>",
"       When eating at fast food restaurants, choose healthy items for yourself as well as your family, like broiled chicken or salad.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Avoid sugar-sweetened beverages and excessive alcohol intake. Tips for achieving this goal include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Choose non-sweetened and non-alcoholic beverages, like water, at meals and parties.",
"      </li>",
"      <li>",
"       Avoid occasions centered around alcohol.",
"      </li>",
"      <li>",
"       Avoid making sugar-sweetened beverages and alcohol an essential part of family gatherings.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Keep calorie intake balanced with needs and activity level.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804547246\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H263299977\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=see_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/15/6387?source=see_link\">",
"      Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/54/7012?source=see_link\">",
"      Patient information: Coronary heart disease in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/38/40546?source=see_link\">",
"      Patient information: Vitamin supplements (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/56/24450?source=see_link\">",
"      Patient information: Can foods or supplements lower cholesterol? (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H263299969\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"      Patient information: Starting solid foods during infancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/23/4468?source=see_link\">",
"      Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23175?source=see_link\">",
"      Dietary and nutritional assessment in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=see_link\">",
"      Dietary carbohydrates",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=see_link\">",
"      Dietary fat",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link\">",
"      Nutrition in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link\">",
"      Healthy diet in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Your Disease Risk at Washington University in St. Louis",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.yourdiseaserisk.wustl.edu/\">",
"        www.yourdiseaserisk.wustl.edu",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Hormone Foundation",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.hormone.org/\">",
"        www.hormone.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?27/62/28642?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28642/abstract/1\">",
"      Crowe FL, Roddam AW, Key TJ, et al. Fruit and vegetable intake and mortality from ischaemic heart disease: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study. Eur Heart J 2011; 32:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28642/abstract/2\">",
"      Park Y, Subar AF, Hollenbeck A, Schatzkin A. Dietary fiber intake and mortality in the NIH-AARP diet and health study. Arch Intern Med 2011; 171:1061.",
"     </a>",
"    </li>",
"    <li>",
"     World Cancer Research Fund and American Institute for Cancer Research. Colorectal cancer report 2010: Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer. file://www.wcrf.org/PDFs/Colorectal%20cancer%20report%20summary%202011.pdf (Accessed on September 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28642/abstract/4\">",
"      Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28642/abstract/5\">",
"      Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28642/abstract/6\">",
"      Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28642/abstract/7\">",
"      Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28642/abstract/8\">",
"      Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341:427.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f27_62_28642=[""].join("\n");
var outline_f27_62_28642=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HEALTHY DIET OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           FRUITS AND VEGETABLES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           FIBER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           FAT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           FOLATE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           ANTIOXIDANTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           CALCIUM AND VITAMIN D",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ALCOHOL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           CALORIC INTAKE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           GENERAL RECOMMENDATIONS FOR A HEALTHY DIET",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/31/39413\" title=\"figure 1\">",
"           Nutrition label fiber PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/61/29661\" title=\"table 1\">",
"           Fiber in foods PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/58/29611\" title=\"table 2\">",
"           Foods with calcium PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f27_62_28643="Visible vessel DU Endosc";
var content_f27_62_28643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Duodenal ulcer with visible vessel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Duodenal ulcer in a patient with recent upper gastrointestinal bleeding. The ulcer base (arrows) is visible as the whitish rim underlying the protruding vessel. The erythematous mound in the center of the ulcer represents an arteriole that has eroded into the lumen of the duodenum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28643=[""].join("\n");
var outline_f27_62_28643=null;
var title_f27_62_28644="Atrophie blanche on foot";
var content_f27_62_28644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Atrophie blanche",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrophic, white, stellate scars consistent with atrophie blanche are present on the lower extremity in this patient with livedoid vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28644=[""].join("\n");
var outline_f27_62_28644=null;
var title_f27_62_28645="Arthritis and exercise";
var content_f27_62_28645=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Arthritis and exercise (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/62/28645/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28645/contributors\" id=\"au6359\">",
"       Maureen R Gecht-Silver, MPH, OTR/L",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28645/contributors\" id=\"au369\">",
"       Alison M Duncombe, PT, OCS, FAAOMPT",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/62/28645/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28645/contributors\" id=\"se5073\">",
"       RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/62/28645/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28645/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?27/62/28645?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ARTHRITIS AND EXERCISE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Exercise is known to have benefits for people with arthritis. However, many people with arthritis do not exercise, often because of joint or muscle pain, weakness, fatigue, or joint swelling. This can lead to loss of joint motion, stiffness, and muscle weakness and tightness. These problems can worsen fatigue and can cause joints to become unstable.",
"    </p>",
"    <p>",
"     However, exercise can decrease pain and can enhance quality of life. Exercise is most beneficial if it is done on a regular basis. Most people can find a way to exercise without increasing their symptoms.",
"    </p>",
"    <p>",
"     This topic describes the benefits of exercise for people with arthritis, including disease-specific exercise recommendations.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SUCCESS WITH EXERCISE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Stick with it",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of factors can improve the chances of sticking with an exercise program long-term, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Follow a simple regimen",
"      </li>",
"      <li>",
"       Set attainable goals",
"      </li>",
"      <li>",
"       Understand the importance and benefits of exercise",
"      </li>",
"      <li>",
"       Interact with others while exercising (ie, with exercise groups)",
"      </li>",
"      <li>",
"       Follow up regularly with a healthcare provider, such as a physical therapist or personal trainer, to provide encouragement and to make adjustments to the regimen",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Exercise in a supervised setting may improve the chances of continuing long term, compared with unsupervised, home-based programs. However, people who are self-motivated and exercise at home may enjoy the benefits of equal effectiveness, lower costs, and more convenience.",
"    </p>",
"    <p>",
"     Information on general exercise can be found elsewhere. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      \"Patient information: Exercise (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Benefits of daily activities",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people are not interested in a formal exercise program but are able to perform daily activities such as light housework, shopping, gardening, clearing walks and driveways, caring for a child or grandchild, caring for an older person, leisure walking, or exercising in a pool. There are health benefits (largely cardiovascular) from these activities.",
"    </p>",
"    <p>",
"     Exercise can be broken up into three or four 10-minute sessions per day; it does not need to be continuous to produce health benefits. Moderate intensity exercise is most effective if it is performed on most days of the week. However, exercising only one or two days per week is better than not exercising at all.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      HOW CAN I PREPARE TO EXERCISE?",
"     </span>",
"    </p>",
"    <p>",
"     All people, especially those with arthritis, benefit from a balanced program of flexibility, strengthening, and endurance or aerobic exercise.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Talk to your doctor",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with arthritis can successfully exercise on their own. Before beginning an exercise program, contact your doctor or other healthcare provider to be sure it is safe. Specific questions to ask include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Are there specific exercises or movements that should be avoided? For example, after hip replacement, patients often have hip movement restrictions early in the recovery; patients with inflamed joints may be told to do range of motion exercises only.",
"      </li>",
"      <li>",
"       Are there specific exercises that should be included to maintain optimal health? For example, people with rheumatoid arthritis benefit from regular hand and wrist exercises to maintain range of motion and function. (See",
"       <a class=\"local\" href=\"#H16\">",
"        'Disease-specific exercise suggestions'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Do I need to be evaluated by a physical or occupational therapist before starting to exercise? If you answer \"yes\" to the questions below, an evaluation may be helpful.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Do stiffness, limited motion, or joint deformities make it difficult or painful to move?",
"      </li>",
"      <li>",
"       Have past exercise attempts been unsuccessful due to pain that does not go away with rest or a reduced exercise program?",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Pain, stiffness, and fatigue are barriers to exercise success for many people with arthritis. Preparing for exercise can minimize these issues. Some people benefit from a warm shower prior to exercise. Cardiovascular warm-ups and cool-downs are recommended for all exercisers.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Warm up",
"     </span>",
"     &nbsp;&mdash;&nbsp;The purpose of the warm-up is to improve circulation and to increase the temperature of muscles and joint structures so that the body is less stiff, movement is easier, and risk of injury is decreased. If you are successful, your body will feel slightly warmer than when you started. Stretching is best done after your exercise session as part of your cool down. Some people like to stretch after their warm-up.",
"    </p>",
"    <p>",
"     People with arthritis may need a longer warm-up and cool-down. A three to five minute warm-up is recommended for the general population, while 10 to 15 minutes is optimal for people with arthritis. However, if you are walking slowly or exercising less than 10 minutes, you do not need a separate warm up-and cool-down.",
"    </p>",
"    <p>",
"     Sample warm-up activities:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Walk or bike at half normal speed",
"      </li>",
"      <li>",
"       Sit and perform range of motion",
"       <span class=\"nowrap\">",
"        exercises/flexibility",
"       </span>",
"       exercises starting at the head and neck and progressing to the feet and ankles (ideally using the same muscles that will be involved in the exercise)",
"      </li>",
"      <li>",
"       March in place",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Cool down",
"     </span>",
"     &nbsp;&mdash;&nbsp;The purpose of the cool-down is to return your heart rate to a few beats above normal. This prevents a sudden drop in blood pressure, feelings of nausea, fainting, and dizziness.",
"    </p>",
"    <p>",
"     Sample cool-down activities:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Slowing down your walking or biking etc, gradually",
"      </li>",
"      <li>",
"       Lifting light weights",
"      </li>",
"      <li>",
"       Range of motion activities",
"      </li>",
"      <li>",
"       Stretching exercises",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Stretching",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stretching returns muscles to their full length and reduces soreness after exercise. People with arthritis need to be more cautious if they have lax joints (extra mobility or hyperflexibility) or malaligned joints (eg, hand deformities, bowlegged). Flexibility exercises can include modified yoga and tai chi, as well as stretches.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      ARTHRITIS EXERCISES",
"     </span>",
"    </p>",
"    <p>",
"     Exercises to improve muscle strength and build endurance are important components of an arthritis treatment program. Aquatic exercise and land-based exercise are effective at improving strength, function, and physical fitness.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Strengthening exercises",
"     </span>",
"     &nbsp;&mdash;&nbsp;Strengthening exercises can help to improve joint stability and decrease pain. Examples of exercises that build strength include the use of free weights, weight machines, or body weight (eg, modified squats to build knee strength).",
"    </p>",
"    <p>",
"     People with lax or malaligned knees should use caution with certain strengthening exercises because improving quadriceps strength (the muscles in the thighs) may speed the progression of preexisting arthritis. A physical therapist who specializes in treating arthritis-related knee problems can provide specific advice and can recommend exercises to balance strength building. Treatment may include modified exercises and appropriate bracing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Tips for success",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Movements should be smooth, not jerky.",
"      </li>",
"      <li>",
"       Care should be taken to avoid gripping the weight or exercise machine handle too tightly.",
"      </li>",
"      <li>",
"       The weight should be light enough that the movement can be performed 8 to 10 times (one set) without pain or excessive fatigue.",
"      </li>",
"      <li>",
"       To avoid fatigue and joint stress, alternate one set of arm exercises with one set of leg exercises (eg, one set of biceps curls, one set of quadriceps curls, one set of triceps curls, one set of hamstrings curls, then repeat the circuit).",
"      </li>",
"      <li>",
"       The weight can be increased when 10 repetitions can be performed with ease and when the increased weight does not increase joint pain.",
"      </li>",
"      <li>",
"       People with inflammatory arthritis should err on the side of caution, and they should start with a lighter weight and increase slowly. For example, arm exercises can start with as little as 1 to 2 pounds (0.5 to 1 kilogram).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Endurance exercises",
"     </span>",
"     &nbsp;&mdash;&nbsp;Endurance exercises work to increase the heart and breathing rates, which can improve heart health, lower blood pressure, and improve fitness. Exercise does not need to be strenuous; during moderate intensity endurance exercises, you should be able to carry on a conversation.",
"    </p>",
"    <p>",
"     The type and amount of endurance exercise recommended depends upon a person's current fitness level. A person who has avoided exercise due to pain or lack of success might need to begin with just five minutes of slow walking. Low-impact exercises are preferable to minimize stress on the joints. Swimming and biking are low-impact or no-impact forms of endurance exercise that can be safely performed by most people with arthritis.",
"    </p>",
"    <p>",
"     Aquatic exercises are of particular benefit for those with severe disease",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a low fitness level, especially rheumatoid arthritis. The buoyancy provided by water decreases pressure on joints and allows a person to exercise without the constraints imposed by body weight. Aquatic exercise programs often include group exercises in the water or walking in water. If you like to swim but have shoulder or neck issues that make it difficult to turn the head, you may need to consult with a therapist to design a successful swimming program. Some people can successfully reduce neck movement by using a snorkel and mask.",
"    </p>",
"    <p>",
"     In general, exercise should start at a low intensity and for a short time. It is normal to feel some joint or muscle soreness after exercising, although soreness should not last more than two hours. If pain or fatigue lasts into the next day, the exercise was probably too long or too vigorous.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Protect the joints",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with arthritis need to take a few extra precautions to protect their joints while exercising. The following tips are recommended.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Walk on flat level surfaces, especially if prone to hip, knee, foot, or ankle problems",
"      </li>",
"      <li>",
"       Wear supportive footwear such as athletic shoes and use a shoe insert that supports the arches and provides cushioning (eg, Spenco) to reduce impact on hips, knees, and feet. The shoe's original liner may be fine, although an insert with additional cushioning is often helpful for people with foot or knee pain.",
"      </li>",
"      <li>",
"       Avoid jarring movements and high impact activities such as running",
"      </li>",
"      <li>",
"       Respect pain, do not ignore it, and monitor for pain during exercise",
"      </li>",
"      <li>",
"       Start slow and increase activity gradually",
"      </li>",
"      <li>",
"       Pay attention to posture and alignment",
"      </li>",
"      <li>",
"       Do not take excess pain medication prior to exercise; this can mask pain and cause you to over-exercise",
"      </li>",
"      <li>",
"       Caution is recommended after a knee or hip replacement. High impact sports such as running, football, baseball, basketball, and soccer are not recommended. However, participation in non-impact or low-impact sports such as swimming, cycling, or walking is encouraged.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Specific exercise instructions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Instructions for specific exercises for people with arthritis are available from the following resources:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Institute on Aging website",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nia.nih.gov/health/publication/exercise-physical-activity-your-everyday-guide-national-institute-aging-1\">",
"        file://www.nia.nih.gov/health/publication/exercise-physical-activity-your-everyday-guide-national-institute-aging-1",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Arthritis Helpbook [",
"       <a class=\"abstract\" href=\"UTD.htm?27/62/28645/abstract/1\">",
"        1",
"       </a>",
"       ]",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      DISEASE-SPECIFIC EXERCISE SUGGESTIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Inflammatory arthritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Inflammatory arthritis is a condition that causes swelling and pain in joints. Examples of inflammatory arthritis include rheumatoid arthritis, psoriatic arthritis, spondyloarthropathy, and ankylosing spondylitis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/10/30881?source=see_link&amp;anchor=H5#H5\">",
"      \"Patient information: Arthritis (Beyond the Basics)\", section on 'Inflammatory arthritis'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       During an acute flare-up, reduce intensity and exercise time",
"      </li>",
"      <li>",
"       Many people need to rest during the day; long naps should be avoided to preserve nighttime sleep",
"      </li>",
"      <li>",
"       Avoid resistance exercise involving affected joints during acute flare-ups",
"      </li>",
"      <li>",
"       Do daily range of",
"       <span class=\"nowrap\">",
"        motion/flexibility",
"       </span>",
"       as tolerated",
"      </li>",
"      <li>",
"       Avoid high-impact activities, especially while taking oral steroids",
"      </li>",
"      <li>",
"       Protect the joints, as described above (see",
"       <a class=\"local\" href=\"#H14\">",
"        'Protect the joints'",
"       </a>",
"       above)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Rheumatoid arthritis (RA)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rheumatoid arthritis is a chronic inflammatory condition that can affect many tissues throughout the body. The joints are usually most severely affected. The number and type of joints affected by rheumatoid arthritis can vary widely, although joints on both sides of the body are usually involved. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"      \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link&amp;anchor=H6#H6\">",
"      \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\", section on 'Exercise'",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link&amp;anchor=H7#H7\">",
"      \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\", section on 'Physical and occupational therapy'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Morning stiffness related to RA often improves after performing stretching exercises, taking a warm shower,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       using warm-up exercises. Performing flexibility exercises before sleeping can reduce morning stiffness (",
"       <a class=\"graphic graphic_picture graphicRef79565 \" href=\"UTD.htm?40/2/40995\">",
"        picture 1",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef64407 \" href=\"UTD.htm?28/12/28864\">",
"        picture 2",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef57600 \" href=\"UTD.htm?31/2/31777\">",
"        picture 3",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef52289 \" href=\"UTD.htm?42/7/43121\">",
"        picture 4",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef75309 \" href=\"UTD.htm?43/13/44242\">",
"        picture 5",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Avoid extreme neck movements and do not put pressure on the back of the neck. Yoga positions such as the plough, headstands, and shoulder stands should not be performed. A safe stretch for the neck is shown here (",
"       <a class=\"graphic graphic_picture graphicRef79565 \" href=\"UTD.htm?40/2/40995\">",
"        picture 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Avoid overstretching or applying too much force over malaligned joints, especially knees and fingers (most common for people with RA). Modify &ldquo;all-fours&rdquo; exercises (positioning on hands and knees) by using towel rolls or yoga blocks to avoid overstretching the wrists.",
"      </li>",
"      <li>",
"       Be sure to include hand and wrist exercises in your daily routine (",
"       <a class=\"graphic graphic_picture graphicRef81293 \" href=\"UTD.htm?32/36/33345\">",
"        picture 6",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef53043 \" href=\"UTD.htm?10/47/10992\">",
"        picture 7",
"       </a>",
"       ). After doing dishes or after showering is a good time to do these exercises because hands are warmer and more flexible.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Ankylosing spondylitis (AS)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ankylosing spondylitis (AS) is a chronic, inflammatory disease that primarily affects the back, neck, and sometimes hips. The most common symptom of AS is pain in the low back and hips. Pain, stiffness, and limited mobility in other joints also occur in some patients. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"      \"Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Flexibility exercises for the neck, back, shoulders, and hips are especially important to maintain range of motion (",
"       <a class=\"graphic graphic_picture graphicRef79565 \" href=\"UTD.htm?40/2/40995\">",
"        picture 1",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef64407 \" href=\"UTD.htm?28/12/28864\">",
"        picture 2",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef57600 \" href=\"UTD.htm?31/2/31777\">",
"        picture 3",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef52289 \" href=\"UTD.htm?42/7/43121\">",
"        picture 4",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef75309 \" href=\"UTD.htm?43/13/44242\">",
"        picture 5",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef61695 \" href=\"UTD.htm?25/41/26256\">",
"        picture 8",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Be sure to include breathing and chest expansion exercises in your exercise program.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Take a deep breath, allowing the chest to expand as much as possible",
"      </li>",
"      <li>",
"       Hold the breath for a count of three",
"      </li>",
"      <li>",
"       Exhale slowly through the mouth; rest for a count of three",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Muscle strengthening for the extensor muscles of the back and hips is needed to maintain erect posture (",
"       <a class=\"graphic graphic_picture graphicRef61695 \" href=\"UTD.htm?25/41/26256\">",
"        picture 8",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef58290 \" href=\"UTD.htm?23/45/24287\">",
"        picture 9",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef69481 \" href=\"UTD.htm?19/48/20230\">",
"        picture 10",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Pay attention to keeping the neck aligned with the trunk to minimize pain during activity.",
"      </li>",
"      <li>",
"       Swimming is an excellent form of exercise if you are feeling stiff. A snorkel and mask can allow you to swim without turning your head to breathe.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Systemic lupus erythematosus (SLE)",
"     </span>",
"     &nbsp;&mdash;&nbsp;SLE is a chronic inflammatory disease that affects various organs of the body. Joint symptoms occur in almost all patients and are often the earliest sign of SLE. The arthritis tends to occur in different parts of the body and does not usually affect both sides of the body the same way. Only a few joints are affected at any time. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"      \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Fatigue, shortness of breath, and pain with a deep breath (pleurisy) are common in people with SLE",
"      </li>",
"      <li>",
"       Pace yourself and break up exercise sessions into short sessions.",
"      </li>",
"      <li>",
"       Begin with breathing exercises and pay attention to breathing during exercise",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Take a deep breath, allowing the chest to expand as much as possible",
"      </li>",
"      <li>",
"       Hold the breath for a count of three",
"      </li>",
"      <li>",
"       Exhale slowly through the mouth; rest for a count of three",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Protect the joints during exercise (see",
"       <a class=\"local\" href=\"#H14\">",
"        'Protect the joints'",
"       </a>",
"       above)",
"      </li>",
"      <li>",
"       If you start to have pain in your hip or groin, check with your clinician. These can be signs that the head (top) of the femur is not receiving adequate blood flow, which can quickly destroy the joint and can potentially require joint replacement surgery.",
"      </li>",
"      <li>",
"       Performing stretching or flexibility exercises at night may help to reduce morning stiffness (",
"       <a class=\"graphic graphic_picture graphicRef79565 \" href=\"UTD.htm?40/2/40995\">",
"        picture 1",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef64407 \" href=\"UTD.htm?28/12/28864\">",
"        picture 2",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef57600 \" href=\"UTD.htm?31/2/31777\">",
"        picture 3",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef52289 \" href=\"UTD.htm?42/7/43121\">",
"        picture 4",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef75309 \" href=\"UTD.htm?43/13/44242\">",
"        picture 5",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Osteoarthritis (OA)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Osteoarthritis (OA) occurs as a result of a gradual loss of cartilage from the joints. OA can affect almost any joint, although it is most commonly seen in the hands, knees, hips, and spine. Common symptoms include pain, stiffness, some loss of joint motion, and changes in the shape of affected joints. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"      \"Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cartilage, which is worn down with OA, needs motion to help the joints stay healthy. People with OA generally benefit from a general exercise program that promotes healthy cartilage.",
"      </li>",
"      <li>",
"       Painful joints should be moved through a full range of motion every day to maintain flexibility and to slow deterioration of cartilage. For example, if the knees are affected, bend and extend the knees as far as comfortably possible several times per day.",
"      </li>",
"      <li>",
"       If you have knee OA, knee strengthening exercises can reduce pain and make it easier to walk, get up and down from a chair, and climb stairs (",
"       <a class=\"graphic graphic_picture graphicRef69481 \" href=\"UTD.htm?19/48/20230\">",
"        picture 10",
"       </a>",
"       and",
"       <a class=\"graphic graphic_picture graphicRef64474 \" href=\"UTD.htm?30/40/31361\">",
"        picture 11",
"       </a>",
"       ). Be sure to keep the joints in line by avoiding twisting motions or moving at an angle.",
"      </li>",
"      <li>",
"       Low impact activities (biking, swimming) are recommended when knees, hips, and spine are affected.",
"      </li>",
"      <li>",
"       Knee braces or other supports (eg, a Neoprene sleeve) may be helpful if there is pain while walking.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, some knee braces are of little value for people who have active arthritis, significant joint instability, malaligned knees (bow-legged), or knees that &ldquo;give out&rdquo; as a result of arthritis. With a clinician's referral, an orthotist can provide an appropriate brace for these conditions and can provide instructions for wearing the brace correctly.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Fibromyalgia",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common signs and symptoms of fibromyalgia are fatigue; tender points around the shoulders, back, hips, and knees; and generalized aching and stiffness. Joints do not become swollen as a result of fibromyalgia alone. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/17/24854?source=see_link\">",
"      \"Patient information: Fibromyalgia (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Exercise, especially endurance exercises and gentle strengthening, is key to managing this condition",
"      </li>",
"      <li>",
"       Avoid very prolonged or vigorous exercise as this may worsen symptoms",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2502076729\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21385418\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=see_link\">",
"      Patient information: Arthritis and exercise (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/52/835?source=see_link\">",
"      Patient information: Psoriatic arthritis in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/6/7267?source=see_link\">",
"      Patient information: Psoriatic arthritis in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21385426\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=see_link\">",
"      Patient information: Psoriatic arthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/17/24854?source=see_link\">",
"      Patient information: Fibromyalgia (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=see_link\">",
"      Nonpharmacologic and preventive therapies of rheumatoid arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35896?source=see_link\">",
"      Overview of joint protection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Disease",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"        www.niams.nih.gov",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Rheumatology",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"        www.rheumatology.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Arthritis Foundation",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Spondylitis Association",
"       <br/>",
"       Phone: 1-800-777-8189",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.spondylitis.org/\">",
"        www.spondylitis.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?27/62/28645/abstract/1-13\">",
"      1-13",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 30, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?27/62/28645?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Lorig K, Fries JF. The Arthritis Helpbook, Sixth Edition, Perseus Books, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/2\">",
"      H&auml;kkinen A, Sokka T, Kotaniemi A, Hannonen P. A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis Rheum 2001; 44:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/3\">",
"      Eversden L, Maggs F, Nightingale P, Jobanputra P. A pragmatic randomised controlled trial of hydrotherapy and land exercises on overall well being and quality of life in rheumatoid arthritis. BMC Musculoskelet Disord 2007; 8:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/4\">",
"      Slemenda C, Heilman DK, Brandt KD, et al. Reduced quadriceps strength relative to body weight: a risk factor for knee osteoarthritis in women? Arthritis Rheum 1998; 41:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/5\">",
"      Liemohn W. Exercise and arthritis. Exercise and the back. Rheum Dis Clin North Am 1990; 16:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/6\">",
"      Suomi R, Collier D. Effects of arthritis exercise programs on functional fitness and perceived activities of daily living measures in older adults with arthritis. Arch Phys Med Rehabil 2003; 84:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/7\">",
"      Hurkmans E, van der Giesen FJ, Vliet Vlieland TP, et al. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev 2009; :CD006853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/8\">",
"      Bennell KL, Hinman RS. A review of the clinical evidence for exercise in osteoarthritis of the hip and knee. J Sci Med Sport 2011; 14:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/9\">",
"      Kelley GA, Kelley KS, Jones DL. Efficacy and effectiveness of exercise on tender points in adults with fibromyalgia: a meta-analysis of randomized controlled trials. Arthritis 2011; 2011:125485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/10\">",
"      Kettunen JA, Kujala UM. Exercise therapy for people with rheumatoid arthritis and osteoarthritis. Scand J Med Sci Sports 2004; 14:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/11\">",
"      Wang CY, Chiang PY, Lee HS, Wei JC. The effectiveness of exercise therapy for ankylosing spondylitis: a review. Int J Rheum Dis 2009; 12:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/12\">",
"      O'Brien AV, Jones P, Mullis R, et al. Conservative hand therapy treatments in rheumatoid arthritis--a randomized controlled trial. Rheumatology (Oxford) 2006; 45:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28645/abstract/13\">",
"      Valdes K, Marik T. A systematic review of conservative interventions for osteoarthritis of the hand. J Hand Ther 2010; 23:334.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f27_62_28645=[""].join("\n");
var outline_f27_62_28645=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ARTHRITIS AND EXERCISE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SUCCESS WITH EXERCISE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           HOW CAN I PREPARE TO EXERCISE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           ARTHRITIS EXERCISES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           DISEASE-SPECIFIC EXERCISE SUGGESTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/2/40995\" title=\"picture 1\">",
"           Lateral neck flexion PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/12/28864\" title=\"picture 2\">",
"           Knee chest stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/2/31777\" title=\"picture 3\">",
"           Hamstring stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/7/43121\" title=\"picture 4\">",
"           Gastrocnemius stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/13/44242\" title=\"picture 5\">",
"           Shoulder ROM with cane PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/36/33345\" title=\"picture 6\">",
"           Wrist extensor stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/47/10992\" title=\"picture 7\">",
"           Finger flexion extension PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/41/26256\" title=\"picture 8\">",
"           Press up PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/45/24287\" title=\"picture 9\">",
"           Trunk lift PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/48/20230\" title=\"picture 10\">",
"           Forward step up PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/40/31361\" title=\"picture 11\">",
"           Quarter squat PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f27_62_28646="Management of Henoch-Schnlein purpura (IgA vasculitis)";
var content_f27_62_28646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28646/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28646/contributors\">",
"     Fatma Dedeoglu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28646/contributors\">",
"     Susan Kim, MD, MMSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28646/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28646/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28646/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28646/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28646/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/62/28646/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Henoch-Sch&ouml;nlein purpura (HSP), also called IgA vasculitis (IgAV) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/1\">",
"     1",
"    </a>",
"    ], is the most common systemic vasculitis of childhood. Ninety percent of cases occur in the pediatric age group. In contrast to other forms of systemic vasculitis, HSP (IgAV) is usually self-limited and is characterized by a tetrad of clinical manifestations that vary in their presence and order of presentation.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpable purpura in patients with neither thrombocytopenia nor coagulopathy",
"     </li>",
"     <li>",
"      Arthralgia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arthritis",
"     </li>",
"     <li>",
"      Abdominal pain",
"     </li>",
"     <li>",
"      Renal disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of HSP (IgAV) is divided into supportive care, symptomatic therapy, and targeted treatment to decrease the risk of complications. The management of HSP (IgAV) will be presented here. The clinical manifestations, pathogenesis, diagnosis, and differential diagnosis of HSP (IgAV) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HSP (IgAV), care is primarily supportive and includes adequate hydration, rest, and symptomatic relief of pain.",
"   </p>",
"   <p>",
"    Most patients may be cared for in the ambulatory setting. In these patients, therapy is directed toward adequate oral hydration and symptomatic relief. Edema of the lower extremities, buttocks, and genital area is improved with bed rest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevating the affected area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with HSP (IgAV), hospitalization is warranted for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inability to maintain adequate hydration with oral intake",
"     </li>",
"     <li>",
"      Severe abdominal pain",
"     </li>",
"     <li>",
"      Significant gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Changes in mental status",
"     </li>",
"     <li>",
"      Severe joint involvement limiting ambulation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      self-care",
"     </li>",
"     <li>",
"      Renal insufficiency (elevated creatinine), hypertension,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nephrotic syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient cannot maintain adequate oral intake of fluids, intravenous hydration is provided in the hospital setting. In addition, parenteral nutrition may be required in patients who have a severe and prolonged course of abdominal symptoms that precludes enteral nutrition.",
"   </p>",
"   <p>",
"    Hospitalized patients also are monitored for potential complications from their disease. Frequent assessment of vital signs, urine output, and hematocrit, as well as serial abdominal examinations and stool examination for blood are required.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with significant anemia may require red blood cell transfusion, as indicated by tachycardia and hypotension in a patient with a low hematocrit level. Blood loss from hemorrhage into the skin, GI tract, or urine rarely depresses red blood cell levels enough to necessitate a transfusion, although superimposed decreased production due to inflammation may result in symptomatic anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=see_link\">",
"       \"Indications for red blood cell transfusion in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with an abdominal examination consistent with either signs of obstruction or peritonitis (\"surgical abdomen\") require prompt evaluation, including surgical consultation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intervention for possible intussusception, bowel infarction, or perforation. Bowel vasculitis often cannot be diagnosed by examination alone. In such cases, diagnostic imaging is necessary. We suggest the use of abdominal ultrasonography, which can detect changes in bowel wall thickness, hematomas, peritoneal fluid, and intussusception [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. Contrast enema studies are not useful because they may not detect small bowel intussusceptions, which are commonly seen in patients with HSP (IgAV) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Gastrointestinal symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with acute changes in behavior or mental status require evaluation for a potential intracranial complication such as hemorrhage. These are rare events in HSP (IgAV). Most central nervous system findings are transient and do not need further intervention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Other organ involvement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with renal disease may be hypertensive and require antihypertensive therapy. Close monitoring of fluid and electrolyte management is imperative in patients with decreased renal function. Patients who present with nephrotic syndrome, hypertension, or renal insufficiency are at increased risk for long-term renal morbidity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=see_link\">",
"       \"Prevention and management of acute kidney injury (acute renal failure) in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=see_link&amp;anchor=H5#H5\">",
"       \"Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with severe arthritis usually improve with the use of nonsteroidal antiinflammatory medications (NSAIDs). The risk of GI hemorrhage resulting from bowel vasculitis has not been shown to increase when inhibitors of cyclo-oxygenase are used, so these agents are not contraindicated in HSP (IgAV). When these medications fail, administration of glucocorticoids will generally result in a rapid resolution of the arthritis. Rarely, a brief hospitalization may be required in order to provide the medications needed to relieve the arthritis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptomatic therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic treatment for abdominal and joint pain in patients with HSP (IgAV) includes the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or nonsteroidal antiinflammatory drugs (NSAIDs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized controlled studies of the use of NSAIDs for symptomatic relief in patients with HSP (IgAV). There is no suggestion that the risk of GI hemorrhage in a child with bowel vasculitis is increased by the use of cyclooxygenase inhibitors. Thus, we do not hesitate to use NSAIDS in HSP (IgAV) patients to control joint and abdominal pain. In patients with active GI bleeding or glomerulonephritis, however, NSAIDs may be contraindicated because of their effects on platelets and renal perfusion.",
"   </p>",
"   <p>",
"    For symptomatic relief of pain in patients with HSP (IgAV), we suggest the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , 10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    divided into two doses per day, because of its ease of dosing. In adolescents and adults, a maximum total daily dose of 1500 mg may be used for a few days. For longer-term use, a maximum dose of 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is suggested.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    and other NSAIDs are equally effective and may be better tolerated in some patients, although ibuprofen requires more frequent dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of glucocorticoids in patients with HSP (IgAV) is controversial. Patients with HSP (IgAV) who have gastrointestinal involvement, including bowel wall edema, may have disrupted absorption of enteral medications. Thus, failure of NSAIDs or oral glucocorticoids to benefit certain patients may be due to poor absorption.",
"   </p>",
"   <p>",
"    Reported benefits of glucocorticoid therapy include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Shortened duration of abdominal pain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/5-9\">",
"       5-9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased risk of intussusception (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Gastrointestinal complications'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Decreased risk of gastrointestinal procedures (endoscopy, imaging, and surgery) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased risk of recurrence",
"     </li>",
"     <li>",
"      Decreased risk of renal involvement (see",
"      <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=see_link&amp;anchor=H7#H7\">",
"       \"Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Treatment'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of the literature that included 3 randomized trials and 12 retrospective reports attempted to determine whether glucocorticoids were beneficial and addressed the above specific outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/5\">",
"     5",
"    </a>",
"    ]. Based upon their analysis, the authors concluded that glucocorticoids may shorten the duration of abdominal pain and lessen the risk of developing persistent renal disease. However, the analysis was limited, as most of the data were retrospective in nature, the definitions of renal involvement varied, and the dosing regimens and mode of delivery of glucocorticoid therapy differed. As a result, conclusions drawn from the analysis must be viewed with caution. Indeed, a prospective study of 223 children in Finland found no effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    on the timing of the appearance of nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/11\">",
"     11",
"    </a>",
"    ] or on the clinical course during six months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/12\">",
"     12",
"    </a>",
"    ]. Similarly a separate meta-analysis reported no differences in the risk of persistent kidney disease at 6 months (3 studies) and 12 months (3 studies) in children given prednisone for 14 to 28 days at presentation compared to those who received placebo or supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In view of this absence of definitive evidence of long-term benefits of glucocorticoids in HSP (IgAV), we suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, maximum dose of 60 to 80 mg per day) be used only in patients with symptoms severe enough to affect their oral intake, interfere with their ability to ambulate and perform activities of daily living,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who require hospitalization. In patients who cannot tolerate oral medications, equivalent doses of parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    may be administered (0.8 to 1.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, maximum dose of 64 mg per day). Intravenous methylprednisolone may be more beneficial early in the disease course when patients have active gastrointestinal disease, due to submucosal edema and hemorrhage altering absorption of oral medications. We do not recommend the use of glucocorticoids to prevent renal disease, as the currently available data do not support such a role for this intervention.",
"   </p>",
"   <p>",
"    When glucocorticoids are used for treating HSP (IgAV), it is important to remember that inflammation may be ameliorated, but the pathophysiology of the disease does not appear to be affected. Accordingly, the glucocorticoid dose must be lowered very slowly, typically over four to eight weeks, lest a disease flare be precipitated by overly aggressive medication tapering.",
"   </p>",
"   <p>",
"    Although many clinicians describe a rapid symptomatic improvement in patients who receive glucocorticoids, data, as noted above, are insufficient to confirm such an effect. As a result, we do not recommend routine glucocorticoid therapy for all patients with HSP (IgAV), as data demonstrating benefit are inconclusive, especially regarding a reduction in the risk of renal involvement. In general, glucocorticoids are best avoided if the symptoms of HSP (IgAV) are not severe enough to warrant hospitalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DISEASE MODIFYING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HSP (IgAV), therapy is most commonly targeted toward preventing or ameliorating gastrointestinal and renal complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gastrointestinal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common gastrointestinal complication in patients with HSP (IgAV) is intussusception. The reported incidence is 3.5 percent in hospitalized patients with severe abdominal pain. Although one retrospective report did suggest that glucocorticoids prevent intussusception [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/8\">",
"     8",
"    </a>",
"    ], other studies have failed to demonstrate a reduction with glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]. This failure to demonstrate benefit may be an artifact of the low prevalence rate of gastrointestinal complications and the small number of patients studied [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/6,14\">",
"     6,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the previously mentioned randomized placebo-controlled trial of glucocorticoids, two of the patients who received placebo and none of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    -treated group developed intussusception [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/14\">",
"     14",
"    </a>",
"    ]. Although this result did not reach statistical significance, the study might not have been large enough to detect a benefit of prednisone in the prevention of gastrointestinal complications.",
"   </p>",
"   <p>",
"    Overall, the risk of intussusception is small and the early use of glucocorticoids solely for this purpose is not warranted. Furthermore, should steroids be used after an intussusception has occurred, therapy might obscure the signs of compromised bowel viability, potentially increasing the danger to the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of initial active renal disease in HSP (IgAV) and renal transplantation for end-stage renal disease are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=see_link&amp;anchor=H7#H7\">",
"     \"Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short- and long-term outcomes of children with HSP (IgAV) are generally excellent. In the absence of significant renal disease, the initial episode of HSP (IgAV) typically resolves within one month. In two-thirds of children, there are no recurrent episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In the remaining one-third of patients, HSP (IgAV) recurs at least once, typically within four months of the initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. Each subsequent episode has similar clinical findings but is generally milder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shorter in duration than the preceding one. Morbidity in the initial phase of HSP (IgAV) is primarily a result of gastrointestinal complications, including intussusception and, less commonly, bowel ischemia, bowel perforation, or pancreatitis.",
"   </p>",
"   <p>",
"    The long-term morbidity in patients with HSP (IgAV) is a result of renal disease. The risk of progressive renal disease is increased in adults. The severity of the renal involvement correlates with the severity of the initial renal presentation and histologic changes seen on renal biopsy. Risk factors for a worse renal prognosis include nephrotic range proteinuria, elevated serum creatinine, hypertension, and certain histologic findings. The supportive data are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=see_link&amp;anchor=H5#H5\">",
"     \"Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ninety percent of children who develop renal involvement do so within two months of onset, and 97 percent within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/18\">",
"     18",
"    </a>",
"    ]. Accordingly, we routinely recommend that all patients with HSP (IgAV) be followed with urinalysis and blood pressure monitoring weekly or biweekly for the first one to two months after presentation. The previously mentioned Finnish study suggested that home urine dipstick testing was adequate for detecting development of nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/11\">",
"     11",
"    </a>",
"    ]. Once the disease appears to be subsiding, additional follow-up for urine and blood pressure monitoring should be scheduled monthly at first, then every other month until one year after the initial presentation. To identify patients who may develop late renal disease, we recommend continued screening (eg, urinalysis and blood pressure measurements) by the primary care clinician during subsequent well-child visits.",
"   </p>",
"   <p>",
"    A serum creatinine should be obtained to assess renal function in any patient with a significant or persistent urinary abnormalities or elevated blood pressure.",
"   </p>",
"   <p>",
"    Patients with persistent proteinuria, hypertension, or renal insufficiency should be referred to a nephrologist for further evaluation and treatment. In addition, pregnant women with a history of HSP (IgAV) should be monitored closely, as they have a higher risk of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28646/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"./henoch-schonlein-purpura-iga-vasculitis-the-basics?source=see_link\">",
"       \"Patient information: Henoch-Sch&ouml;nlein purpura (IgA vasculitis) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with Henoch-Sch&ouml;nlein purpura (HSP), also called IgA vasculitis (IgAV), may be cared for in the ambulatory setting with therapy directed toward adequate oral hydration, bed rest, and symptomatic relief of joint and abdominal pain.",
"     </li>",
"     <li>",
"      Hospitalization is indicated in patients who fail to maintain oral hydration and require the administration of intravenous fluids. Inpatient management may also be necessary to manage patients who have significant gastrointestinal bleeding, severe abdominal pain, changes in mental status, severe joint involvement limiting ambulation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      self-care, or evidence of significant renal disease (elevated creatinine, hypertension, or proteinuria). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with joint",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abdominal pain, we suggest the use of a nonsteroidal antiinflammatory agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      (10 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      divided into two doses per day). A maximum dose of naproxen of 1500 mg per day may be used for a few days provided that adequate hydration is maintained. If more than a week of NSAID treatment is necessary, the dose of naproxen should not exceed 1000 mg per day. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nonsteroidal antiinflammatory agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe abdominal pain that interferes with their oral intake and who fail to respond to a nonsteroidal antiinflammatory agent, we suggest the use of systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) for children or adults, with a maximum dose of 60 to 80 mg per day, or equivalent doses of parenteral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (0.8 to 1.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, maximum dose of 64 mg per day). Glucocorticoids should be tapered slowly, by no more than 25 percent per week, lest symptoms relapse. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend glucocorticoid administration to prevent persistent renal disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although prognosis is excellent in children with HSP (IgAV), a small minority of patients (&lt;1 percent) develop long-term complications, primarily renal disease. In adults, the risk of significant renal disease is increased. At present, there is no known therapeutic regimen to forestall development of renal involvement. Therapy for optimal control of HSP (IgAV)-related nephritis or nephrosis is discussed elsewhere. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=see_link&amp;anchor=H7#H7\">",
"       \"Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have developed HSP (IgAV) should be seen in follow-up with screening for urinary abnormalities and elevated blood pressure to identify patients with significant and potentially progressive renal involvement. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/1\">",
"      Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/2\">",
"      Chang WL, Yang YH, Lin YT, Chiang BL. Gastrointestinal manifestations in Henoch-Sch&ouml;nlein purpura: a review of 261 patients. Acta Paediatr 2004; 93:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/3\">",
"      Choong CK, Beasley SW. Intra-abdominal manifestations of Henoch-Sch&ouml;nlein purpura. J Paediatr Child Health 1998; 34:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/4\">",
"      Schwab J, Benya E, Lin R, Majd K. Contrast enema in children with Henoch-Sch&ouml;nlein purpura. J Pediatr Surg 2005; 40:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/5\">",
"      Weiss PF, Feinstein JA, Luan X, et al. Effects of corticosteroid on Henoch-Sch&ouml;nlein purpura: a systematic review. Pediatrics 2007; 120:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/6\">",
"      Rosenblum ND, Winter HS. Steroid effects on the course of abdominal pain in children with Henoch-Schonlein purpura. Pediatrics 1987; 79:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/7\">",
"      Leung SP. Use of intravenous hydrocortisone in Henoch-Schonlein purpura. J Paediatr Child Health 2001; 37:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/8\">",
"      ALLEN DM, DIAMOND LK, HOWELL DA. Anaphylactoid purpura in children (Schonlein-Henoch syndrome): review with a follow-up of the renal complications. AMA J Dis Child 1960; 99:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/9\">",
"      Szer IS. Gastrointestinal and renal involvement in vasculitis: management strategies in Henoch-Sch&ouml;nlein purpura. Cleve Clin J Med 1999; 66:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/10\">",
"      Weiss PF, Klink AJ, Localio R, et al. Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Sch&ouml;nlein purpura. Pediatrics 2010; 126:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/11\">",
"      Jauhola O, Ronkainen J, Koskimies O, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Arch Dis Child 2010; 95:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/12\">",
"      Jauhola O, Ronkainen J, Koskimies O, et al. Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. Arch Dis Child 2010; 95:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/13\">",
"      Chartapisak W, Opastirakul S, Hodson EM, et al. Interventions for preventing and treating kidney disease in Henoch-Sch&ouml;nlein Purpura (HSP). Cochrane Database Syst Rev 2009; :CD005128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/14\">",
"      Huber AM, King J, McLaine P, et al. A randomized, placebo-controlled trial of prednisone in early Henoch Sch&ouml;nlein Purpura [ISRCTN85109383]. BMC Med 2004; 2:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/15\">",
"      Saulsbury FT. Henoch-Sch&ouml;nlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 1999; 78:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/16\">",
"      Meadow SR. The prognosis of Henoch Schoenlein nephritis. Clin Nephrol 1978; 9:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/17\">",
"      Trapani S, Micheli A, Grisolia F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 2005; 35:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/18\">",
"      Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005; 90:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28646/abstract/19\">",
"      Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Sch&ouml;nlein purpura: a retrospective cohort study. Lancet 2002; 360:666.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6407 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28646=[""].join("\n");
var outline_f27_62_28646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMATIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonsteroidal antiinflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DISEASE MODIFYING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gastrointestinal complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=related_link\">",
"      Indications for red blood cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"./henoch-schonlein-purpura-iga-vasculitis-the-basics?source=related_link\">",
"      Patient information: Henoch-Sch&ouml;nlein purpura (IgA vasculitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=related_link\">",
"      Prevention and management of acute kidney injury (acute renal failure) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=related_link\">",
"      Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_62_28647="Kikuchi's disease";
var content_f27_62_28647=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Kikuchi's disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28647/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28647/contributors\">",
"     Michael J Richards, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28647/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28647/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28647/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28647/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/62/28647/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kikuchi's disease, also called Kikuchi-Fujimoto disease or Kikuchi's histiocytic necrotizing lymphadenitis, was originally described in young women and is a rare, benign condition of unknown cause usually characterized by cervical lymphadenopathy and fever. Histopathology of the involved lymph nodes differentiates Kikuchi's disease from several more serious conditions that it may mimic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the pathogenesis of Kikuchi's disease is unknown, the clinical presentation, course, and histologic changes suggest an immune response of T cells and histiocytes to an infectious agent. Numerous inciting agents have been proposed, including Epstein Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], human herpesvirus 6, human herpesvirus 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/3\">",
"     3",
"    </a>",
"    ], human immunodeficiency virus (HIV), parvovirus B19 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/4\">",
"     4",
"    </a>",
"    ], paramyxoviruses, parainfluenza virus, Yersinia enterocolitica, and Toxoplasma. In one report, EBV was detected by in situ hybridization in tissue in all of 10 patients examined [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], but immunohistochemistry detected EBV-encoded protein in only one of these patients. An observation that is consistent with a viral etiology is increased levels of interferon-alpha and of other proteins stimulated by interferon-alpha including 2',5'-oligoadenylate synthetase and tubuloreticular structures in the cytoplasm of stimulated lymphocytes, histiocytes, and vascular endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apoptotic cell death mediated by cytotoxic CD8 positive T lymphocytes is the principal mechanism of cellular destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Histiocytes may act as enhancers. The apoptosis appears to be induced by the Fas-Fas ligand system. Morphologic characteristics of apoptotic cells including nuclear chromatin condensation and fragmentation along the nuclear membrane with intact organelles, and histiocytes phagocytosing karyorrhectic debris (apoptotic bodies) are found on transmission electron microscopy.",
"   </p>",
"   <p>",
"    A possible role for interferon-gamma and interleukin-6 in the pathogenesis of this syndrome is suggested by one study of four men with biopsy-proven Kikuchi's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/11\">",
"     11",
"    </a>",
"    ]. During the acute phase of illness, these patients had elevated serum levels of interferon gamma and IL-6 but not interferon alpha, tumor necrosis factor, or interleukin-2. The interferon-gamma and IL-6 levels returned to normal during convalescence. Subsequent reports support this role [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/12\">",
"     12",
"    </a>",
"    ]. Analysis of lymph nodes biopsies in patients with Kikuchi's disease show T-bet-expressing CD4 cells accompanied by T-bet-positive CD8 and B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kikuchi's syndrome shares sex and age predisposition as well as histologic features with systemic lupus erythematosus (SLE). Tubuloreticular structures in the lymphocytes and endothelial cells in patients with SLE have been observed to be similar to those seen in Kikuchi's disease. One ultrastructural study proposed that Kikuchi's syndrome reflects a self-limited, SLE-like autoimmune condition caused by virus-infected transformed lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=see_link\">",
"     \"Epidemiology and pathogenesis of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While initially described in young women, Kikuchi's disease clearly also occurs in men. The ratio of affected males to females in three series was 1:4, 1:1.6, and 1:1.26, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In a Korean report of 20 individuals younger than 18 years of age with Kikuchi's disease, the gender distribution was equal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/18\">",
"     18",
"    </a>",
"    ]. Most patients are younger than 40 years of age, but this condition has been reported in patients ranging in age from 6 to 80 years, most of whom were previously well [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The mean age at presentation in a United States series was 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ethnic distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although initially described in two separate cases from Japan, Kikuchi's disease has since been found in all racial and ethnic groups and in many countries, including the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15,22\">",
"     15,22",
"    </a>",
"    ]. In a study of 88 patients with Kikuchi's disease in the United States, 75 percent were Caucasian [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15\">",
"     15",
"    </a>",
"    ]. The frequency of this condition varies widely in different groups, but it has been most frequently reported from Asia. In a series of 920 lymph node biopsies from Saudi Arabia, only five (0.5 percent) had changes characteristic of Kikuchi's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/23\">",
"     23",
"    </a>",
"    ] compared to 5.7 percent in a report from Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/24\">",
"     24",
"    </a>",
"    ]. In a Korean study of 147 patients presenting to an outpatient clinic, Kikuchi's disease (34.7 percent) and tuberculous adenitis (22.4 percent) were the most common causes of cervical adenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical presentation of Kikuchi's disease is fever and cervical lymphadenopathy in a previously well young woman. Fever is a primary symptom in 30 to 50 percent of patients. It is typically low-grade and persists for about one week [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15\">",
"     15",
"    </a>",
"    ], though rarely for up to one month.",
"   </p>",
"   <p>",
"    In a retrospective literature review that described 244 patients with Kikuchi's disease, the most common symptoms were fever (35 percent), fatigue (7 percent), and joint pain (7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/26\">",
"     26",
"    </a>",
"    ]. The most common clinical and laboratory findings were lymphadenopathy (100 percent), rash (10 percent), arthritis (7 percent), hepatosplenomegaly (3 percent), leukopenia (43 percent), elevated sedimentation rate (40 percent), and anemia (23 percent).",
"   </p>",
"   <p>",
"    Systemic symptoms may accompany fever and lymphadenopathy and appear to be more prominent in patients with extranodal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/27\">",
"     27",
"    </a>",
"    ]. Systemic symptoms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Night sweats",
"     </li>",
"     <li>",
"      Nausea",
"     </li>",
"     <li>",
"      Vomiting",
"     </li>",
"     <li>",
"      Weight loss (in approximately 10 percent)",
"     </li>",
"     <li>",
"      Diarrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of other symptoms and physical findings occur sporadically in patients with Kikuchi's disease. These include rigors, myalgia, arthralgia, chest and abdominal pain, splenomegaly, and hepatomegaly, which may be associated with abdominal lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation in pediatric patients is similar to that in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk of evolution into an autoimmune syndrome may be higher than in adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasional reports describe Kikuchi's disease associated with other conditions, such as Still's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/30\">",
"     30",
"    </a>",
"    ], cryptogenic organizing pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/31\">",
"     31",
"    </a>",
"    ], and following B cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient skin rashes similar to rubella or drug-induced eruptions may be seen in sicker patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/33\">",
"     33",
"    </a>",
"    ]. The presence of a malar \"butterfly rash\" should raise the diagnosis of SLE that, as noted above, has been associated with Kikuchi's disease. Some reports describe skin manifestations in up to 40 percent of patients, including facial erythema; erythematous macules, patches, papules, or plaques; scattered indurated lesions; ulcers; polymorphous light eruptions; leukocytoclastic vasculitis; scale; pruritus; alopecia; conjunctival injection; and oral ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/1,34,35\">",
"     1,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lymph node involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph node involvement is usually cervical and localized in Kikuchi's disease. As an example, all 79 patients in a Chinese report had cervical node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/36\">",
"     36",
"    </a>",
"    ]. In the United States series of 108 patients, 83 had lymphadenopathy localized to one site, usually cervical and particularly posterior cervical; only three patients had bilateral cervical adenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15\">",
"     15",
"    </a>",
"    ]. There may be more extensive node involvement, or involvement of other sites. These sites include the axillary, epitrochlear, mediastinal, inguinal, intraparotid, iliac, retrocrural, celiac, and peripancreatic nodes.",
"   </p>",
"   <p>",
"    The nodes are usually only moderately enlarged (1 to 2 cm in diameter) but occasionally are much larger (&le;7 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/36\">",
"     36",
"    </a>",
"    ]. They are typically firm, smooth, discrete, and mobile. The nodal enlargement is often associated with dull or acute pain.",
"   </p>",
"   <p>",
"    Rarely, nodal enlargement may be minimal or only mediastinal, or retroperitoneal nodes may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The diagnosis is unlikely to be considered prior to biopsy in such patients who may present as a fever of unknown origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aseptic meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], acute cerebellar symptoms with tremor and ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/41\">",
"     41",
"    </a>",
"    ], thyroiditis and parotid enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/42\">",
"     42",
"    </a>",
"    ], polymyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/43\">",
"     43",
"    </a>",
"    ], hemophagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/44-46\">",
"     44-46",
"    </a>",
"    ], panuveitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/47\">",
"     47",
"    </a>",
"    ], bilateral papillary conjunctivitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/48\">",
"     48",
"    </a>",
"    ], autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/49\">",
"     49",
"    </a>",
"    ], brachial neuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/50\">",
"     50",
"    </a>",
"    ], and peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/51\">",
"     51",
"    </a>",
"    ] have all been reported. In addition, there are reports of antiphospholipid syndrome with multiorgan failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with Kikuchi's disease have a normal complete blood count [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15\">",
"     15",
"    </a>",
"    ], although leukopenia is seen in 20 to 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/16,25\">",
"     16,25",
"    </a>",
"    ]. Atypical lymphocytes have been reported in up to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/36\">",
"     36",
"    </a>",
"    ]. Other less common findings include thrombocytopenia, pancytopenia, and, in those with severe disease, anemia of chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/1,53\">",
"     1,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The erythrocyte sedimentation rate can be normal but was elevated to more than 60",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    in 70 percent of patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/37\">",
"     37",
"    </a>",
"    ]. Other nonspecific findings can include mildly abnormal liver function tests and elevated serum lactate dehydrogenase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in macrophages without atypical cells is the most frequent bone marrow finding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/16\">",
"     16",
"    </a>",
"    ]. In two patients, increased numbers of mature hemophagocytic histiocytes in the bone marrow led to the misdiagnosis of virus-associated hemophagocytic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antinuclear antibodies (ANA), rheumatoid factor, and lupus erythematosus preparations are generally negative. Some patients initially diagnosed with Kikuchi's disease have subsequently developed systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15\">",
"     15",
"    </a>",
"    ], and an ANA test should be performed in patients with suspected Kikuchi's syndrome in order to exclude this diagnosis. One report describes a transient rise in anti-DNA and antiribonuclear protein antibody levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serology for EBV, cytomegalovirus, HIV, toxoplasmosis, Yersinia enterocolitica, cat scratch disease, and other infectious agents is often performed since these infections are considered in the differential diagnosis of fever and lymphadenopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Kikuchi's disease is made by lymph node biopsy. Biopsy should be performed, despite the self-limited nature of this syndrome, in order to exclude more serious conditions requiring aggressive therapy such as lymphoma. Patients with Kikuchi's disease have been misdiagnosed as having lymphoma and treated with cytotoxic agents when physicians and pathologists are unfamiliar with this entity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15\">",
"     15",
"    </a>",
"    ]. Other conditions that have been confused with Kikuchi's disease are tuberculous adenitis, lymphogranuloma venereum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/54\">",
"     54",
"    </a>",
"    ], and Kawasaki disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fine needle aspiration of a lymph node has been performed for diagnosis with attempts to preserve the architectural relationship of different cell types by preparation of cell block sections from tissue fragments [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/57\">",
"     57",
"    </a>",
"    ]. Although excisional biopsy is most often recommended, fine needle aspiration is increasingly useful in the hands of experienced cytopathologists using smears and cell block preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histology of the lymph node in Kikuchi's disease can usually be easily differentiated from most known infectious conditions in the differential diagnosis of fever and lymphadenopathy, but not from that seen in some patients with systemic lupus erythematosus (SLE) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15,19,35\">",
"     15,19,35",
"    </a>",
"    ]. Yellowish necrotic foci may rarely be noted on the cut surface of the node. Microscopic examination usually shows paracortical foci often with necrosis and a histiocytic cellular infiltrate (",
"    <a class=\"graphic graphic_picture graphicRef69416 \" href=\"UTD.htm?23/51/24377\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50349 \" href=\"UTD.htm?18/32/18953\">",
"     picture 2",
"    </a>",
"    ). These foci may be single or multiple. The capsule may be infiltrated, and perinodal inflammation is common. The necrotizing process is often confined to circumscribed areas of eosinophilic fibrinoid material with irregular distribution of fragments of nuclear debris. Overt coagulative necrosis is not a prerequisite for the diagnosis of Kikuchi's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histological appearance changes as the disease progresses.",
"   </p>",
"   <p>",
"    Early biopsies in the \"proliferative phase\" show follicular hyperplasia and paracortical expansion by lymphocytes, T and B cell blasts, plasmacytoid monocytes and histiocytes with numerous apoptoses in the background.",
"   </p>",
"   <p>",
"    In the \"proliferative phase\" the presence of numerous blast cells raises the differential diagnoses of lymphoma, EBV infection, and Herpes simplex infection. Preservation of the nodal architecture, the polyclonal infiltrate, and negative viral immunohistochemistry exclude these conditions.",
"   </p>",
"   <p>",
"    Later biopsies in the \"necrotizing phase\" show necrosis without a neutrophilic infiltrate associated with progressive dominance of histiocytes as the major cell type. The histiocytes often have crescentic nuclei and contain phagocytosed debris. Immunohistochemical stains show CD68 positive plasmacytoid monocytes and histiocytes with predominantly CD8 positive T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/60\">",
"     60",
"    </a>",
"    ]. The absence of neutrophils in the \"necrotizing phase\" is helpful in distinguishing this condition from SLE and drug induced lymphadenopathy.",
"   </p>",
"   <p>",
"    Xanthomatous appearance seems to be a distinct histologic variant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histologic differential diagnosis includes SLE, herpes simplex lymphadenitis, and lymphoma (non-Hodgkin's and Hodgkin's). In SLE, hematoxylin bodies and plasma cells are also seen. In herpes simplex lymphadenitis, there are fewer surrounding mononuclear cells, and neutrophils are usually present. Necrosis associated with Hodgkin lymphoma usually includes neutrophils and, in contrast to Kikuchi's disease, the large atypical cells (Reed-Sternberg cell variants) are CD15, CD30, and CD45 positive. It has been suggested that plasmacytoid dendritic cells more frequently infiltrate the lymph nodes in Kikuchi&rsquo;s disease than in either reactive lymphadenitis or T or B cell lymphoma, irrespective of the age of the Kikuchi&rsquo;s lesion, and thus they may be useful indicators for the cytologic diagnosis of Kikuchi&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the characteristic histopathologic changes seen in lymph nodes of patients with Kikuchi's disease, the histologic features in skin biopsy samples are highly variable and nonspecific. Common histologic findings that may be present include epidermal change (most commonly with necrotic keratinocytes), non-neutrophilic karyorrhectic debris, basal vacuolar change, papillary dermal edema, and a lymphocytic infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/35\">",
"     35",
"    </a>",
"    ]. In a review of skin biopsies from 16 cases, features noted included vacuolar interface changes (in 75 percent), necrotic keratinocytes (in 68 percent), karyorrhexis (in 100 percent), superficial and deep lymphohistiocytic infiltration (in 100 and 56 percent, respectively), and panniculitis (in 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/63\">",
"     63",
"    </a>",
"    ]. Infiltrating cells were predominantly CD68 and CD163 positive histiocytes and CD3 positive T lymphocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) imaging of the affected lymph nodes typically show perinodal infiltration (81 percent), and homogenous nodal contrast enhancement (83 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/64\">",
"     64",
"    </a>",
"    ]. On ultrasound, lymph nodes may appear suspicious for malignancy; 66 percent of a series of 29 lymph nodes evaluated sonographically showed features suggestive of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effective treatment has been established for Kikuchi's disease. Signs and symptoms usually resolve within one to four months.",
"   </p>",
"   <p>",
"    Patients with severe or persisting symptoms have been treated with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/66\">",
"     66",
"    </a>",
"    ], or high dose glucocorticoids with intravenous immunoglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/67\">",
"     67",
"    </a>",
"    ] with apparent benefit. There has been one report of recurrent Kikuchi's disease successfully treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/68\">",
"     68",
"    </a>",
"    ]. Affected patients should be followed for some years because they can develop SLE and recurrences of Kikuchi's disease can occasionally continue for many years. One patient, for example, had four episodes of lymphadenopathy over 18 years and another had two episodes separated by six years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/53,56\">",
"     53,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kikuchi's disease is self-limited in the majority of patients, although recurrences have been reported. In a series of 108 patients, 59 of 64 patients (92 percent) for whom data were available were alive and well at a median of 32 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/15\">",
"     15",
"    </a>",
"    ]. Among 102 patients in Korea between 2001 and 2006, three developed SLE, eight experienced early relapse, and 13 had late recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28647/abstract/69\">",
"     69",
"    </a>",
"    ]. Recurrent cases were symptomatic for longer than initial cases. A positive fluorescent antinuclear antibody test was associated with a higher risk of recurrent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2084079\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kikuchi's disease is a rare, benign condition of unknown cause usually characterized by cervical lymphadenopathy and fever. Histopathology of the involved lymph nodes differentiates Kikuchi's disease from several more serious conditions that it may mimic. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While the pathogenesis of Kikuchi's disease is unknown, the clinical presentation, course, and histologic changes suggest an immune response of T cells and histiocytes to an infectious agent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although initially described in young women, Kikuchi's disease also occurs in men. Most patients are younger than 40 years of age and were previously well. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kikuchi's disease has been most frequently reported from Asia, but has been found in all racial and ethnic groups and in many countries. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ethnic distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common clinical presentation is low-grade fever and cervical lymphadenopathy in a previously well young woman. Patients may also have fatigue, joint pain, rash, arthritis, hepatosplenomegaly, night sweats, nausea, vomiting, weight loss,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymph node involvement is usually cervical and localized. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lymph node involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Kikuchi's disease is made by lymph node biopsy. Microscopic examination usually shows paracortical foci often with necrosis and a histiocytic cellular infiltrate (",
"      <a class=\"graphic graphic_picture graphicRef69416 \" href=\"UTD.htm?23/51/24377\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef50349 \" href=\"UTD.htm?18/32/18953\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antinuclear antibodies should be performed in patients with suspected Kikuchi's disease in order to exclude systemic lupus erythematosus. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Serologic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No effective treatment has been established for Kikuchi's disease. Signs and symptoms usually resolve within one to four months. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/1\">",
"      Yen A, Fearneyhough P, Raimer SS, Hudnall SD. EBV-associated Kikuchi's histiocytic necrotizing lymphadenitis with cutaneous manifestations. J Am Acad Dermatol 1997; 36:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/2\">",
"      Hudnall SD, Chen T, Amr S, et al. Detection of human herpesvirus DNA in Kikuchi-Fujimoto disease and reactive lymphoid hyperplasia. Int J Clin Exp Pathol 2008; 1:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/3\">",
"      Huh J, Kang GH, Gong G, et al. Kaposi's sarcoma-associated herpesvirus in Kikuchi's disease. Hum Pathol 1998; 29:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/4\">",
"      Yufu Y, Matsumoto M, Miyamura T, et al. Parvovirus B19-associated haemophagocytic syndrome with lymphadenopathy resembling histiocytic necrotizing lymphadenitis (Kikuchi's disease). Br J Haematol 1997; 96:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/5\">",
"      Chiu CF, Chow KC, Lin TY, et al. Virus infection in patients with histiocytic necrotizing lymphadenitis in Taiwan. Detection of Epstein-Barr virus, type I human T-cell lymphotropic virus, and parvovirus B19. Am J Clin Pathol 2000; 113:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/6\">",
"      Hudnall SD. Kikuchi-Fujimoto disease. Is Epstein-Barr virus the culprit? Am J Clin Pathol 2000; 113:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/7\">",
"      Rich SA. De novo synthesis and secretion of a 36-kD protein by cells that form lupus inclusions in response to alpha-interferon. J Clin Invest 1995; 95:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/8\">",
"      Iguchi H, Sunami K, Yamane H, et al. Apoptotic cell death in Kikuchi's disease: a TEM study. Acta Otolaryngol Suppl 1998; 538:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/9\">",
"      Ohshima K, Shimazaki K, Kume T, et al. Perforin and Fas pathways of cytotoxic T-cells in histiocytic necrotizing lymphadenitis. Histopathology 1998; 33:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/10\">",
"      Ura H, Yamada N, Torii H, et al. Histiocytic necrotizing lymphadenitis (Kikuchi's disease): the necrotic appearance of the lymph node cells is caused by apoptosis. J Dermatol 1999; 26:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/11\">",
"      Kubota M, Tsukamoto R, Kurokawa K, et al. Elevated serum interferon gamma and interleukin-6 in patients with necrotizing lymphadenitis (Kikuchi's disease). Br J Haematol 1996; 95:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/12\">",
"      Yabe H, Sinzato I, Hashimoto K. [Necrotizing lymphadenitis presenting as mesenteric lymphadenopathy]. Rinsho Ketsueki 1999; 40:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/13\">",
"      J&ouml;hrens K, Anagnostopoulos I, D&uuml;rkop H, Stein H. Different T-bet expression patterns characterize particular reactive lymphoid tissue lesions. Histopathology 2006; 48:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/14\">",
"      Imamura M, Ueno H, Matsuura A, et al. An ultrastructural study of subacute necrotizing lymphadenitis. Am J Pathol 1982; 107:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/15\">",
"      Dorfman RF, Berry GJ. Kikuchi's histiocytic necrotizing lymphadenitis: an analysis of 108 cases with emphasis on differential diagnosis. Semin Diagn Pathol 1988; 5:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/16\">",
"      Asano S, Akaike Y, Jinnouchi H, et al. Necrotizing lymphadenitis: a review of clinicopathological, immunohistochemical and ultrastructural studies. Hematol Oncol 1990; 8:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/17\">",
"      Lin HC, Su CY, Huang CC, et al. Kikuchi's disease: a review and analysis of 61 cases. Otolaryngol Head Neck Surg 2003; 128:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/18\">",
"      Seo JH, Shim HS, Park JJ, et al. A clinical study of histiocytic necrotizing lymphadenitis (Kikuchi's disease) in children. Int J Pediatr Otorhinolaryngol 2008; 72:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/19\">",
"      Tsang WY, Chan JK, Ng CS. Kikuchi's lymphadenitis. A morphologic analysis of 75 cases with special reference to unusual features. Am J Surg Pathol 1994; 18:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/20\">",
"      Lee KY, Yeon YH, Lee BC. Kikuchi-Fujimoto disease with prolonged fever in children. Pediatrics 2004; 114:e752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/21\">",
"      Payne JH, Evans M, Gerrard MP. Kikuchi-Fujimoto disease: a rare but important cause of lymphadenopathy. Acta Paediatr 2003; 92:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/22\">",
"      Turner RR, Martin J, Dorfman RF. Necrotizing lymphadenitis. A study of 30 cases. Am J Surg Pathol 1983; 7:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/23\">",
"      Kutty MK, Anim JT, Sowayan S. Histiocytic necrotising lymphadenitis (Kikuchi-Fujimoto disease) in Saudi Arabia. Trop Geogr Med 1991; 43:68.",
"     </a>",
"    </li>",
"    <li>",
"     Kuo T, Shi LY. Surgical pathology of lymph node biopsy specimens in Taiwan with an update on adult T cell leukaemia/ lymphoma. In: Lymphoid Malignancy: Immunocytology and Cytogenetics, Hanoaka M, Kadin ME, Mikatu A (Eds), Field and Wood, New York City 1990. p.109.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/25\">",
"      Song JY, Cheong HJ, Kee SY, et al. Disease spectrum of cervical lymphadenitis: analysis based on ultrasound-guided core-needle gun biopsy. J Infect 2007; 55:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/26\">",
"      Kucukardali Y, Solmazgul E, Kunter E, et al. Kikuchi-Fujimoto Disease: analysis of 244 cases. Clin Rheumatol 2007; 26:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/27\">",
"      Kuo TT. Cutaneous manifestation of Kikuchi's histiocytic necrotizing lymphadenitis. Am J Surg Pathol 1990; 14:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/28\">",
"      Chuang CH, Yan DC, Chiu CH, et al. Clinical and laboratory manifestations of Kikuchi's disease in children and differences between patients with and without prolonged fever. Pediatr Infect Dis J 2005; 24:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/29\">",
"      Wang TJ, Yang YH, Lin YT, Chiang BL. Kikuchi-Fujimoto disease in children: clinical features and disease course. J Microbiol Immunol Infect 2004; 37:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/30\">",
"      Cousin F, Gr&eacute;zard P, Roth B, et al. Kikuchi disease associated with Still disease. Int J Dermatol 1999; 38:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/31\">",
"      Hua F, Zhu L. Kikuchi Fujimoto disease associated with cryptogenic organizing pneumonia: case report and literature review. BMC Infect Dis 2010; 10:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/32\">",
"      Yoshino T, Mannami T, Ichimura K, et al. Two cases of histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto's disease) following diffuse large B-cell lymphoma. Hum Pathol 2000; 31:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/33\">",
"      Kikuchi, M, Takeshita, M, Okamura, S, et al. Histiocytic necrotizing lymphadenitis. Path Clin Med 1983; 1:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/34\">",
"      Yasukawa K, Matsumura T, Sato-Matsumura KC, et al. Kikuchi's disease and the skin: case report and review of the literature. Br J Dermatol 2001; 144:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/35\">",
"      Atwater AR, Longley BJ, Aughenbaugh WD. Kikuchi's disease: case report and systematic review of cutaneous and histopathologic presentations. J Am Acad Dermatol 2008; 59:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/36\">",
"      Kuo TT. Kikuchi's disease (histiocytic necrotizing lymphadenitis). A clinicopathologic study of 79 cases with an analysis of histologic subtypes, immunohistology, and DNA ploidy. Am J Surg Pathol 1995; 19:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/37\">",
"      Norris AH, Krasinskas AM, Salhany KE, Gluckman SJ. Kikuchi-Fujimoto disease: a benign cause of fever and lymphadenopathy. Am J Med 1996; 101:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/38\">",
"      Bailey EM, Klein NC, Cunha BA. Kikuchi's disease with liver dysfunction presenting as fever of unknown origin. Lancet 1989; 2:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/39\">",
"      Sato Y, Kuno H, Oizumi K. Histiocytic necrotizing lymphadenitis (Kikuchi's disease) with aseptic meningitis. J Neurol Sci 1999; 163:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/40\">",
"      Mathew LG, Cherian T, Srivastava VM, Raghupathy P. Histiocytic necrotizing lymphadenitis (Kikuchi's disease) with aseptic meningitis. Indian Pediatr 1998; 35:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/41\">",
"      Moon JS, Il Kim G, Koo YH, et al. Kinetic tremor and cerebellar ataxia as initial manifestations of Kikuchi-Fujimoto's disease. J Neurol Sci 2009; 277:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/42\">",
"      Keogh MA, Williamson RM, Denaro CP. Kikuchi's disease associated with parotidomegaly, thyroiditis and a rash in a young man. Aust N Z J Med 2000; 30:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/43\">",
"      Wilkinson CE, Nichol F. Kikuchi-Fujimoto disease associated with polymyositis. Rheumatology (Oxford) 2000; 39:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/44\">",
"      Chen JS, Chang KC, Cheng CN, et al. Childhood hemophagocytic syndrome associated with Kikuchi's disease. Haematologica 2000; 85:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/45\">",
"      Kelly J, Kelleher K, Khan MK, Rassam SM. A case of haemophagocytic syndrome and Kikuchi-Fujimoto disease occurring concurrently in a 17-year-old female. Int J Clin Pract 2000; 54:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/46\">",
"      Lim GY, Cho B, Chung NG. Hemophagocytic lymphohistiocytosis preceded by Kikuchi disease in children. Pediatr Radiol 2008; 38:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/47\">",
"      P&eacute;rez Alvarez MJ, Moreno L&oacute;pez M. [Panuveitis as a possible ophthalmic complication of Kikuchi-Fujimoto disease]. Arch Soc Esp Oftalmol 2005; 80:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/48\">",
"      Galor A, Georgy M, Leder HA, et al. Papillary conjunctivitis associated with Kikuchi disease. Cornea 2008; 27:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/49\">",
"      Shusang V, Marelli L, Beynon H, et al. Autoimmune hepatitis associated with Kikuchi-Fujimoto's disease. Eur J Gastroenterol Hepatol 2008; 20:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/50\">",
"      Sugiyama A, Araki E, Arakawa K, et al. [A case of subacute necrotizing lymphadenitis complicated with brachial plexus neuritis]. Rinsho Shinkeigaku 1998; 38:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/51\">",
"      Longaretti P, Savasta S, Caimmi D, et al. Kikuchi-Fujimoto disease complicated by peripheral neuropathy. Pediatr Neurol 2012; 46:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/52\">",
"      de Larra&ntilde;aga GF, Remondino GI, Forastiero RR, et al. Catastrophic antiphospholipid syndrome and Kikuchi-Fujimoto disease: the first case reported. Lupus 2005; 14:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/53\">",
"      Smith KG, Becker GJ, Busmanis I. Recurrent Kikuchi's disease. Lancet 1992; 340:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/54\">",
"      Mital D, Desai V, Chin K. Kikuchi-Fujimoto syndrome presenting to a sexual health clinic. Int J STD AIDS 2009; 20:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/55\">",
"      Dorfman RF, Warnke R. Lymphadenopathy simulating the malignant lymphomas. Hum Pathol 1974; 5:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/56\">",
"      Nieman RB. Diagnosis of Kikuchi's disease. Lancet 1990; 335:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/57\">",
"      Kung IT, Ng WF, Yuen RW, Chan JK. Kikuchi's histiocytic necrotizing lymphadenitis. Diagnosis by fine needle aspiration. Acta Cytol 1990; 34:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/58\">",
"      Tsang WY, Chan JK. Fine-needle aspiration cytologic diagnosis of Kikuchi's lymphadenitis. A report of 27 cases. Am J Clin Pathol 1994; 102:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/59\">",
"      Mannar&agrave; GM, Boccato P, Rinaldo A, et al. Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease) diagnosed by fine needle aspiration biopsy. ORL J Otorhinolaryngol Relat Spec 1999; 61:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/60\">",
"      Ohshima K, Karube K, Hamasaki M, et al. Apoptosis- and cell cycle-associated gene expression profiling of histiocytic necrotising lymphadenitis. Eur J Haematol 2004; 72:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/61\">",
"      Kuo TT, Lo SK. Significance of histological subtypes of Kikuchi's disease: comparative immunohistochemical and apoptotic studies. Pathol Int 2004; 54:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/62\">",
"      Kishimoto K, Tate G, Kitamura T, et al. Cytologic features and frequency of plasmacytoid dendritic cells in the lymph nodes of patients with histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease). Diagn Cytopathol 2010; 38:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/63\">",
"      Kim JH, Kim YB, In SI, et al. The cutaneous lesions of Kikuchi's disease: a comprehensive analysis of 16 cases based on the clinicopathologic, immunohistochemical, and immunofluorescence studies with an emphasis on the differential diagnosis. Hum Pathol 2010; 41:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/64\">",
"      Kwon SY, Kim TK, Kim YS, et al. CT findings in Kikuchi disease: analysis of 96 cases. AJNR Am J Neuroradiol 2004; 25:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/65\">",
"      Youk JH, Kim EK, Ko KH, Kim MJ. Sonographic features of axillary lymphadenopathy caused by Kikuchi disease. J Ultrasound Med 2008; 27:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/66\">",
"      Jang YJ, Park KH, Seok HJ. Management of Kikuchi's disease using glucocorticoid. J Laryngol Otol 2000; 114:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/67\">",
"      Lin DY, Villegas MS, Tan PL, et al. Severe Kikuchi's disease responsive to immune modulation. Singapore Med J 2010; 51:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/68\">",
"      Rezai K, Kuchipudi S, Chundi V, et al. Kikuchi-Fujimoto disease: hydroxychloroquine as a treatment. Clin Infect Dis 2004; 39:e124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28647/abstract/69\">",
"      Song JY, Lee J, Park DW, et al. Clinical outcome and predictive factors of recurrence among patients with Kikuchi's disease. Int J Infect Dis 2009; 13:322.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5507 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-37992F4EF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28647=[""].join("\n");
var outline_f27_62_28647=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2084079\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ethnic distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lymph node involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serologic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2084079\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5507\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5507|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/51/24377\" title=\"picture 1\">",
"      Kikuchis disease lymph node histopathology 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/32/18953\" title=\"picture 2\">",
"      Kikuchis disease lymph node histopathology 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=related_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_62_28648="SUNCT and SUNA headache syndromes: Clinical features and diagnosis";
var content_f27_62_28648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28648/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28648/contributors\">",
"     Manjit S Matharu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28648/contributors\">",
"     Anna S Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28648/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28648/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28648/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28648/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/62/28648/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The TACs include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite their common elements, the TACs differ in attack duration and frequency, as well as the response to therapy (",
"    <a class=\"graphic graphic_table graphicRef65541 \" href=\"UTD.htm?41/12/42188\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cluster headache has the longest attack duration and relatively low attack frequency",
"     </li>",
"     <li>",
"      Paroxysmal hemicrania has intermediate duration and intermediate attack frequency",
"     </li>",
"     <li>",
"      SUNCT has the shortest attack duration and the highest attack frequency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of recognizing these syndromes resides in their excellent but highly selective response to treatment. Hence, early diagnosis will often lead to appropriate treatment and rapid relief of pain.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of SUNCT and SUNA will be reviewed here. The management of these syndromes and the other trigeminal autonomic cephalalgias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2264?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=see_link\">",
"     \"Pathophysiology of the trigeminal autonomic cephalalgias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) is a rare primary headache syndrome first reported in 1978 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/4\">",
"     4",
"    </a>",
"    ], and later described more fully [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. It is currently grouped with cluster headache and paroxysmal hemicrania as a trigeminal autonomic cephalalgia (TAC), based upon the combination of head pain and activation of cranial autonomic efferents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. In 2004, SUNCT syndrome was included in the second edition of the International Classification of Headache Disorders-2 (ICHD-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/3\">",
"     3",
"    </a>",
"    ], as was the related syndrome of short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) (",
"    <a class=\"graphic graphic_table graphicRef74387 \" href=\"UTD.htm?14/4/14412\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both SUNCT and SUNA are rare headache syndromes, but the prevalence and incidence are uncertain. A study from Australia reported an estimated prevalence and annual incidence of 6.6 and 1.2 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, an epidemiologic study from Norway found two subjects with SUNCT-like syndromes in a population of 1838, corresponding to a prevalence of 109 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical age of onset is between 35 and 65, as seen in approximately two-thirds of primary SUNCT cases, but ranges from 5 to 88 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SUNCT appears to have a male predominance, with an earlier study reporting a male to female ratio of 4.25 to 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/5\">",
"     5",
"    </a>",
"    ]. In two later series, the male to female ratio was approximately 1.4 to 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. The decreasing male predominance in SUNCT and the emergence of new cases at the extremes of age of onset probably reflect an increasing recognition of these conditions rather than fundamental changes.",
"   </p>",
"   <p>",
"    Data for SUNA are insufficient to draw conclusions, but one report of nine patients included three men and six women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;SUNCT and SUNA are characterized by sudden brief attacks of severe unilateral head pain in orbital, periorbital, or temporal regions, accompanied by ipsilateral cranial autonomic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In SUNCT, the ipsilateral autonomic symptoms at a minimum consist of both conjunctival injection and lacrimation, and there may be other cranial autonomic symptoms, such as nasal congestion, rhinorrhea, ptosis, or eyelid edema.",
"   </p>",
"   <p>",
"    In SUNA, the autonomic symptoms may include conjunctival injection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lacrimation, or there may be other cranial autonomic symptoms (eg, nasal congestion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rhinorrhea, or eyelid edema).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Site of pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain in SUNCT and SUNA is unilateral and typically located in orbital, supraorbital, or temporal regions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. In addition, retroorbital pain is common.",
"   </p>",
"   <p>",
"    A minority of patients with SUNCT and SUNA have pain in other cranial areas, including the top, side or back of head, the nose, trigeminal V2 and V3 regions, the teeth, the neck,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the ear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Duration, frequency and temporal profile of individual attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICHD-2 criteria for SUNCT specifies an attack length of 5 to 240 seconds, with 3 to 200 attacks per day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/3\">",
"     3",
"    </a>",
"    ]. In a series of 43 patients with SUNCT and nine with SUNA, attacks could be categorized into one or more of three forms (",
"    <a class=\"graphic graphic_figure graphicRef74409 \" href=\"UTD.htm?30/38/31331\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single stabs of pain with a mean duration of 58 seconds (range 1-600 seconds)",
"     </li>",
"     <li>",
"      Groups of stabs of pain with a mean attack duration of 396 seconds (range 10-1200)",
"     </li>",
"     <li>",
"      \"Saw-tooth\" attack of continuous pain with multiple superimposed stabs and a mean attack duration of 1160 seconds (range 5-12,000)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients had more than one of these different types of attacks, and there was wide inter-patient variation in the length of attacks and number of attacks per day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"     13",
"    </a>",
"    ]. Since groups of stabs or saw-tooth attacks were made up of many individual stab attacks, a single attack could be perceived as longer than the 240 seconds specified by the ICHD-2 criteria, potentially leading to wrong diagnoses of paroxysmal hemicrania or cluster headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Periodicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, SUNCT is an episodic disorder, with bouts of attacks alternating with remissions. In an earlier report of 21 patients, symptomatic bouts typically occurred once or twice a year and lasted from days to months, with remissions lasting months at a time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/5\">",
"     5",
"    </a>",
"    ]. Results from another series of 24 patients with",
"    <span class=\"nowrap\">",
"     SUNCT/SUNA",
"    </span>",
"    suggested that the episodic form (attacks lasting seven days to one year, separated by a pain-free period lasting one month or longer) was more common than the chronic form (14 versus 10 subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the time since diagnosis was relatively short for most of the patients in this series, and the natural progression of these syndromes points to a tendency to become chronic. In a larger series of 52 patients with longer follow-up, a chronic form was noted in 27 of 43 patients (63 percent) with SUNCT and in all nine patients with SUNA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, cluster headache is episodic in the majority of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Interictal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not a classic symptom, background pain between attacks is sometimes present in patients with SUNCT. In one of the larger series, persistent background pain was present in 20 of 43 patients (47 percent) with SUNCT and two of nine with SUNA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"     13",
"    </a>",
"    ]. A persistent dull interictal ache with SUNCT was also described in two cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is one reported kindred of a family history of SUNCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/16\">",
"     16",
"    </a>",
"    ]. However, SUNCT and SUNA are so rare that an accurate evaluation of their genetic status is difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple triggers have been associated with SUNCT attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Touching the face or scalp",
"     </li>",
"     <li>",
"      Bathing or showering",
"     </li>",
"     <li>",
"      Washing or brushing hair",
"     </li>",
"     <li>",
"      Shaving",
"     </li>",
"     <li>",
"      Nose blowing",
"     </li>",
"     <li>",
"      Chewing or eating",
"     </li>",
"     <li>",
"      Brushing teeth",
"     </li>",
"     <li>",
"      Talking",
"     </li>",
"     <li>",
"      Coughing",
"     </li>",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Light (including sunlight and fluorescent lights)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neck movement may precipitate attacks in some patients or abort attacks in others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/5,6,18\">",
"     5,6,18",
"    </a>",
"    ]. Some triggers characteristically associated with cluster headache, such as alcohol, smoke, strong smells and a warm environment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/19\">",
"     19",
"    </a>",
"    ], can also trigger SUNCT or SUNA in a small proportion of patients.",
"   </p>",
"   <p>",
"    Patients can have a mixture of spontaneous and triggered attacks, but purely triggered attacks are rarely reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"     13",
"    </a>",
"    ]. A potential explanation is that some cases of purely triggered attacks may have been incorrectly diagnosed as trigeminal neuralgia. Thus, it is useful to recognize that occasional patients with SUNCT syndrome may experience only triggered attacks. In one of the larger series of 43 patients with SUNCT, a mixture of spontaneous and triggered attacks, purely spontaneous attacks, and purely triggered attacks occurred in 84, 14 and 2 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lack of refractory period",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike trigeminal neuralgia, SUNCT attacks generally do not have a refractory period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/5,10,13\">",
"     5,10,13",
"    </a>",
"    ]. In our series of 43 patients with SUNCT, spontaneous or triggered attacks could occur immediately after cessation of the previous attack in 41 patients (95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"     13",
"    </a>",
"    ]. For SUNA, attacks without a refractory period were observed in eight of nine patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic examination is usually normal in SUNCT, although ipsilateral trigeminal sensory findings are present in occasional patients. In our series, abnormal sensation to pinprick (mainly hypesthesia) in trigeminal V1 or V2 distribution was present in 6 of 43 patients (14 percent) with SUNCT and two of nine with SUNA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"     13",
"    </a>",
"    ]. Others have reported allodynia or hyperesthesia in the face [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/5,20-22\">",
"     5,20-22",
"    </a>",
"    ], a V1 sensory deficit in a patient with post-traumatic SUNCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/23\">",
"     23",
"    </a>",
"    ], and a patient with a persistent ipsilateral Horner syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SUNCT or SUNA is based upon a compatible clinical history, typically in the setting of a normal neurologic examination. The diagnosis is supported by a lack of response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    and oxygen.",
"   </p>",
"   <p>",
"    Brain MRI is suggested for all patients being evaluated for SUNCT and SUNA. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Neuroimaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Classification of Headache Disorders-2 (ICHD-2) criteria for SUNCT require at least 20 attacks fulfilling the following criteria (",
"    <a class=\"graphic graphic_table graphicRef74387 \" href=\"UTD.htm?14/4/14412\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attacks of unilateral, orbital, supraorbital or temporal stabbing or pulsating pain last 5 to 240 seconds",
"     </li>",
"     <li>",
"      Pain is accompanied by ipsilateral conjunctival injection and lacrimation",
"     </li>",
"     <li>",
"      Attacks occur with a frequency from 3 to 200 per day",
"     </li>",
"     <li>",
"      Not attributed to another disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In recognition of the possibility that all patients with generically the same condition might not have both conjunctival injection and tearing, the classification committee suggested that SUNCT syndrome may be a subset of SUNA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/3\">",
"     3",
"    </a>",
"    ]. In SUNA, there may be cranial autonomic symptoms other than conjunctival injection and lacrimation, or indeed only one of those symptoms may be present.",
"   </p>",
"   <p>",
"    The ICHD-2 criteria for SUNA require at least 20 attacks fulfilling the following criteria (",
"    <a class=\"graphic graphic_table graphicRef74387 \" href=\"UTD.htm?14/4/14412\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attacks of unilateral orbital, supraorbital or temporal stabbing pain lasting from 2 seconds to 10 minutes",
"     </li>",
"     <li>",
"      Pain is accompanied by one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Conjunctival injection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tearing",
"     </li>",
"     <li>",
"      Nasal congestion and or rhinorrhea",
"     </li>",
"     <li>",
"      Eyelid edema",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attacks occur with a frequency of &ge;1 per day for more than half the time",
"     </li>",
"     <li>",
"      Not attributed to another disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Distinguishing features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascertaining the length and type of attacks is necessary to distinguish SUNCT and SUNA from other trigeminal autonomic cephalalgias, and thus obtaining a good history is paramount. This point is particularly important when the episodes consist of a series of saw-tooth pattern attacks or groups of stabs that have a duration longer than the ICHD-2 diagnostic criterion of 240 seconds. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Duration, frequency and temporal profile of individual attacks'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnostic criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The presence of a cutaneous trigger and the lack of a refractory period between attacks, as well as the prominence of cranial autonomic symptoms, distinguish SUNCT from trigeminal neuralgia. In addition, cutaneous (or other) triggering of attacks and the lack of a response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    distinguish SUNCT from paroxysmal hemicrania and from hemicrania continua, which are both indomethacin-responsive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain MRI with good posterior fossa and pituitary imaging is suggested even if there are no unexplained neurologic abnormalities on examination, and brain MRI is recommended if such abnormalities are present. Neuroimaging is useful to exclude secondary SUNCT caused by pituitary, posterior fossa, or focal lesions. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Secondary SUNCT'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link\">",
"     \"Causes, presentation, and evaluation of sellar masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data suggest that in a high proportion of subjects with",
"    <span class=\"nowrap\">",
"     SUNCT/SUNA,",
"    </span>",
"    brain MRI shows an arterial loop contacting or deforming the trigeminal nerve. Given the potential benefit of surgical decompression of the trigeminal nerve, the diagnostic work-up of SUNCT and SUNA should also include dedicated MRI cuts of the trigeminal nerves. (See",
"    <a class=\"local\" href=\"#H18716521\">",
"     'Trigeminal neurovascular loop'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2264?source=see_link&amp;anchor=H24030013#H24030013\">",
"     \"SUNCT and SUNA headache syndromes: Treatment\", section on 'Trigeminal microvascular decompression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Response to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the diagnosis of SUNCT and SUNA is supported by a lack of response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    and oxygen, and by a good response to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    To aid in the diagnosis of SUNCT and SUNA, we suggest trials of intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    (where available) and oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A blinded parenteral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      test (the modified indotest) is useful to rule out paroxysmal hemicrania and hemicrania continua [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. This test is performed in two consecutive sessions with patients at baseline pain. In one session, indomethacin 100 mg is given by intramuscular injection. In the other session, saline placebo is given by intramuscular injection. A positive test requires a significant reduction in attacks after indomethacin but not after placebo. However, intramuscular indomethacin is not available in some countries, including the United States.",
"     </li>",
"     <li>",
"      The response to inhaled oxygen is helpful to exclude the diagnosis of cluster headache [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/28\">",
"       28",
"      </a>",
"      ]. Pure (100 percent) oxygen is applied via a nonrebreathing face mask with a flow rate of at least 7",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      (sometimes more than 10",
"      <span class=\"nowrap\">",
"       L/min)",
"      </span>",
"      for 15 minutes at the start of an attack with the patient sitting in an upright position. Oxygen is generally safe and without side effects. However, patients with severe chronic obstructive pulmonary disease should not be treated with inhaled oxygen because of the risk for developing severe hypercapnia and CO2 narcosis. Oxygen is effective for up to 78 percent of patients with cluster headache. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=see_link&amp;anchor=H4#H4\">",
"       \"Cluster headache: Acute and preventive treatment\", section on 'Oxygen'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a cohort of 10 patients with SUNCT and four with SUNA, the response to intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    was no different than the response to saline placebo in all patients (ie, the test was negative, ruling out paroxysmal hemicrania and hemicrania continua), and oxygen was ineffective in all (ie, suggesting that the diagnosis was not cluster headache) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for SUNCT and SUNA includes the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other trigeminal autonomic cephalalgias (ie, cluster headache and paroxysmal hemicrania)",
"     </li>",
"     <li>",
"      Hemicrania continua",
"     </li>",
"     <li>",
"      Trigeminal neuralgia",
"     </li>",
"     <li>",
"      Secondary causes of SUNCT and SUNA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In cases where attacks appear to be prolonged, the main alternative diagnostic considerations are paroxysmal hemicrania and cluster headache. In cases of constant interictal pain, the main alternative diagnostic consideration is hemicrania continua. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Trigeminal neuralgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SUNCT is often confused with trigeminal neuralgia, which is categorized as one of the cranial neuralgias and central causes of facial pain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/3\">",
"     3",
"    </a>",
"    ]. The distinction between trigeminal autonomic cephalalgias, such as SUNCT, and trigeminal neuralgia is, at least in part, the degree of cranial autonomic activation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to SUNCT and SUNA, trigeminal neuralgia can be precipitated by trivial stimuli such as washing, shaving, smoking, talking, and brushing the teeth, although attacks can occur spontaneously. The pains usually remit for variable periods. Neurovascular compression in the root entry zone of the trigeminal nerve in the cerebellopontine angle cistern is widely believed to be the essential mechanism for the pathogenesis of trigeminal neuralgia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link\">",
"     \"Trigeminal neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the short, stabbing nature of the attacks, the cutaneous triggering, and the association of cranial autonomic symptoms with pain in the trigeminal V1 distribution, the differentiation between trigeminal neuralgia and SUNCT has often been difficult, especially in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However the degree of cranial autonomic features in SUNCT is greater than in trigeminal neuralgia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/29,32\">",
"     29,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Secondary SUNCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;SUNCT is usually a primary headache syndrome. However, there are a number of cases that are potentially secondary to intracranial lesions, typically located either in the posterior fossa or in the pituitary gland, as described below. In addition, there are case reports of SUNCT following viral meningitis or meningoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/33,34\">",
"     33,34",
"    </a>",
"    ] and traumatic head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/23,35\">",
"     23,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also a report of SUNCT secondary to an infraorbital metastatic bronchial carcinoid [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/36\">",
"     36",
"    </a>",
"    ]. Although not in the posterior fossa, this report would meet proposed criteria to identify causal links in secondary SUNCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/37\">",
"     37",
"    </a>",
"    ]. These criteria are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A close temporal relationship between the associated disease and the onset of pain",
"     </li>",
"     <li>",
"      Side concordance between the unilateral pain and the lesion, if localized",
"     </li>",
"     <li>",
"      Prompt remission after etiologic medical therapy, or remission after surgery; sufficient post-treatment follow-up is needed to exclude recurrence of the headache attacks or improvement due to spontaneous remission",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Posterior fossa lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of SUNCT or SUNA associated with a posterior fossa abnormality include the following cases:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ipsilateral cerebellopontine arteriovenous malformation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Brainstem cavernous hemangioma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Posterior fossa lesion associated with",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Severe basilar impression causing pontomedullary compression in a patient with osteogenesis imperfecta [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Craniostosis resulting in a foreshortened posterior fossa [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Brainstem infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pilocytic astrocytoma expanding to the trigeminal root entry zone [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vascular loops compressing the trigeminal nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13,45\">",
"       13,45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Parietal and parieto-occipital space occupying lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pathologic white matter lesions associated with multiple sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vertebral artery dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pituitary lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;SUNCT has been described in patients both with microprolactinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13,48\">",
"     13,48",
"    </a>",
"    ] and macroprolactinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13,49,50\">",
"     13,49,50",
"    </a>",
"    ], with attacks occurring on the side ipsilateral to the side of the tumor. In addition, another patient with a pituitary macroadenoma had symptoms of SUNCT that were labeled as trigeminal neuralgia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/51\">",
"     51",
"    </a>",
"    ]. Headache symptoms can precede pituitary symptoms by 3 to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/49,51\">",
"     49,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such cases suggest a role for a direct mode of action in pituitary macroadenomas, but this mechanism would not account satisfactorily for microadenomas. An alternative hypothesis is that the attacks are mediated predominantly by a neurohormonal mechanism rather than by the size or invasiveness of the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/50,52\">",
"     50,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18716521\">",
"    <span class=\"h3\">",
"     Trigeminal neurovascular loop",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, several studies have reported the presence on brain MRI of a vascular loop contacting or compressing the trigeminal nerve ipsilateral to the pain of",
"    <span class=\"nowrap\">",
"     SUNCT/SUNA.",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In",
"      one series of 24 patients with",
"      <span class=\"nowrap\">",
"       SUNCT/SUNA,",
"      </span>",
"      17 patients had MRI with dedicated views of the trigeminal nerve, and an aberrant arterial loop contacting or deforming the symptomatic trigeminal was found in 15 cases (88 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an earlier series of 52 patients with",
"      <span class=\"nowrap\">",
"       SUNCT/SUNA,",
"      </span>",
"      44 were studied with cranial imaging (mainly MRI), and a vascular loop compressing the trigeminal nerve was reported in only three patients (7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"       13",
"      </a>",
"      ]. However, the subjects in this study were not investigated systematically with dedicated trigeminal views on MRI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings raise the possibility that peripheral mechanisms play a key role in the pathophysiology of SUNCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28648/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, some patients with",
"    <span class=\"nowrap\">",
"     SUNCT/SUNA",
"    </span>",
"    may benefit from trigeminal microvascular decompression, as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2264?source=see_link&amp;anchor=H24030013#H24030013\">",
"     \"SUNCT and SUNA headache syndromes: Treatment\", section on 'Trigeminal microvascular decompression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trigeminal autonomic cephalalgias are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features. The headache disorders included in this category are cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both SUNCT and SUNA are rare headache syndromes, but the precise prevalence and incidence are unknown. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SUNCT and SUNA are characterized by sudden brief attacks of severe unilateral head pain in orbital, periorbital or temporal regions, accompanied by ipsilateral cranial autonomic symptoms. In SUNCT, the ipsilateral autonomic symptoms consist of both conjunctival injection and lacrimation. In SUNA, the autonomic symptoms may include only one of conjunctival injection or lacrimation, or there may be other cranial autonomic symptoms (eg, nasal congestion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rhinorrhea, or eyelid edema). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with SUNCT or SUNA, attacks can take one or more of three forms (",
"      <a class=\"graphic graphic_figure graphicRef74409 \" href=\"UTD.htm?30/38/31331\">",
"       figure 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Duration, frequency and temporal profile of individual attacks'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Single stabs of pain",
"     </li>",
"     <li>",
"      Groups of stabs of pain",
"     </li>",
"     <li>",
"      \"Saw-tooth\" pattern of continuous pain with multiple superimposed stabs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SUNCT can be an episodic or chronic disorder. Attacks can be precipitated by multiple known triggers. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Periodicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Triggers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of SUNCT or SUNA is based upon a compatible clinical history, typically in the setting of a normal neurologic examination. Ascertaining the length and type of attacks is necessary to distinguish SUNCT and SUNA from other trigeminal autonomic cephalalgias. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For all patients with suspected SUNCT and SUNA, we suggest brain MRI with good posterior fossa and pituitary imaging beside dedicated MRI sections of the trigeminal nerve to exclude a secondary cause. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of SUNCT or SUNA is supported by lack of response to intramuscular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (not available in every country) and oxygen. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Response to treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis for SUNCT and SUNA includes cluster headache, paroxysmal hemicrania, hemicrania continua, trigeminal neuralgia, and secondary causes of SUNCT and SUNA. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/1\">",
"      Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 1997; 120 ( Pt 1):193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/2\">",
"      Goadsby PJ. Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 2005; 161:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/3\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     Sjaastad, O, Russell, D, Horven, I, Bunnaes, U. Multiple neuralgiform unilateral headache attacks associated with conjunctival injection and appearing in clusters. A nosological problem. Proceedings of the Scandinavian Migraine Society. Arhus, Denmark 1978. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/5\">",
"      Pareja JA, Sjaastad O. SUNCT syndrome. A clinical review. Headache 1997; 37:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/6\">",
"      Sjaastad O, Saunte C, Salvesen R, et al. Shortlasting unilateral neuralgiform headache attacks with conjunctival injection, tearing, sweating, and rhinorrhea. Cephalalgia 1989; 9:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/7\">",
"      May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/8\">",
"      Williams MH, Broadley SA. SUNCT and SUNA: clinical features and medical treatment. J Clin Neurosci 2008; 15:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/9\">",
"      Sjaastad O, Bakketeig LS. Cluster headache prevalence. V&aring;g&aring; study of headache epidemiology. Cephalalgia 2003; 23:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/10\">",
"      Matharu MS, Cohen AS, Boes CJ, Goadsby PJ. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review. Curr Pain Headache Rep 2003; 7:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/11\">",
"      S&eacute;khara T, Pelc K, Mewasingh LD, et al. Pediatric SUNCT Syndrome. Pediatr Neurol 2005; 33:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/12\">",
"      Vikelis M, Xifaras M, Mitsikostas DD. SUNCT syndrome in the elderly. Cephalalgia 2005; 25:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/13\">",
"      Cohen AS, Matharu MS, Goadsby PJ. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or cranial autonomic features (SUNA)--a prospective clinical study of SUNCT and SUNA. Brain 2006; 129:2746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/14\">",
"      Pareja JA, Joubert J, Sjaastad O. SUNCT syndrome. Atypical temporal patterns. Headache 1996; 36:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/15\">",
"      Matharu MS, Cohen AS, Goadsby PJ. SUNCT syndrome responsive to intravenous lidocaine. Cephalalgia 2004; 24:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/16\">",
"      Gantenbein AR, Goadsby PJ. Familial SUNCT. Cephalalgia 2005; 25:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/17\">",
"      Cohen AS, Gantenbein AR, Goadsby PJ. Abnormal blink reflex studies in a patient with supraorbital neuralgia. Cephalalgia 2006; 26:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/18\">",
"      Calvo JF, Bruera OC, de Lourdes Figuerola M, et al. SUNCT syndrome: clinical and 12-year follow-up case report. Cephalalgia 2004; 24:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/19\">",
"      Matharu MS, Goadsby PJ. Trigeminal autonomic cephalgias. J Neurol Neurosurg Psychiatry 2002; 72 Suppl 2:ii19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/20\">",
"      Graff-Radford SB. SUNCT syndrome responsive to gabapentin (Neurontin). Cephalalgia 2000; 20:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/21\">",
"      Sabatowski R, Huber M, Meuser T, Radbruch L. SUNCT syndrome: a treatment option with local opioid blockade of the superior cervical ganglion? A case report. Cephalalgia 2001; 21:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/22\">",
"      Raimondi E, Gardella L. SUNCT syndrome. Two cases in Argentina. Headache 1998; 38:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/23\">",
"      Putzki N, Nirkko A, Diener HC. Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome? Cephalalgia 2005; 25:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/24\">",
"      Prakash KM, Lo YL. SUNCT syndrome in association with persistent Horner syndrome in a Chinese patient. Headache 2004; 44:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/25\">",
"      Cohen AS. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing. Cephalalgia 2007; 27:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/26\">",
"      Matharu MS, Cohen AS, Frackowiak RS, Goadsby PJ. Posterior hypothalamic activation in paroxysmal hemicrania. Ann Neurol 2006; 59:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/27\">",
"      Matharu MS, Cohen AS, McGonigle DJ, et al. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache 2004; 44:747.",
"     </a>",
"    </li>",
"    <li>",
"     Lance, JW, Goadsby, PJ. Mechanism and Management of Headache. 7th ed, Elsevier, New York 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/29\">",
"      Goadsby PJ, Matharu MS, Boes CJ. SUNCT syndrome or trigeminal neuralgia with lacrimation. Cephalalgia 2001; 21:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/30\">",
"      Sesso RM. SUNCT syndrome or trigeminal neuralgia with lacrimation and conjunctival injection? Cephalalgia 2001; 21:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/31\">",
"      Cohen AS, Matharu MS, Goadsby PJ. SUNCT syndrome in the elderly. Cephalalgia 2004; 24:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/32\">",
"      Sjaastad O, Pareja JA, Zukerman E, et al. Trigeminal neuralgia. Clinical manifestations of first division involvement. Headache 1997; 37:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/33\">",
"      Ito Y, Yamamoto T, Ninomiya M, et al. Secondary SUNCT syndrome caused by viral meningitis. J Neurol 2009; 256:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/34\">",
"      Eguia P, Garcia-Monco JC, Ruiz-Lavilla N, et al. SUNCT and trigeminal neuralgia attributed to meningoencephalitis. J Headache Pain 2008; 9:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/35\">",
"      Jacob S, Saha A, Rajabally Y. Post-traumatic short-lasting unilateral headache with cranial autonomic symptoms (SUNA). Cephalalgia 2008; 28:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/36\">",
"      Black D, Swanson J, Eross E, Cutrer FM. Secondary SUNCT due to intraorbital, metastatic bronchial carcinoid. Cephalalgia 2005; 25:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/37\">",
"      Trucco M, Mainardi F, Maggioni F, et al. Chronic paroxysmal hemicrania, hemicrania continua and SUNCT syndrome in association with other pathologies: a review. Cephalalgia 2004; 24:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/38\">",
"      Bussone G, Leone M, Dalla Volta G, et al. Short-lasting unilateral neuralgiform headache attacks with tearing and conjunctival injection: the first \"symptomatic\" case? Cephalalgia 1991; 11:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/39\">",
"      Morales F, Mostacero E, Marta J, Sanchez S. Vascular malformation of the cerebellopontine angle associated with \"SUNCT\" syndrome. Cephalalgia 1994; 14:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/40\">",
"      De Benedittis G. SUNCT syndrome associated with cavernous angioma of the brain stem. Cephalalgia 1996; 16:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/41\">",
"      ter Berg JW, Goadsby PJ. Significance of atypical presentation of symptomatic SUNCT: a case report. J Neurol Neurosurg Psychiatry 2001; 70:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/42\">",
"      Mor&iacute;s G, Ribacoba R, Solar DN, Vidal JA. SUNCT syndrome and seborrheic dermatitis associated with craneosynostosis. Cephalalgia 2001; 21:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/43\">",
"      Penart A, Firth M, Bowen JR. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) following presumed dorsolateral brainstem infarction. Cephalalgia 2001; 21:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/44\">",
"      Bl&auml;ttler T, Capone Mori A, Boltshauser E, Bassetti C. Symptomatic SUNCT in an eleven-year-old girl. Neurology 2003; 60:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/45\">",
"      K&ouml;seoglu E, Karaman Y, K&uuml;c&uuml;k S, Arman F. SUNCT syndrome associated with compression of trigeminal nerve. Cephalalgia 2005; 25:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/46\">",
"      Vilisaar J, Constantinescu CS. SUNCT in multiple sclerosis. Cephalalgia 2006; 26:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/47\">",
"      Jacob S, Rajabally Y. Short-lasting unilateral neuralgiform headache with cranial autonomic symptoms (SUNA) following vertebral artery dissection. Cephalalgia 2007; 27:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/48\">",
"      Levy MJ, Matharu MS, Goadsby PJ. Prolactinomas, dopamine agonists and headache: two case reports. Eur J Neurol 2003; 10:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/49\">",
"      Massiou H, Launay JM, Levy C, et al. SUNCT syndrome in two patients with prolactinomas and bromocriptine-induced attacks. Neurology 2002; 58:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/50\">",
"      Matharu MS, Levy MJ, Merry RT, Goadsby PJ. SUNCT syndrome secondary to prolactinoma. J Neurol Neurosurg Psychiatry 2003; 74:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/51\">",
"      Ferrari MD, Haan J, van Seters AP. Bromocriptine-induced trigeminal neuralgia attacks in a patient with a pituitary tumor. Neurology 1988; 38:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/52\">",
"      Levy MJ, J&auml;ger HR, Powell M, et al. Pituitary volume and headache: size is not everything. Arch Neurol 2004; 61:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28648/abstract/53\">",
"      Irimia P, Gonz&aacute;lez-Redondo R, Dom&iacute;nguez PD, et al. Microvascular decompression may be effective for refractory SUNCT regardless of symptom duration. Cephalalgia 2010; 30:626.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3336 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28648=[""].join("\n");
var outline_f27_62_28648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Site of pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Duration, frequency and temporal profile of individual attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Periodicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interictal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Triggers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lack of refractory period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Distinguishing features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Response to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Secondary SUNCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Posterior fossa lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pituitary lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18716521\">",
"      - Trigeminal neurovascular loop",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3336\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3336|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/38/31331\" title=\"figure 1\">",
"      SUNCT SUNA attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3336|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/12/42188\" title=\"table 1\">",
"      Clinical features trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/4/14412\" title=\"table 2\">",
"      Diagnostic criteria SUNCT SUNA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=related_link\">",
"      Cluster headache: Acute and preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=related_link\">",
"      Paroxysmal hemicrania: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=related_link\">",
"      Pathophysiology of the trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2264?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_62_28649="Methods to overcome radiation resistance in head and neck cancer";
var content_f27_62_28649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Methods to overcome radiation resistance in head and neck cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28649/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28649/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28649/contributors\">",
"     Everett E Vokes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28649/contributors\">",
"     David S Yoo, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28649/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28649/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28649/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28649/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/62/28649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) plays a major role in the management of patients with head and neck squamous cell carcinoma. However, locoregional failure remains a significant problem [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/1\">",
"     1",
"    </a>",
"    ]. Individual patients, even those with similarly sized and staged tumors, can respond differently to RT. Radioresistance is a broad term that describes the relative resistance of individual cells, tissues, organs, or entire organisms to the biologic effects of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concomitant administration of chemotherapy with RT, referred to as concurrent chemoradiation, is the most effective approach to overcoming radioresistance, although this approach is not always feasible or successful [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/1\">",
"     1",
"    </a>",
"    ]. Mechanisms of radioresistance to RT in head and neck cancer and strategies used to overcome this resistance are presented here. Concurrent chemoradiotherapy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF RADIORESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many factors affect the responsiveness of tumors to radiation therapy (RT). Relevant factors included the primary tumor (volume, size, grade) or the patient (hemoglobin levels, smoking status) and biologic factors (hypoxia, intrinsic radiosensitivity, proliferation status, expression of deoxyribonucleic acid (DNA) repair genes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical factors affecting radiation response",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Primary tumor characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complexity and variability of clinical outcomes in head and neck cancer are reflected in the spectrum of T stage descriptors used in the American Joint Committee on Cancer-International Union for Cancer Control (AJCC-UICC) TNM staging system for the different primary sites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/3\">",
"     3",
"    </a>",
"    ]. Larger tumors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with more extensive local invasion have higher T classifications, corresponding to a likely higher malignant cell burden and poorer prognosis.",
"   </p>",
"   <p>",
"    Radiation-related cell killing is a random event; the potentially lethal DNA double-strand breaks induced by irradiation are distributed randomly throughout the radiation-sensitive cells and will not kill them all. As tumor burden increases, the probability of lethally damaging all of the cancer cells decreases, even if the total dose is escalated to high levels.",
"   </p>",
"   <p>",
"    The location of the primary tumor site may influence response to therapy. As an example, oral cavity tumors demonstrate poorer response to RT than laryngeal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/4\">",
"     4",
"    </a>",
"    ]. Tumor grade may also play a role. Well-differentiated tumors, which retain the ability to accelerate repopulation during RT, are characteristically more radioresistant than their moderately and poorly differentiated counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Repopulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hemoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower pretreatment hemoglobin levels (&lt;14.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for men and &lt;13",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for women) are correlated with reduced local control and survival in patients with head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, the relationship between hemoglobin concentration, tumor oxygenation status, and radioresistance is complex. Most anemic patients have tumors that are hypoxic, but the absence of anemia does not ensure that a tumor will be well oxygenated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Smoking status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with head and neck cancer who continue to smoke during RT have lower rates of response and survival than patients who do not smoke during RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Biological factors determining radiation response",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hypoxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high-energy photons used in RT exert their biologic effects via secondary electrons generated in tissue through a process known as the Compton effect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/9\">",
"     9",
"    </a>",
"    ]. These secondary electrons induce DNA damage through both direct and indirect actions. With direct action, the electrons interact with and ionize atoms of the DNA helix. With indirect action, the electrons first ionize molecules around the DNA, such as water, producing highly reactive free radical species that then interact with and damage DNA. Unrepaired DNA damage leads to inhibition of cell proliferation, fatal chromosomal aberrations, and cell death. For photon radiation, the indirect mechanism predominates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of oxygen enhances the indirect process by prolonging the life span of the highly reactive free radicals generated by indirect ionization. Additionally, oxygen decreases the ability of cells to repair sublethal DNA damage, reacting with the broken ends of DNA to create stable organic peroxides that are not as readily repaired [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/10\">",
"     10",
"    </a>",
"    ]. Well-oxygenated cells are two and one-half to three times more radiosensitive than hypoxic cells (pO2 &lt;10 mmHg), a relationship described by the oxygen enhancement ratio (OER): the ratio of RT doses needed in hypoxic versus aerobic conditions to achieve the same biologic effect.",
"   </p>",
"   <p>",
"    Intratumor hypoxia can be chronic, arising as the tumor outgrows the limits of its blood supply, or acute, when there is a disruption in microregional blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/11\">",
"     11",
"    </a>",
"    ]. Tumor hypoxia in head and neck cancer correlates with radioresistance and is an adverse prognostic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In one report, patients with a median tumor pO2 &gt;10 mmHg compared to those with tumor pO2 levels &lt;10 mmHg had significantly better two-year local control (82 versus 41 percent), disease-free survival (70 versus 31 percent) and overall survival (80 versus 46 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other biologic mechanisms also modulate the link between hypoxia and radiosensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/10\">",
"     10",
"    </a>",
"    ]. Many signaling pathways are impacted by hypoxia, including those involved in angiogenesis, glucose transport, pH regulation, and erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, the hypoxia-inducible factor (HIF) family of transcription factors plays an important role in the cellular response to oxygen homeostasis in vivo. HIF-1-alpha overexpression is seen in over half of all head and neck cancers and correlates with poor response to RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The overexpression of the HIF-1-regulated hypoxia-related protein lysyl oxidase is associated with increased metastases, progression, and death in patients with head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, there is also evidence that HIF-1 inhibition may both suppress and enhance the effects of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Repopulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repopulation is defined as regrowth of tumor cells after the initiation of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/20\">",
"     20",
"    </a>",
"    ]. Accelerated tumor cell repopulation is an important factor contributing to the radioresistance of head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/21\">",
"     21",
"    </a>",
"    ]. Potential mechanisms include accelerated stem cell division, loss in asymmetrical division, and cell recruitment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accelerated stem cell division describes the shortening of the cell cycle after the start of RT. Loss in asymmetry refers to the shift in stem cells from asymmetric division, which produces one stem cell and one progenitor cell with limited self-renewal potential, to symmetric division, which gives rise to two identical stem cells. Lastly, quiescent cells in G0 phase may be recruited to re-enter more active phases of the cell cycle.",
"   </p>",
"   <p>",
"    Cyclins, cyclin inhibitors, Ki-67, and the epidermal growth factor receptor (EGFR) may all serve as markers of tumor proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/14\">",
"     14",
"    </a>",
"    ]. Expression of Ki-67 and EGFR has been associated with radioresistance and has been studied to select patients for and predict response to regimens aimed to overcome repopulation, such as accelerated radiotherapy or anti-EGFR therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/20,23,24\">",
"     20,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Inherent tumor cell radioresistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differences in intrinsic tumor cell radiosensitivity are seen experimentally and may contribute significantly to radiation failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Head and neck cancers associated with the human papillomavirus (HPV) have an improved prognosis relative to HPV negative tumors. There is some data to suggest that the better prognosis of these tumors may be attributable to their enhanced sensitivity to chemotherapy and radiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cancer stem cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential role of cancer stem cells in radioresistance has been demonstrated in an increasing number of solid cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. If not eliminated by RT, stem cells have the capacity to self-renew and differentiate into the heterogeneous cells that constitute a tumor mass [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Experimental evidence suggests that a higher proportion of cancer stem cells within a tumor correlate with higher radioresistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/33\">",
"     33",
"    </a>",
"    ]. Furthermore, cancer stem cells have been shown to possess inherent resistance mechanisms, such as amplified checkpoint activation and DNA damage repair [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/34\">",
"     34",
"    </a>",
"    ]. Extrinsic factors, such as hypoxia, may also impact on the radioresistance of cancer stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioresistance may also occur as a consequence of other biologic factors: amplification of DNA repair genes, increased cellular production of free radical scavengers (eg, glutathione), activation of certain proto-oncogenes, and stromal interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, the excision repair cross-complementation group 1 protein (ERCC1) is a drug-resistance related DNA repair protein that prevents apoptosis of cancer cells by removing platinum-DNA adducts generated by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . ERCC1 may also play a role in the repair of radiation-induced DNA damage. High expression of ERCC1 in nasopharyngeal cancer patients has been associated with poor survival after concurrent chemoradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, cells with a mutated p53 tumor suppressor gene fail to arrest at the",
"    <span class=\"nowrap\">",
"     G1/S",
"    </span>",
"    cell cycle checkpoint following irradiation and are less likely to undergo apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/37\">",
"     37",
"    </a>",
"    ]. Similarly, overexpression of survivin, an oncogene of the inhibitor of apoptosis (IAP) family, may contribute to treatment resistance via negative regulation of programmed cell death and enhanced DNA repair [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radioresistance involves a complex interplay between biologic processes. Investigators are applying genomics, proteomics, and gene expression profiling techniques to identify new targets and novel interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     STRATEGIES TO OVERCOME RADIORESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple strategies have been developed and tested in randomized clinical trials to improve the clinical results obtained with conventional radiation therapy (RT) given alone. The most successful techniques to date have combined RT with concurrent systemic therapy (either chemotherapy or molecularly targeted agents).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262962680\">",
"    <span class=\"h1\">",
"     CONCURRENT SYSTEMIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262963170\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent chemoradiotherapy exploits the additive and synergistic effects that result when chemotherapy and RT are used together. Preclinical studies suggest that many chemotherapeutic agents contribute to improved outcomes through additive effects, via the independent cytotoxic action of the drugs themselves, as well as through synergistic effects in which the drugs alter cell radiosensitivity.",
"   </p>",
"   <p>",
"    Chemotherapy agents with radiosensitizing properties in vitro include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    . Many mechanisms have been proposed to explain how the addition of chemotherapy augments the effects of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Making DNA more susceptible to radiation damage and augmenting cell killing",
"     </li>",
"     <li>",
"      Interfering with cellular DNA repair after sublethal or potentially lethal damage (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reducing tumor cell repopulation by enhancing the cytotoxic effect (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reducing the population of hypoxic tumor cells (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C)",
"     </li>",
"     <li>",
"      Exerting cytotoxic effects in the radioresistant S phase (camptothecins)",
"     </li>",
"     <li>",
"      Redistribution and accumulation of cells into the more radiosensitive G2 and M phases (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Promoting apoptosis",
"     </li>",
"     <li>",
"      Inhibiting angiogenesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Concurrent chemoradiotherapy improves locoregional control and survival compared to RT alone for head and neck cancer patients with unresectable disease and for those in whom a functional organ preservation strategy provides a nonsurgical alternative for cure while maintaining quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/1\">",
"     1",
"    </a>",
"    ]. To date, concurrent chemoradiation remains the most effective strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262963057\">",
"    <span class=\"h2\">",
"     Molecularly targeted agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecularly targeted agents may also potentiate the effects of radiation by targeting specific cell signaling pathways involved with radioresistance.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    , a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), inhibits tumor proliferation and has been shown to improve locoregional control and overall survival in combination with RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H281027372#H281027372\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Epidermal growth factor inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other novel agents, which are in preclinical or early clinical investigation, target key components of various signaling pathways, including those for angiogenesis (VEGF), DNA repair and apoptosis (PARP), hypoxia (HIF-1), and proliferation",
"    <span class=\"nowrap\">",
"     (PI3-kinase/AKT)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Altered fractionation RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT regimens using accelerated fractionation regimen can shorten the overall treatment duration, thereby attempting to minimize tumor repopulation as a cause of treatment failure. Pure hyperfractionation regimens, by treating twice daily with smaller fraction sizes, permit a higher total radiation dose without increasing late toxicity. Late effects on normal tissues are influenced by the individual dose fraction size. Altered fractionation strategies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link&amp;anchor=H1493367204#H1493367204\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\", section on 'Accelerated fractionation RT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link&amp;anchor=H99325300#H99325300\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\", section on 'Hyperfractionation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Altered fractionation of the RT has also been studied in conjunction with concurrent chemotherapy. The results of these studies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H281027852#H281027852\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'RT treatment plan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262962536\">",
"    <span class=\"h1\">",
"     OTHER APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other approaches have been studied clinically in an effort to overcome the radiation response observed clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Targeting hypoxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxia may be an important contributor to radiation resistance. Several different strategies have been aimed at reducing the effects of hypoxia on radiation resistance. None of these have achieved widespread clinical utilization. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Hypoxia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262963472\">",
"    <span class=\"h3\">",
"     Hypoxic cell sensitizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most extensively studied agents are the hypoxic cell sensitizers or oxygen mimetics, including misonidazole, nimorazole, and other related compounds. These have been studied in numerous randomized trials in patients with head and neck cancer, most extensively in Europe.",
"   </p>",
"   <p>",
"    A systematic review of the literature and meta-analysis analyzed results from 18 trials that included almost 3400 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/45\">",
"     45",
"    </a>",
"    ]. The addition of these agents significantly improved locoregional control and decreased disease-specific deaths (odds ratios [ORs] 0.76, 95% CI 0.66-0.88 and 0.74, 95% CI 0.64-0.86, respectively), although the difference in overall survival was not significant (OR 0.87, 95% CI 0.75-1.02, p = 0.08).",
"   </p>",
"   <p>",
"    Clinical interest in these drugs has been hampered by their marginal efficacy as well as dose-limiting toxicities (eg, delayed peripheral neuropathy with misonidazole).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbaric oxygen therapy increases the amount of oxygen in the blood and has been studied in a variety of tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/46\">",
"     46",
"    </a>",
"    ]. The amount of dissolved plasma oxygen is 0.3",
"    <span class=\"nowrap\">",
"     mL/dL",
"    </span>",
"    at 1.0 atmosphere; this is increased to 1.5",
"    <span class=\"nowrap\">",
"     mL/dL",
"    </span>",
"    upon administration of 100 percent oxygen, and to 6",
"    <span class=\"nowrap\">",
"     mL/dL",
"    </span>",
"    with hyperbaric oxygen delivered at 3.0 atm. Despite this theoretical advantage, studies using hyperbaric oxygen during RT for head and neck cancer have been disappointing.",
"   </p>",
"   <p>",
"    A systemic review and meta-analysis that included nine trials with 624 patients found that hyperbaric oxygen significantly improved locoregional control and decreased disease-specific deaths (odds ratio [OR] 0.46, 95% CI 0.33-0.64 and OR 0.58 95% CI 0.42-0.81, respectively), although the difference in overall survival was not statistically significant (OR 0.73, 95% CI 0.51-1.05, p = 0.09) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262963415\">",
"    <span class=\"h3\">",
"     Carbogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inhalation of either pure normobaric oxygen or carbogen (95 percent oxygen-5 percent carbon dioxide) during RT, potentially combined with oral nicotinamide (a hypoxic cell sensitizer) and accelerated radiation (ARCON treatment), has been investigated as another method for increasing the local oxygen concentration.",
"   </p>",
"   <p>",
"    A meta-analysis of five trials containing 784 patients using these oxygen inhalation approaches found that locoregional control, disease-specific deaths, and overall survival were not significantly improved using these approaches (ORs 0.73, 0.83, and 0.96, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262963905\">",
"    <span class=\"h3\">",
"     Functional imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic studies such as dynamic contrast-enhanced magnetic resonance imaging and hypoxia-specific positron emission tomography (PET) scans can non-invasively and indirectly measure tumor hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Work is ongoing to establish reproducible and relevant imaging correlations that can guide future clinical decision making. With their ability to capture and display regional differences in hypoxia within tumors, these imaging modalities provide potential physical targets for radiation dose escalation via highly conformal RT delivery technologies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. However, serial imaging has shown day to day variability in the spatial distribution of tumor hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/52\">",
"     52",
"    </a>",
"    ]. Moving targets can be missed, and thus may be a source of local failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Hypoxic cell cytotoxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tirapazamine is an hypoxic cell cytotoxic that selectively killed hypoxic cells in preclinical experiments and phase I-II studies and potentiated the effects of RT and chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/53\">",
"     53",
"    </a>",
"    ]. However, a large phase III trial failed to demonstrate a survival advantage for the addition of tirapazamine to radiation and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/54\">",
"     54",
"    </a>",
"    ]. A second phase III trial was closed early due to excess mortality when tirapazamine was combined with cisplatin plus RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Correction of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of anemia, with either transfusion or the use of erythropoiesis-stimulating agents, has been postulated to decrease tumor hypoxia, reduce radioresistance, and thereby improve clinical outcomes. However, there is no direct evidence to support these approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262963824\">",
"    <span class=\"h3\">",
"     Transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion prior to and during treatment failed to improve the outcome in patients with low hemoglobin levels in the Danish Head and Neck Cancer (DAHANCA) 5 study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/56\">",
"     56",
"    </a>",
"    ]. In this trial, patients were randomly assigned to the hypoxic radiosensitizer nimorazole or placebo. In addition, 171 patients with low hemoglobin levels (women &lt;13",
"    <span class=\"nowrap\">",
"     g/dl",
"    </span>",
"    and men &lt;14.5",
"    <span class=\"nowrap\">",
"     g/dl)",
"    </span>",
"    were randomly assigned to transfusion or not. Although transfusion increased hemoglobin levels for most patients, receipt of transfusion did not improve locoregional control, disease-specific survival, or overall survival (hazard ratios [HRs] 0.99, 1.07, and 1.10, respectively). Correction of baseline anemia might improve the efficacy of RT in the subset of patients with more severe anemia, but there currently is no evidence to support this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262963844\">",
"    <span class=\"h3\">",
"     Erythropoiesis-stimulating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythropoiesis-stimulating agents can reduce chemotherapy-induced anemia and the need for transfusions in head and neck cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Retrospective data demonstrated that erythropoiesis-stimulating agents used prior to or during chemoradiation in oral cavity and oropharyngeal tumors corrected anemia and overcame the adverse prognostic effect of low pretreatment hemoglobin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/59\">",
"     59",
"    </a>",
"    ]. However, subsequent prospective trials have failed to confirm a clinical benefit from this approach. In fact, many trials were closed based upon interim analyses due to consistently worse outcomes in patients who received erythropoiesis- stimulating agents during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large multi-institutional phase III trial, 351 anemic (hemoglobin &lt;13",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for men and &lt;12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for women) patients undergoing RT were randomly assigned to epoetin beta, with the goal of raising hemoglobin concentration to &ge;15",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in men and &ge;14",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in women, or placebo. Locoregional progression-free survival was significantly worse in those assigned to epoetin beta than to placebo (adjusted relative risk (RR) 1.62, 95% CI 1.22-2.14) as was overall survival (RR for death 1.39, 95% CI 1.05-1.84) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Cochrane review examined the use of erythropoiesis-stimulating agents with RT or chemoradiotherapy in five trials with a total of 1397 head and neck cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/62\">",
"     62",
"    </a>",
"    ]. Of note, the target hemoglobin concentration was higher than recommended in four of the five trials. Significantly worse overall survival was seen in the patients who received an erythropoiesis-stimulating agent (odds ratio 0.73; 95 percent CI 0.58 to 0.91; p = 0.005).",
"   </p>",
"   <p>",
"    Reasons for the adverse outcomes associated with the use of erythropoiesis-stimulating agents during RT are unclear. These trials attempted to correct hemoglobin concentration to supraphysiologic levels, and it has been suggested that an excess of thromboembolic events may have contributed to the worse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/63\">",
"     63",
"    </a>",
"    ]. Erythropoiesis-stimulating agents may also promote tumor progression, as erythropoietin receptors are expressed in head and neck cancer cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/64\">",
"     64",
"    </a>",
"    ]. A follow-up analysis of samples from a phase III trial found that increased expression of the erythropoietin receptor was associated with a poorer local progression-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The issues surrounding the use of erythropoiesis-stimulating agents in cancer patients are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Currently, the Food and Drug Administration (FDA) requires all erythropoiesis-stimulating agents to be prescribed and used under a risk evaluation and mitigation strategy (REMS) with clear understanding by treating physicians and patients of the poorer survival, increased risk of treatment failure, and life-threatening side effects associated with their use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/66\">",
"     66",
"    </a>",
"    ]. Transfusion remains an acceptable option to treat anemia in patients with head and neck cancer undergoing RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Radioprotectors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concomitant administration of a systemic agent that protects normal tissues from the effects of irradiation may reduce treatment-related toxicity, potentially allowing for the use of higher RT doses to overcome radioresistance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"       Amifostine",
"      </a>",
"      , a thiol-containing compound that may act as a free radical scavenger, has been shown to reduce the risk of xerostomia in head and neck cancer patients treated with RT alone; its role in combination with chemoradiotherapy and the higher doses of radiation used in contemporary treatment regimens remains uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722454217#H722454217\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Amifostine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=see_link\">",
"       Palifermin",
"      </a>",
"      , a recombinant keratinocyte growth factor, significantly decreased the incidence of severe mucositis in randomized trials in patients with head and neck cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722454631#H722454631\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Palifermin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    has an established role in conjunction with the use of higher doses of radiation and to try to overcome radioresistance and risk of locoregional failure in patients with head and neck cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262963571\">",
"    <span class=\"h2\">",
"     Hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermia involves the heating of tissues to supraphysiologic temperatures; its concurrent use with RT may enhance the tumor response to radiation via additive and synergistic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The independent cytotoxic effects of hyperthermia are complementary to RT. Cells in S-phase, the most radioresistant part of the cell cycle, are the most sensitive to hyperthermia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Moreover, unlike RT, hypoxic conditions may also make cells more sensitive to hyperthermia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/74\">",
"     74",
"    </a>",
"    ]. Synergistic radiosensitization by hyperthermia may occur via inhibition of DNA repair pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Finally, at more moderate temperatures, hyperthermia can improve blood flow, leading to increased perfusion, reoxygenation, and decreased hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials in locally advanced HNSCC patients showed improved tumor control with the use of hyperthermia concurrent with RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28649/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. However, these trials were conducted in small numbers of patients using older techniques and dosing regimens, and their clinical relevance is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple clinical and biologic factors contribute to the development of radioresistance, which remains a significant obstacle to optimal locoregional disease control in patients with squamous cell carcinomas of the head and neck. Large tumors, continued smoking, and pretreatment anemia are clinical factors that have been inversely correlated with locoregional control. Tumor hypoxia, repopulation, cancer stem cells, and inherent differences in tumor cell radiosensitivity are biologic factors that have been identified as strongly correlating with radioresistance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of radioresistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Concurrent chemoradiotherapy currently is the standard of care to improve outcomes in patients who are treated with RT for head and neck cancer. Concurrent chemoradiotherapy improves locoregional control and survival compared to RT alone for head and neck cancer patients with unresectable disease and for those in whom a functional organ preservation strategy provides a nonsurgical alternative for cure while maintaining quality of life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Various approaches to target hypoxia have been evaluated in randomized clinical trials. Although these techniques may improve locoregional control, their clinical impact is less than that of concurrent chemoradiotherapy and they do not have a major role in the management of head and neck cancer patients. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Targeting hypoxia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the correction of anemia has a strong theoretical rationale, the available evidence does not support the routine use of transfusions or erythropoiesis stimulating agents in patients with head and neck cancer, and these approaches may actually worsen outcomes. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Correction of anemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/1\">",
"      Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011; 100:33.",
"     </a>",
"    </li>",
"    <li>",
"     Hall EJ, Giaccia AJ. Radiobiology for the radiologist, 6th, Lippincott, Williams and Wilkins, Philadelphia 2006.",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/4\">",
"      Dinshaw KA, Agarwal JP, Ghosh-Laskar S, et al. Radical radiotherapy in head and neck squamous cell carcinoma: an analysis of prognostic and therapeutic factors. Clin Oncol (R Coll Radiol) 2006; 18:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/5\">",
"      Hansen O, Overgaard J, Hansen HS, et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol 1997; 43:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/6\">",
"      Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998; 42:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/7\">",
"      Prosnitz RG, Yao B, Farrell CL, et al. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2005; 61:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/8\">",
"      Duffy SA, Ronis DL, McLean S, et al. Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol 2009; 27:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/9\">",
"      Compton AH. On the Mechanism of X-Ray Scattering. Proc Natl Acad Sci U S A 1925; 11:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/10\">",
"      Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 2007; 26:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/11\">",
"      Horsman MR. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol 1995; 34:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/12\">",
"      Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/13\">",
"      Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/14\">",
"      Silva P, Homer JJ, Slevin NJ, et al. Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Clin Otolaryngol 2007; 32:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/15\">",
"      Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61:2911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/16\">",
"      Winter SC, Shah KA, Han C, et al. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006; 107:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/17\">",
"      Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/18\">",
"      Le QT, Harris J, Magliocco AM, et al. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol 2009; 27:4281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/19\">",
"      Harada H, Itasaka S, Zhu Y, et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 2009; 100:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/20\">",
"      Tarnawski R, Fowler J, Skladowski K, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys 2002; 54:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/21\">",
"      Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/22\">",
"      Marcu L, van Doorn T, Olver I. Modelling of post-irradiation accelerated repopulation in squamous cell carcinomas. Phys Med Biol 2004; 49:3767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/23\">",
"      Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23:5560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/24\">",
"      Couture C, Raybaud-Diog&egrave;ne H, T&ecirc;tu B, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002; 94:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/25\">",
"      Gerweck LE, Vijayappa S, Kurimasa A, et al. Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res 2006; 66:8352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/26\">",
"      Ogawa K, Boucher Y, Kashiwagi S, et al. Influence of tumor cell and stroma sensitivity on tumor response to radiation. Cancer Res 2007; 67:4016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/27\">",
"      Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/28\">",
"      Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 2006; 24:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/29\">",
"      Milas L, Hittelman WN. Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin Radiat Oncol 2009; 19:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/30\">",
"      O'Brien CA, Kreso A, Dick JE. Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol 2009; 19:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/31\">",
"      Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66:9339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/32\">",
"      Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res 2006; 66:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/33\">",
"      Yaromina A, Krause M, Thames H, et al. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol 2007; 83:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/34\">",
"      Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/35\">",
"      Heddleston JM, Li Z, Lathia JD, et al. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/36\">",
"      Lee HW, Hwang YH, Han JH, et al. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer. Oral Oncol 2010; 46:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/37\">",
"      Guillouf C, Rosselli F, Krishnaraju K, et al. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 1995; 10:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/38\">",
"      Jiang G, Ren B, Xu L, et al. Survivin may enhance DNA double-strand break repair capability by up-regulating Ku70 in human KB cells. Anticancer Res 2009; 29:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/39\">",
"      Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol 2007; 4:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/40\">",
"      Khosravi Shahi P, Fern&aacute;ndez Pineda I. Tumoral angiogenesis: review of the literature. Cancer Invest 2008; 26:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/41\">",
"      Moeller BJ, Dreher MR, Rabbani ZN, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005; 8:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/42\">",
"      Jorgensen TJ. Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther 2009; 8:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/43\">",
"      Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008; 9:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/44\">",
"      Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008; 35:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/45\">",
"      Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. Radiother Oncol 2011; 100:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/46\">",
"      Bennett MH, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev 2012; 4:CD005007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/47\">",
"      Newbold K, Castellano I, Charles-Edwards E, et al. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/48\">",
"      Lapi SE, Voller TF, Welch MJ. Positron Emission Tomography Imaging of Hypoxia. PET Clin 2009; 4:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/49\">",
"      Rischin D, Fisher R, Peters L, et al. Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. Int J Radiat Oncol Biol Phys 2007; 69:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/50\">",
"      S&oslash;vik A, Malinen E, Olsen DR. Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys 2009; 73:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/51\">",
"      Flynn RT, Bowen SR, Bentzen SM, et al. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol 2008; 53:4153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/52\">",
"      Lin Z, Mechalakos J, Nehmeh S, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 2008; 70:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/53\">",
"      Brown JM, Wang LH. Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Des 1998; 13:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/54\">",
"      Rischin D, Peters LJ, O'Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28:2989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/55\">",
"      Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007; 4:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/56\">",
"      Hoff CM, Hansen HS, Overgaard M, et al. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study. Radiother Oncol 2011; 98:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/57\">",
"      Dunphy FR, Harrison BR, Dunleavy TL, et al. Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy. Cancer 1999; 86:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/58\">",
"      Dunphy FR, Dunleavy TL, Harrison BR, et al. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 1997; 79:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/59\">",
"      Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/60\">",
"      Henke M, Laszig R, R&uuml;be C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/61\">",
"      Machtay M, Pajak TF, Suntharalingam M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys 2007; 69:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/62\">",
"      Lambin P, Ramaekers BL, van Mastrigt GA, et al. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev 2009; :CD006158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/63\">",
"      Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/64\">",
"      Mohyeldin A, Lu H, Dalgard C, et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005; 7:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/65\">",
"      Miller CP, Lowe KA, Valliant-Saunders K, et al. Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells 2009; 27:2353.",
"     </a>",
"    </li>",
"    <li>",
"     FDA website available online at file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM109375 (Accessed on October 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/67\">",
"      Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol 2011; 29:2808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/68\">",
"      Henke M, Alfonsi M, Foa P, et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol 2011; 29:2815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/69\">",
"      Jones EL, Oleson JR, Prosnitz LR, et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005; 23:3079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/70\">",
"      Prosnitz LR, Maguire P, Anderson JM, et al. The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy. Int J Radiat Oncol Biol Phys 1999; 45:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/71\">",
"      van der Zee J, Gonz&aacute;lez Gonz&aacute;lez D, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000; 355:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/72\">",
"      Westra A, Dewey WC. Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1971; 19:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/73\">",
"      TERASIMA T, TOLMACH LJ. Variations in several responses of HeLa cells to x-irradiation during the division cycle. Biophys J 1963; 3:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/74\">",
"      Gerweck LE, Nygaard TG, Burlett M. Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Res 1979; 39:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/75\">",
"      Mivechi NF, Miyachi H, Scanlon KJ. Heat radiosensitization and the level of DNA polymerases alpha and beta of human colony-forming unit-granulocyte-macrophage and myeloid leukemias sensitive and resistant to chemotherapeutic agents. Cancer Res 1990; 50:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/76\">",
"      Raaphorst GP, Ng CE, Yang DP. Thermal radiosensitization and repair inhibition in human melanoma cells: a comparison of survival and DNA double strand breaks. Int J Hyperthermia 1999; 15:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/77\">",
"      Brizel DM, Scully SP, Harrelson JM, et al. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res 1996; 56:5347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/78\">",
"      Datta NR, Bose AK, Kapoor HK, Gupta S. Head and neck cancers: results of thermoradiotherapy versus radiotherapy. Int J Hyperthermia 1990; 6:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28649/abstract/79\">",
"      Valdagni R, Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys 1994; 28:163.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3371 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.55.141.10-EC79731216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28649=[""].join("\n");
var outline_f27_62_28649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF RADIORESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical factors affecting radiation response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Primary tumor characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hemoglobin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Smoking status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Biological factors determining radiation response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hypoxia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Repopulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Inherent tumor cell radioresistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cancer stem cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      STRATEGIES TO OVERCOME RADIORESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262962680\">",
"      CONCURRENT SYSTEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H262963170\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H262963057\">",
"      Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Altered fractionation RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262962536\">",
"      OTHER APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Targeting hypoxia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262963472\">",
"      - Hypoxic cell sensitizers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262963415\">",
"      - Carbogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262963905\">",
"      - Functional imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Hypoxic cell cytotoxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Correction of anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262963824\">",
"      - Transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262963844\">",
"      - Erythropoiesis-stimulating agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Radioprotectors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H262963571\">",
"      Hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_62_28650="Overview of water-soluble vitamins";
var content_f27_62_28650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of water-soluble vitamins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28650/contributors\">",
"     Sassan Pazirandeh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28650/contributors\">",
"     Clifford W Lo, MD, MPH, ScD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28650/contributors\">",
"     David L Burns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28650/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28650/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/62/28650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/62/28650/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/62/28650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamins are a number of chemically unrelated families of organic substances that cannot be synthesized by humans but need to be ingested in the diet in small quantities to prevent disorders of metabolism. They are divided into water-soluble and fat-soluble vitamins (",
"    <a class=\"graphic graphic_table graphicRef63827 \" href=\"UTD.htm?12/15/12541\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Many of the vitamin deficiency diseases, such as rickets (vitamin D), scurvy (vitamin C), beriberi (thiamine), and pellagra (niacin), have been almost completely eliminated in developed countries. Great interest and controversy continues into whether vitamin supplementation can prevent cancer, heart disease, upper respiratory infections, and other common diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best dietary sources for most of the water-soluble vitamins are fruits and vegetables; these also contain many related substances such as flavins and carotenoids which are generally not recognized as vitamins but may have protective effects against various diseases. This topic review will focus on the water-soluble vitamins excluding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    and vitamin B12, which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Minerals and fat-soluble vitamins are also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=see_link\">",
"     \"Overview of vitamin A\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=see_link\">",
"     \"Overview of vitamin D\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=see_link\">",
"     \"Overview of vitamin E\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link\">",
"     \"Overview of vitamin K\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link\">",
"     \"Overview of dietary trace minerals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several systems have been used to describe nutritional requirements of a population. Dietary Reference Intakes (DRIs) were developed by the Food and Nutrition Board of the Institute of Medicine to guide nutrient intake in a variety of settings. Under this system, requirements can be expressed as a Recommended Dietary Allowance (RDA), which is defined as the dietary intake that is sufficient to meet the daily nutrient requirements of 97 percent of the individuals in a specific life stage group. If there is insufficient data to determine an RDA for a given nutrient, requirements can be expressed as an Adequate Intake (AI), which is an estimation of the nutrient intake necessary to maintain a healthy state. These terms are described in greater detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28631?source=see_link\">",
"     \"Dietary history and recommended dietary intake in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VITAMIN B1 (THIAMINE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiamine, first named \"the antiberiberi factor\" in 1926, has a historical value due to the very early description of Beriberi in the Chinese medical texts, as far back as 2697 BC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/1\">",
"     1",
"    </a>",
"    ]. Formerly known as vitamin B1, thiamine is soluble in water and partly soluble in alcohol. Thiamine consists of a pyrimidine and a thiazole moiety, both of which are essential for its activity (",
"    <a class=\"graphic graphic_figure graphicRef77100 \" href=\"UTD.htm?1/40/1664\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiamine is found in larger quantities in food products such as yeast, legumes, pork, rice, and cereals. Milk products, fruits, and vegetables are poor sources of thiamine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/1\">",
"     1",
"    </a>",
"    ]. The thiamine molecule is denatured at high pH and high temperatures. Hence, cooking, baking, and canning of some foods as well as pasteurization can destroy thiamine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiamine is absorbed in the small intestine via both passive diffusion and active transport. The maximal absorption of thiamine is in the jejunum and ileum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/3\">",
"     3",
"    </a>",
"    ]. Thiamine passes through the mucosal cells to enter the blood stream via a sodium and ATP dependent pump. Bound to albumin, it is carried by the portal circulation to the liver. Thiamine enters the red blood cells by passive diffusion while its entry into other cells is via an active energy requiring process [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/3\">",
"     3",
"    </a>",
"    ]. The highest concentrations are found in the skeletal muscles, the liver, the heart, the kidneys, and the brain. Thiamine's biologic half-life is approximately 10 to 20 days; due to limited tissue storage, continuous supplementation is required [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/3\">",
"     3",
"    </a>",
"    ]. Through a series of metabolic processes, thiamine is incorporated into many phosphorylated esters, including thiamine pyrophosphate (TPP) and thiamine monophosphate (TMP). Thiamine and all of its metabolites are excreted in the urine. Biliary excretion is a minor route of its homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiamine is an important cofactor for enzymes involved in amino-acid and carbohydrate metabolism. Functioning along with many coenzymes such as flavin and NAD, thiamine serves as a catalyst in the conversion of pyruvate to acetyl CoA, an oxidative decarboxylation reaction mediated by pyruvate dehydrogenase:",
"   </p>",
"   <p>",
"    Pyruvate + CoA + NAD &rarr; Acetyl CoA + CO2 + NADH + H &nbsp;",
"   </p>",
"   <p>",
"    Thiamine is also involved in many other cellular metabolic activities such as the transketolation of the pentose phosphate pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/3\">",
"     3",
"    </a>",
"    ]. Thiamine has a role in the initiation of nerve impulse propagation that is independent of its coenzyme functions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiamine deficiency can be assessed by measuring the blood thiamine concentration, erythrocyte thiamine transketolase (ETKA), or transketolase urinary thiamine excretion (with or without a 5 mg thiamine load) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/5\">",
"     5",
"    </a>",
"    ]. Most laboratories now measure blood thiamine concentration directly, in preference to the ETKA method [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/6\">",
"     6",
"    </a>",
"    ]. The ETKA method is a functional test and results are influenced by the hemoglobin concentration.",
"   </p>",
"   <p>",
"    Thiamine deficiency has been associated with three disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beriberi (infantile and adult)",
"     </li>",
"     <li>",
"      Wernicke-Korsakoff syndrome",
"     </li>",
"     <li>",
"      Leigh's syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Infantile beriberi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beriberi in infants becomes clinically apparent between the ages of two and three months. The clinical features are variable and may include a fulminant cardiac syndrome with cardiomegaly, tachycardia, a loud piercing cry, cyanosis, dyspnea, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/7\">",
"     7",
"    </a>",
"    ]. A form of aseptic meningitis has also been described in which the affected infants exhibit vomiting, nystagmus, purposeless movements, and seizure, despite a \"normal\" cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2003, infantile beriberi was discovered in a series of infants in Israel, due to feeding with a soy-based formula that was inadvertently deficient in thiamine&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/9\">",
"     9",
"    </a>",
"    ]. Most of the infants with severe symptoms at the time of diagnosis, which included cardiomyopathy and seizures, had severe permanent disabilities even after thiamine was replaced. Among infants with apnea or seizures at presentation, all had moderate or severe intellectual disability when reevaluated five years later, and most had chronic epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/10\">",
"     10",
"    </a>",
"    ]. A few of the severely affected infants died. Many other infants were asymptomatic or had nonspecific symptoms while being fed the thiamine-deficient diet (eg, vomiting, irritability or failure to thrive). However, follow-up testing revealed delays in language and motor development [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adult beriberi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult beriberi is described as dry or wet. Dry beriberi is the development of a symmetrical peripheral neuropathy characterized by both sensory and motor impairments, mostly of the distal extremities. Wet beriberi includes a neuropathy, as well as signs of cardiac involvement with cardiomegaly, cardiomyopathy, congestive heart failure, peripheral edema, and tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beriberi has been reported as a complication of weight loss surgery, presenting as a polyneuropathy with a burning sensation in the extremities, weakness, and falls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Several of the case reports have been in adolescents, but whether this nutritional complication is more common in the adolescent age group as compared to adults undergoing weight loss surgery has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16122?source=see_link\">",
"     \"Surgical management of severe obesity in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thiamine deficiency can occur as a complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    if adequate thiamine supplements are not provided. As an example, during the late 1990s, there were multiple reports of symptomatic thiamine deficiency among recipients of parenteral nutrition during a widespread shortage of parenteral multivitamins in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have suggested that patients with heart failure, especially those treated with loop diuretics, may be thiamine deficient and should be treated with 50 to 200 mg of thiamine per day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. However, this remains controversial because of questions involving assay validity and a lack of controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Wernicke-Korsakoff syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wernicke-Korsakoff syndrome is the best known neurologic complication of thiamine (vitamin B1) deficiency. The term refers to two different syndromes, each representing a different stage of the disease. Wernicke's encephalopathy (WE) is an acute syndrome requiring emergent treatment to prevent death and neurologic morbidity. Korsakoff's syndrome (KS) refers to a chronic neurologic condition that usually occurs as a consequence of WE. It is characterized by impaired short-term memory and confabulation with otherwise grossly normal cognition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the chronic neurologic complications of alcohol\", section on 'Korsakoff's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    WE is a triad of nystagmus, ophthalmoplegia, and ataxia, along with confusion. This combination is almost exclusively described in chronic alcoholics with thiamine deficiency. The two entities are not separate diseases, but a spectrum of signs and symptoms. There may be a genetic predisposition for the development of WE since not all thiamine deficient patients are affected. Impairment in the synthesis of one of the important enzymes of the pentose phosphate pathway (erythrocyte transketolase) may explain such a predisposition [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=see_link\">",
"     \"Wernicke's encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    WE is treated with thiamine supplementation. A range of replacement doses have been used successfully, but large doses are typically used because they appear to be safe. It is common practice to delay giving dextrose to alcoholic patients until thiamine supplementation has been initiated to avoid precipitating Wernicke's encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=see_link&amp;anchor=H14#H14\">",
"     \"Wernicke's encephalopathy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Leigh syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiamine deficiency has occasionally been reported in infants presenting with features of Leigh syndrome, a progressive subacute necrotizing encephalomyopathy. This is a sporadic mitochondrial disorder with a subacute neurologic course. It is manifested with ataxia, dysarthria, movement disorders, areflexia, muscle atrophy, and weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H21#H21\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Leigh syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No real syndrome of excess thiamine exists since the kidneys can rapidly clear almost all excess thiamine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/21\">",
"     21",
"    </a>",
"    ]. Its half-life is 9.5 to 18.5 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RDA for thiamine in the United States is 1.2 mg daily for adult men and 1.1 mg daily for adult women (about 0.5",
"    <span class=\"nowrap\">",
"     mg/1000",
"    </span>",
"    kcal), and 1.4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    during pregnancy and lactation (",
"    <a class=\"graphic graphic_table graphicRef69963 \" href=\"UTD.htm?11/20/11585\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thiamine can be administered via intravenous and intramuscular routes. For the treatment of patients with beriberi, the daily doses range from 50 to 100 mg for 7 to 14 days. Then an oral dose of 10 mg per day is given until full recovery is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     VITAMIN B2 (RIBOFLAVIN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin B2, or riboflavin, is a member of naturally occurring compounds known as flavins. Flavins have a critical role in numerous biochemical reactions. First identified in the early 1900s, riboflavin was isolated in 1935 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Riboflavin is supplied in many foods, including meats, fish, eggs and milk, green vegetables, yeast, and enriched foods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Riboflavin's chemical nomenclature is 7,8-dimethyl-10 (1'-D-ribityl) isoalloxazine (",
"    <a class=\"graphic graphic_figure graphicRef77100 \" href=\"UTD.htm?1/40/1664\">",
"     figure 1",
"    </a>",
"    ). In the free form, it is a base, but in nature and in vivo, it is mostly found as a component of flavin-adenine dinucleotide (FAD). The 5'-hydroxymethyl terminus of the vitamin is phosphorylated to form a phosphate ester, allowing it to be incorporated into a different coenzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary flavins are bound to albumin and other riboflavin-specific carrier proteins and are released from their protein-bound state via gastric acid and proteolytic enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/25\">",
"     25",
"    </a>",
"    ]. In the proximal small intestine, riboflavin is absorbed passively along its concentration gradient across the intestinal mucosa. This involves a saturable transport system that is passive and not sodium dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/26\">",
"     26",
"    </a>",
"    ]. There also appears to be some enterohepatic circulation for riboflavin facilitated by bile salts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/25\">",
"     25",
"    </a>",
"    ]. Riboflavin eventually reaches the hepatocytes where its metabolism into flavin mononucleotide (FMN) and flavin-adenine dinucleotide (FAD) takes place.",
"   </p>",
"   <p>",
"    The metabolic conversions of flavin take place in the cytoplasm of cells of the body, particularly in the liver, heart, and kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/24\">",
"     24",
"    </a>",
"    ]. Riboflavin is first phosphorylated to form FMN, which can either be further phosphorylated into FAD, or become incorporated as part of a certain coenzyme-flavin complex. Both of the phosphorylation reactions are ATP dependent. As the more common form of flavin in humans, FAD is often complexed with other proteins to form flavoproteins with oxidizing and hydrogenating abilities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/25\">",
"     25",
"    </a>",
"    ]. Most of the riboflavin stores in the body are in the forms of flavoproteins. Urinary levels of the vitamin only indirectly reflect dietary intake or riboflavin catabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Riboflavin is an essential component of coenzymes involved in multiple cellular metabolic pathways, including the energy producing respiratory pathways. Flavoproteins are catalysts in a number of mitochondrial oxidative and reductive reactions and function as electron transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Riboflavin deficiency is more common than generally appreciated. Many cases are undetected due to the mild nature and nonspecific signs and symptoms of deficiency. Plasma riboflavin concentrations tend to reflect recent dietary intake. Urinary riboflavin excretion and the erythrocyte glutathione reductase assay are better functional indices of riboflavin deficiency.",
"   </p>",
"   <p>",
"    Significant deficiency syndromes are characterized by sore throat, hyperemia of pharyngeal mucous membranes, edema of mucous membranes, cheilitis, stomatitis, glossitis (",
"    <a class=\"graphic graphic_picture graphicRef54472 \" href=\"UTD.htm?8/39/8821\">",
"     picture 1",
"    </a>",
"    ), normocytic-normochromic anemia, and seborrheic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/27\">",
"     27",
"    </a>",
"    ]. Whether all these changes are due to riboflavin deficiency is not always clear since riboflavin deficiency is often accompanied by other water-soluble vitamin deficiencies, which can cause similar symptoms (",
"    <a class=\"graphic graphic_table graphicRef78426 \" href=\"UTD.htm?1/19/1341\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/28\">",
"     28",
"    </a>",
"    ]. Pure deficiency of riboflavin is rare, although it has been described in areas of the third world where starvation is prevalent and access to food is limited. Other settings in which riboflavin deficiency may be noted include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with anorexia nervosa",
"     </li>",
"     <li>",
"      Individuals who avoid dairy products (such as people with lactose intolerance) since dairy products are a good source of riboflavin",
"     </li>",
"     <li>",
"      Patients with malabsorptive syndromes such as celiac sprue, malignancies, and short bowel syndrome",
"     </li>",
"     <li>",
"      Rare inborn errors of metabolism in which there is a defect in riboflavin synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Long-term use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      and other barbiturates, which may lead to oxidation of riboflavin and impair its function [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive amounts of riboflavin are usually not absorbed due to the limited water-solubility and the inability of the human gastrointestinal tract to absorb toxic doses of the compound [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RDA for riboflavin is 1.3 mg daily for adult men and 1.1 mg daily for adult women (about 0.6 mg per 1000 kcal); requirements rise to 1.4 mg daily during pregnancy and 1.6 mg daily during lactation (",
"    <a class=\"graphic graphic_table graphicRef69963 \" href=\"UTD.htm?11/20/11585\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/22,31\">",
"     22,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some intramitochondrial beta-oxidation defects may respond to riboflavin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    .) In addition, patients with HIV infection who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    may develop lactic acidosis that is reversed by riboflavin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39332?source=see_link\">",
"     \"Electrolyte disturbances with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     VITAMIN B3 (NIACIN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pellagra (meaning \"raw skin\") was first described in Spain and Italy in the mid 18th century. It is characterized by a photosensitive pigmented dermatitis (typically located in sun-exposed areas), diarrhea, and dementia. During the early 1900s, pellagra was epidemic amongst the corn eating population of southeastern United States. Pellagra is now extremely uncommon in the western world except as a complication of alcoholism, anorexia nervosa, or malabsorptive disease. Pellagra due to dietary deficiency can still be seen in India, in parts of China, and Africa.",
"   </p>",
"   <p>",
"    For centuries since its first description in 1735 by Spanish physician Casal, it was thought to be an infectious disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/33\">",
"     33",
"    </a>",
"    ]. However, in 1937, Elvehjen and his colleagues discovered that nicotinic acid was effective in the treatment of pellagra in dogs. In the 1950s, tryptophan, a precursor of niacin, replaced it in the treatment of pellagra and research connected the low source of niacin and tryptophan in corn-containing foods to the development of pellagra [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/34\">",
"     34",
"    </a>",
"    ]. Niacin had been isolated since 1867, but it was not until 1937 that it became known as the anti-pellagra factor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Niacin is widely distributed in plant and animal foods. Good sources include yeast, meats (especially liver), cereals, legumes, and seeds. It is theoretically possible to maintain adequate niacin status on a high protein diet of 100",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    since tryptophan can be converted to a niacin derivative in the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Chemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicotinic acid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    are the two common forms of the vitamin most often referred to as niacin&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef57133 \" href=\"UTD.htm?42/9/43165\">",
"     figure 2",
"    </a>",
"    ). Through a series of biochemical reactions in the mitochondria, niacin, nicotinamide, and tryptophan form nicotinamide adenine dinucleotide (NAD) and NAD phosphate (NADP). NAD and NADP are the active forms of niacin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the chief dietary forms of niacin, NAD and NADP are first hydrolyzed in the intestinal lumen by enzymes leading to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    . Nicotinamide is converted by intestinal flora to nicotinic acid. The two forms of niacin are then absorbed and released into plasma via passive and facilitated diffusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/35\">",
"     35",
"    </a>",
"    ]. Through a passive process, niacin is rapidly taken up by the liver, kidneys, and erythrocytes. Intracellular nicotinamide and nicotinic acid are quickly converted to coenzyme forms NAD and NADP, which are stored in tissues with high metabolic activities (ie, muscle and liver).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many enzymatic reactions depend upon NAD and NADP. The role of the niacin moiety is to accept electrons or to donate hydrogen ions. The majority of these NAD-dependent enzymes are involved in reactions such as oxidation of fatty acids and other reactions that yield chemical structures containing high energy bonds [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/36\">",
"     36",
"    </a>",
"    ]. NADP is a cofactor in the reductive synthesis of the fatty acids and steroids. As essential components of redox reactions and hydrogen transport, NAD and NADP are crucial in the synthesis and metabolism of carbohydrates, fatty acids, and proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Pellagra",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, pellagra is a rare entity in the United States, but is still a common manifestation of niacin deficiency in poorer countries where the local diet consists of cereal, corn, or sorghum. In industrialized countries, pellagra tends to occur in alcoholics, and has been reported as a complication of bariatric surgery or anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most characteristic finding is the presence of a symmetric hyperpigmented rash, similar in color to a sunburn, which is present in the exposed areas of skin (",
"    <a class=\"graphic graphic_picture graphicRef69889 \" href=\"UTD.htm?25/40/26245\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/36\">",
"     36",
"    </a>",
"    ]. Other clinical findings are a red tongue and many non-specific symptoms, such as diarrhea and vomiting. Neurologic symptoms include insomnia, anxiety, disorientation, delusions, dementia, and encephalopathy.",
"   </p>",
"   <p>",
"    Niacin deficiency can also be seen in three other settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carcinoid syndrome, in which metabolism of tryptophan is to 5-OH tryptophan and serotonin rather than to nicotinic acid. This leads to the deficiency of active forms of niacin and the development of pellagra. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"       \"Clinical features of the carcinoid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prolonged use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      , since isoniazid depletes stores of pyridoxal phosphate, which enhances the production of tryptophan, a precursor of niacin. Several other drugs induce niacin deficiency by inhibiting the conversion of tryptophan to niacin, including 5-fluorouracil,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      , 6-mercaptopurine, hydantoin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"       ethionamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/39\">",
"       39",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Hartnup disease (",
"      <a class=\"external\" href=\"file://omim.org/entry/234500\">",
"       MIM #234500",
"      </a>",
"      ), an autosomal recessive congenital disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/40\">",
"       40",
"      </a>",
"      ]. Hartnup disease is associated with a defect of a membrane transport in the intestinal and renal cells normally responsible for the absorption of tryptophan (one of the precursors of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"       nicotinamide",
"      </a>",
"      -adenine dinucleotide). Through this pathway, around 50 percent of the daily niacin needs are synthesized. Due to the resulting niacin deficiency, all the symptoms of pellagra can be expected. The diagnosis is made by detecting a number of neutral amino acids in the urine, something that is not seen with dietary pellagra. The treatment is aimed towards depleting stores and supplementing the diet with niacin as well as proteins and amino acids [",
"      <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of the hereditary ataxias\", section on 'Aminoacidurias'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most documented and best known side effect of niacin is the flushing reaction associated with the crystalline nicotinic acid and not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/42\">",
"     42",
"    </a>",
"    ]. Symptoms are dose-dependent yet variable from person to person. The flushing can be experienced in a mild form while taking doses as small as 10 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/43\">",
"     43",
"    </a>",
"    ]. Despite the inconvenience and the undesirability of the reactions, there are no serious sequelae from flushing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In pharmacological doses (eg, 1000 to 3000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    common side effects of niacin are flushing, nausea, vomiting, pruritus, hives, elevation in serum aminotransferases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/44\">",
"     44",
"    </a>",
"    ], and constipation. A niacin-induced myopathy has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/45\">",
"     45",
"    </a>",
"    ]. Caution should be used in patients with a history of gout, since niacin is also known to elevate serum uric acid concentration.",
"   </p>",
"   <p>",
"    Severe toxicity reactions are reported in doses of 2 to 6 grams per day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/43\">",
"     43",
"    </a>",
"    ]. At such high doses, the hepatic metabolism becomes saturated, and side effects of this drug can be more frequently encountered. When less than 1 g of nicotinic acid was ingested per day, only a handful of anecdotal cases of toxicity has been reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/46\">",
"     46",
"    </a>",
"    ]. One clinical trial assigned two groups of subjects to either a long or a short-acting formula of niacin, each starting at 500 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/47\">",
"     47",
"    </a>",
"    ]. Subjects were followed for several months during which the dose of niacin was raised every six weeks by about 500 mg. There was no gastrointestinal or liver toxicity below 1000 mg of niacin per day. The extent of the toxicity was minimal and mostly gastrointestinal in the immediate release group, while mild liver enzyme elevation was noticed only in the slow release group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/47\">",
"     47",
"    </a>",
"    ]. There is some speculation that the metabolites of nicotinic acid in these high concentrations may lead to growth retardation in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Therapeutic roles",
"    </span>",
"    &nbsp;&mdash;&nbsp;In moderate to high doses (1 to 3 grams a day) niacin is a well-established antihyperlipidemic agent, decreasing total and LDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/49\">",
"     49",
"    </a>",
"    ]. The Cholesterol-Lowering Atherosclerosis Study (CLAS II and II), for example, showed that a combination of niacin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    significantly reduced the progression of atherosclerotic related coronary artery complications (52 versus 15 percent in the control group). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    .) To reduce the flushing side effects, a sustained-release formulation is available for these purposes. However, these longer acting forms may be associated with more gastrointestinal and hepatotoxic side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/34\">",
"     34",
"    </a>",
"    ]. Lower starting doses of crystalline niacin or premedication of the patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    can attenuate these adverse effects and side effects. A more recent clinical role for nicotinic acid given in high doses has been suggested for delaying the onset of diabetes in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RDA for Niacin is 16 NEs (Niacin Equivalents) daily for adult males, and 14 NEs daily for adult females, rising to 18 NE during pregnancy, and 17 NE daily during lactation (",
"    <a class=\"graphic graphic_table graphicRef69963 \" href=\"UTD.htm?11/20/11585\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/22\">",
"     22",
"    </a>",
"    ]. One NE is equal to 1 mg of niacin, which is equal to 60 mg of dietary tryptophan. These doses are far below the anti-hyperlipidemic doses of niacin and are not associated with toxicity. Requirements may be increased for individuals on dialysis, or for those with malabsorptive processes (eg, after bariatric surgery, as discussed above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     VITAMIN B5 (PANTOTHENIC ACID)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pantothenic acid (PA) was first synthesized successfully in 1940 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/51\">",
"     51",
"    </a>",
"    ]. It was not until 1947 when its biologically active form, known as Coenzyme A (CoA), was recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/52\">",
"     52",
"    </a>",
"    ]. PA is an essential cofactor in many acetylation reactions in vivo including tricarboxylic acid cycle (TCA), fatty acid synthesis and breakdown, as well as other mitochondrial and cytosolic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major dietary sources of pantothenic acid are egg yolk, liver, kidney, broccoli, and milk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/51\">",
"     51",
"    </a>",
"    ]. Substantial concentrations of pantothenic acid are also found in chicken, beef, potatoes, and whole grains [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/22\">",
"     22",
"    </a>",
"    ]. In the diet, pantothenic acid is mainly in the form of CoA. Panthothenic acid is also produced by bacteria in the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once ingested and broken down, CoA is hydrolyzed in the small intestine to form pantothenic acid&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef57133 \" href=\"UTD.htm?42/9/43165\">",
"     figure 2",
"    </a>",
"    ). It is then absorbed in the jejunum and secreted into the bloodstream via a sodium-dependent transport system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/54\">",
"     54",
"    </a>",
"    ]. Most cells of the body take up pantothenic acid via the same sodium-dependent mechanism. Once inside the cell, pantothenic acid undergoes a number of ATP-dependent phosphorylations to become CoA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/55\">",
"     55",
"    </a>",
"    ]. Excess pantothenic acid is hydrolyzed and excreted as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/20/37184?source=see_link\">",
"     cysteamine",
"    </a>",
"    and pantothenate via the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;CoA has a crucial role in the synthesis of many molecules, including vitamins A, D, cholesterol, steroids, heme A, fatty acids, amino acids, and proteins. Coenzyme A also has an essential role in the first step of the TCA cycle, by binding with oxaloacetate to form citrate and then succinyl-CoA. Other",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    -dependent processes, such as beta-oxidation of fatty acids and the oxidative degradation of amino acids (which usually occur after mRNA translation) are important steps for stabilization and activation of many proteins in vivo. Many peptide hormones, such as ACTH, undergo such acetylation in order to become biologically active [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many animal models have been used to study the deficiency of panthenoic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/51\">",
"     51",
"    </a>",
"    ]. In rats, growth failure, hemorrhage, and necrosis of adrenal cortex, dermatitis, and achromotrichia (gray hair) have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/58\">",
"     58",
"    </a>",
"    ]. In primates, there is some evidence for impaired synthesis of heme, leading to anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/51\">",
"     51",
"    </a>",
"    ]. Pantothenic acid deficiency is rare in humans. It has been noted in severely malnourished individuals, usually in situations of famine and war. Clinical manifestations can include paresthesias and dysesthesias, referred to as \"burning feet syndrome.\" Human volunteers who were fed a pantothenate antimetabolite for three months developed burning, distal paresthesias, and gastrointestinal distress. Because pantothenate is essential to most living organisms, microbiologic assays have been used to quantify concentrations in blood and urine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no known toxicity for pantothenic acid. Excess intake is excreted by the kidneys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended intake for pantothenic acid is expressed as Adequate Intake (AI) rather than Recommended Dietary Allowance (RDA) indicating that there is not adequate data to specify the percentage of individuals whose requirement is met by this intake. The AI is 5 mg daily for adult men and women, 6 mg daily for pregnant women, and 7 mg daily during lactation (",
"    <a class=\"graphic graphic_table graphicRef69963 \" href=\"UTD.htm?11/20/11585\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     VITAMIN B6 (PYRIDOXINE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paul Gyorgy separated a factor from the antipellagra factor in the 1930s that he named vitamin B6, or pyridoxine. The related compounds, pyridoxal and pyridoxamine, were later shown to have similar activity. Forms include pyridoxine, pyridoxal, and pyridoxamine, as well as 5' phosphates (",
"    <a class=\"graphic graphic_figure graphicRef77100 \" href=\"UTD.htm?1/40/1664\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyridoxine and pyridoxamine are predominantly found in plant foods; pyridoxal is most commonly derived from animal foods. Meats, whole grains, vegetables, and nuts are the best sources. Cooking, food processing, and storage can reduce vitamin B6 availability by 10 to 50 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyridoxal phosphate is used for Schiff base formation during the transamination of amino acids. Pyridoxal phosphate is also involved in decarboxylation of amino acids, gluconeogenesis, conversion of tryptophan to niacin, sphingolipid biosynthesis, neurotransmitter synthesis, immune function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/60\">",
"     60",
"    </a>",
"    ], and steroid hormone modulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Deficiency and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt deficiencies of vitamin B6 are probably rare. Marginal deficiencies may be more common, manifested as nonspecific stomatitis, glossitis, cheilosis, irritability, confusion, and depression. A number of genetic syndromes affecting PLP-dependent enzymes such as homocystinuria, cystathioninuria, and xanthurenic aciduria mimic vitamin B6 deficiency.",
"   </p>",
"   <p>",
"    Depressed concentrations of PLP have been reported in asthma, diabetes, alcoholism, heart disease, pregnancy, breast cancer, Hodgkin lymphoma, and sickle-cell anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/61\">",
"     61",
"    </a>",
"    ]. Cystathionine synthase is a PLP-dependent enzyme which produces cystathionine from serine and homocysteine. As a result, vitamin B6 deficiency can lead to elevations in plasma homocysteine concentrations, a risk factor for the development of atherosclerosis and venous thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following methods can be used to assess for vitamin B6 deficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean plasma pyridoxal-5-phophate (PLP) concentration can be measured; normal ranges from 27 to 75",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      for males and 26 to 93",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      for females.",
"     </li>",
"     <li>",
"      Erythrocyte transaminase activity with and without PLP added has been used as a functional test of pyridoxine status.",
"     </li>",
"     <li>",
"      Urinary 4-pyridoxic acid excretion greater than 3.0",
"      <span class=\"nowrap\">",
"       mmol/day",
"      </span>",
"      can be used as an indicator of adequate short-term vitamin B6 status.",
"     </li>",
"     <li>",
"      Urinary excretion of xanthurenic acid is normally less than 65",
"      <span class=\"nowrap\">",
"       mmol/day",
"      </span>",
"      following a 2 g tryptophan load.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pyridoxine has been used to treat patients with Down's syndrome, autism, gestational diabetes, carpal tunnel syndrome, premenstrual syndrome, depression, and diabetic neuropathy, with variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of peripheral neuropathy, dermatoses, photosensitivity, dizziness, and nausea have been reported with long-term megadoses of pyridoxine over 250",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    a few cases of neuropathy appear to have been caused by chronic intake of 100 to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RDA of pyridoxine is 1.3 mg daily for younger men and women, and rises to 1.7 mg daily for men older than 50 years, and 1.5 mg daily for women older than 50 years. The RDA is 1.9 mg daily during pregnancy, and 2.0 mg daily during lactation (",
"    <a class=\"graphic graphic_table graphicRef69963 \" href=\"UTD.htm?11/20/11585\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     BIOTIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of growth factors found in yeast, originally called \"bios,\" were separated early in the 20th century and eventually identified as myoinositol, pantothenate, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    . Biotin was also found in liver and variously called vitamin H, coenzyme R, factor S, factor W, vitamin Bw, and protective factor X, because it protected against a type of dermatosis and loss of hair in animals that was associated with the intake of raw egg whites.",
"   </p>",
"   <p>",
"    The characterization of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    as a vitamin was based on its role (deficiency) in carboxylase deficiency syndromes. Biotin functions as a cofactor to the carboxylase enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     Biotin",
"    </a>",
"    can be found in a variety of plants, but is found in highest levels in the liver, egg yolk, soybean products, and yeast [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Chemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     Biotin",
"    </a>",
"    consists of two cyclic molecules: a ureido and a tetrahydro-thiophene ring (",
"    <a class=\"graphic graphic_figure graphicRef57133 \" href=\"UTD.htm?42/9/43165\">",
"     figure 2",
"    </a>",
"    ). In vivo, it is found in a number of different isomers, not all of which are active enzymatically [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/68\">",
"     68",
"    </a>",
"    ]. D-biotin is the only biologically active isomer. Biocytin, bound with lysine, is also active. Many analogs of biotin are actually antagonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than the ingested forms of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    , a number of bacteria in the gut synthesize biotin as a by-product of their proteolytic actions. Biotin is mostly absorbed in the proximal small intestine, and to a lesser degree in the cecum. Unabsorbed gut biotin is excreted in the feces. Excess serum biotin is excreted via the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     Biotin",
"    </a>",
"    is an essential component of several enzyme complexes in mammals, all of which are involved in carbohydrate and lipid metabolism. They include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acetyl-CoA carboxylase (ACC)",
"     </li>",
"     <li>",
"      Pyruvate carboxylase (PC)",
"     </li>",
"     <li>",
"      Propionyl CoA carboxylase (PCC)",
"     </li>",
"     <li>",
"      Beta-methylcrotonyl CoA carboxylase (MCC)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     Biotin",
"    </a>",
"    acts as a CO2 carrier on the surface of each enzyme. As a result, it has an essential role in many processes, including protein and DNA synthesis and cell replication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     Biotin",
"    </a>",
"    deficiency was first noted in patients who were on long-term parenteral nutrition prior to routine biotin supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/70\">",
"     70",
"    </a>",
"    ]. It is now reported only rarely. Decreased function of the biotin-dependent carboxylases can have a number of metabolic consequences. The enzyme pyruvate carboxylase, for example, is involved in converting pyruvate to oxaloacetate in a number of tissues in which gluconeogenesis occurs. Oxalate is later converted to glucose. In the setting of biotin deficiency, pyruvate levels rise and are converted to lactic acid. Another example is the synthesis of succinyl-CoA from several amino acids (ie, valine, isoleucine, and methionine), which requires the enzymatic action of propionyl CoA carboxylase. Biotin deficiency leads to build up of propionyl-CoA, which gets metabolized into odd-chain fatty acids.",
"   </p>",
"   <p>",
"    The clinical manifestations of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    deficiency may not be solely due to decreased intake of biotin. Consumption of large amounts of raw egg whites (which contain avidin, a substance that binds to biotin and prevents its utilization), can also lead to biotin deficiency. In addition, secondary biotin deficiency can occur due to lack of a specific enzyme (biotinidase), which is required for recycling of biotin (see",
"    <a class=\"local\" href=\"#H51\">",
"     'Multiple carboxylase deficiency'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    deficiency are nonspecific and may include changes in mental status, myalgia, dysesthesias, anorexia, and nausea. Chronic deficiency can lead to a maculosquamous dermatitis of the extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/68\">",
"     68",
"    </a>",
"    ]. Because of its role in lipid metabolism, biotin deficiency can lead to defects in metabolism of long-chain fatty acids. The resulting deficiency of essential fatty acids is often manifested by dermatologic changes such as seborrheic dermatitis and alopecia.",
"   </p>",
"   <p>",
"    Normal serum",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    concentrations are around 1500",
"    <span class=\"nowrap\">",
"     pmol/L.",
"    </span>",
"    Normal urine biotin excretion is around 160",
"    <span class=\"nowrap\">",
"     nmol/day,",
"    </span>",
"    using biotin bioassays measuring growth of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    or other microorganisms, or radioligand assays with labeled avidin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h3\">",
"     Multiple carboxylase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple carboxylase deficiency (MCD) refers to one of two inherited defects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    metabolism. The infantile form is caused by a deficiency of holocarboxylase synthetase (HCS) and presents in the first week of life with lethargy, poor muscle tone, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/72\">",
"     72",
"    </a>",
"    ]. A later-onset form is caused by biotinidase deficiency and is associated with a slow but progressive loss of biotin in the urine, leading to organic aciduria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/73\">",
"     73",
"    </a>",
"    ]; it is characterized by ataxia, ketoacidosis, dermatitis, seizures, myoclonus, and nystagmus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the hereditary ataxias\", section on 'Disorders of pyruvate and lactate metabolism'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    MCD is diagnosed definitively by studying enzymes from lymphocytes. Screening for these deficiencies is included in the newborn screen in most states (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=see_link&amp;anchor=H7#H7\">",
"     \"Newborn screening\", section on 'Testing in the United States'",
"    </a>",
"    ). Both infantile and late onset multiple carboxylase deficiency can be treated with pharmacologic doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    . Delayed treatment may fail to reverse the neurologic sequelae and has been associated with neurologic and developmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/59,73\">",
"     59,73",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No toxicity of excess",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    intake has been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are still no accurate data estimating dietary requirements for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    . Adequate intakes are approximately 30 mcg daily for adults according to a report from the Food and Nutrition Board of 1998 (",
"    <a class=\"graphic graphic_table graphicRef69963 \" href=\"UTD.htm?11/20/11585\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h1\">",
"     VITAMIN C (ASCORBIC ACID)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin C (ascorbic acid) has a prominent role in history. The clinical manifestations of scurvy were well described in ancient Egyptian, Greek, and Roman literature. British and European explorers of the renaissance era were ravaged by scurvy. Scurvy was a major cause of morbidity and death amongst much of Europe during the great potato famine, the United States Civil War, the exploration of the North Pole, and the California gold rush. Captain James Cook was one of the first to demonstrate that sailors who spent months at sea could avoid scurvy by maintaining a diet rich in vegetables [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/74\">",
"     74",
"    </a>",
"    ]. James Lind, a British naval surgeon, published his experiences and studies on scurvy aboard ships in a book titled Treatise of the Scurvy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/74\">",
"     74",
"    </a>",
"    ]. During 1928 to 1931, Szent-Gyorgyi isolated hexuronic acid from cabbage, oranges, paprika, and adrenal glands. Hexuronic acid was subsequently termed vitamin C and found to prevent the development of scurvy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important food sources of vitamin C are citrus fruits, tomatoes, potatoes, brussel sprouts, cauliflower, broccoli, strawberries, cabbage, and spinach [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Chemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascorbic acid is the enolic form of an alpha-ketolactone, and is closely akin to the glucose structure (",
"    <a class=\"graphic graphic_figure graphicRef57133 \" href=\"UTD.htm?42/9/43165\">",
"     figure 2",
"    </a>",
"    ). A number of compounds that exhibit the biologic activities of ascorbic acid are generally referred to as vitamin C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascorbic acid is absorbed in the distal small intestine through an energy dependent process. Usual dietary doses of up to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are almost completely absorbed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/77\">",
"     77",
"    </a>",
"    ]. As dietary concentrations increase, a smaller fraction is absorbed; pharmacologic dosing (&gt;1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    can result in absorption rates of &lt;50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood concentrations of ascorbic acid are regulated by renal excretion. Excess amounts are filtered by renal glomeruli and reabsorbed via the tubules to a predetermined threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/79\">",
"     79",
"    </a>",
"    ]. Dehydroascorbic acid, the oxidative product of ascorbic acid metabolism, passively penetrates cellular membranes and is the preferred form for erythrocytes and leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/80\">",
"     80",
"    </a>",
"    ]. The greatest concentrations of ascorbic acid are found in the pituitary, adrenal, brain, leukocytes, and the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascorbic acid is a reversible biologic reductant, and provides reducing equivalents for a number of biochemical reactions involving iron and copper [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/79\">",
"     79",
"    </a>",
"    ]. Because of this property, it functions as a cofactor, enzyme complement, co-substrate, or a strong antioxidant in a variety of reactions and metabolic processes.",
"   </p>",
"   <p>",
"    Ascorbic acid provides electrons needed to reduce molecular oxygen. These anti-oxidant capabilities also stabilize a number of other compounds, including vitamin E and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    . It is a cofactor for reduction of folate to dihydro-and-tetrahydrofolate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h3\">",
"     Fatty acid transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transport of long-chain fatty acids across the mitochondrial membrane is a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    dependent process. Carnitine synthesis requires ascorbic acid as an enzymatic cofactor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h3\">",
"     Collagen synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formation of collagen requires enzymatic hydroxylation of two amino acids: proline and lysine. Ascorbic acid works as a cofactor for the enzyme propyl hydroxylase, which catalyzes formation of hydroxyproline and hydroxylysine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/83\">",
"     83",
"    </a>",
"    ]. Failure of this step in collagen synthesis results in impaired wound healing, defective tooth formation, and deficient osteoblast and fibroblast function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h3\">",
"     Neurotransmitters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthesis of norepinephrine involves a hydroxylation of dopamine by the enzyme dopamine-beta-mono-oxygenase, where ascorbic acid is a required cofactor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h3\">",
"     Prostaglandin metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascorbic acid has a role in prostaglandin and prostacyclin metabolism. It may be capable of attenuating the inflammatory response or even sepsis syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/85\">",
"     85",
"    </a>",
"    ]. A more recent area of interest has been the relationship between ascorbic acid and nitric oxide, a potent vasodilator [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all primates, ascorbic acid is an essential nutrient derived from the diet. Scurvy is a clinical syndrome seen with ascorbic acid deficiency largely due to impaired collagen synthesis with disordered connective tissue. Symptoms (occurring as early as three months after deficient intake) include ecchymoses, bleeding gums (",
"    <a class=\"graphic graphic_picture graphicRef76282 \" href=\"UTD.htm?38/51/39728\">",
"     picture 3",
"    </a>",
"    ), petechiae, coiled hairs, hyperkeratosis (",
"    <a class=\"graphic graphic_picture graphicRef64172 \" href=\"UTD.htm?33/17/34067\">",
"     picture 4",
"    </a>",
"    ), Sjogren's syndrome, arthralgias, and impaired wound healing. Generalized systemic symptoms are weakness, malaise, joint swelling, arthralgias, edema, depression, neuropathy, and vasomotor instability [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, ascorbic acid deficiency occurs mostly in severely malnourished individuals, drug and alcohol abusers, or those living in poverty or on diets devoid of fruits and vegetables [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. In children, breast milk provides an adequate source of ascorbic acid for newborns and infants. In the elderly, institutionalized, or chronically ill patients, scurvy can be seen due to their poor dietary intake [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/89\">",
"     89",
"    </a>",
"    ]. Symptoms of scurvy generally occur when the plasma concentration of ascorbic acid is less than 0.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/90\">",
"     90",
"    </a>",
"    ]. Recent vitamin C intake can normalize plasma ascorbic acid concentrations even if tissue levels are still deficient. Measurement of ascorbic acid in leukocytes is a better measure of body stores but this test is not widely available.",
"   </p>",
"   <p>",
"    The treatment for scurvy is vitamin C supplementation and reversal of the conditions that led to the deficiency. A wide range of replacement doses have been used successfully. For children, recommended doses are 100 mg ascorbic acid given three times daily for one week, then once daily for several weeks until the patient is fully recovered [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/91\">",
"     91",
"    </a>",
"    ]. Adults are usually treated with 300 to 1000 mg daily for one month [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the constitutional symptoms improve within 24 hours of treatment; bruising and gingival bleeding resolve within a few weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h2\">",
"     Therapeutic and prophylactic roles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several therapeutic and prophylactic roles have been described for vitamin C, including prevention of cardiovascular disease and cancer. However, current evidence does not support the use of vitamin C supplementation for disease prevention. Vitamin C may have a minor role in preventing the common cold. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H24#H24\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Cataracts and macular degeneration'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of side effects of ascorbic acid have been reported in the literature. Large doses of vitamin C (in gram quantities) can give false negative stool guaiac results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/94\">",
"     94",
"    </a>",
"    ] and have been associated with diarrhea and abdominal bloating. There has been some controversy in the literature regarding high intake and increased oxalate production. Some reports conclude that excessive use of vitamin C is a risk factor for calcium oxalate nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/95\">",
"     95",
"    </a>",
"    ]. However, a prospective epidemiologic study demonstrated that consumption of high doses of vitamin C (1500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    lowered the relative risk of calcium oxalate stones compared to 250 mg or less of vitamin C per day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/96\">",
"     96",
"    </a>",
"    ]. Thus, the relationship of high-dose vitamin C ingestion and calcium oxalate stones is tentative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Patients with a predisposition to form oxalate stones or those on hemodialysis should avoid excessive use of vitamin C.",
"   </p>",
"   <p>",
"    Ingestion of large quantities of ascorbic acid has been rarely associated with fatal cardiac arrhythmias in patients with iron overload, presumably due to oxidative injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/99\">",
"     99",
"    </a>",
"    ]. Thus, it may be reasonable to advise patients to avoid ascorbic acid supplements, but there is no reason to discourage the consumption of fresh fruits or vegetables containing vitamin C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link\">",
"     \"Treatment of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69\">",
"    <span class=\"h2\">",
"     Requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RDA for ascorbic acid is 75 mg per day for most women and 90 mg per day for men; pregnant or lactating women and the elderly have requirements up to 120",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef69963 \" href=\"UTD.htm?11/20/11585\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/66\">",
"     66",
"    </a>",
"    ]. This is based upon the minimum requirement to prevent scurvy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/79\">",
"     79",
"    </a>",
"    ]. Requirements for smokers are increased by as much as 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70\">",
"    <span class=\"h1\">",
"     OTHER VITAMINS AND PSEUDOVITAMINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lecithin, choline (precursors for acetylcholine), inositol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    (long-chain fatty acid transporter), lipoic acid, lutein, zeaxanthin, other flavonoids and carotenoids probably could be classed as vitamins because humans cannot synthesize them, but dietary sources usually provide ample amounts and clinical deficiencies are extremely rare. In addition, there are many substances that have been promoted as vitamins in the popular press but have little support in the scientific literature, including laetrile (\"vitamin B17,\" amygdalin), pangamic acid (\"vitamin B15,\" diisopropylamine dichloroacetate), and gerovital (\"vitamin H3\") [",
"    <a class=\"abstract\" href=\"UTD.htm?27/62/28650/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71\">",
"    <span class=\"h1\">",
"     VITAMIN B12 AND FOLIC ACID",
"    </span>",
"    &nbsp;&mdash;&nbsp;These water-soluble vitamins are discussed in detail in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2997416\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamins are a number of chemically unrelated families of organic substances that cannot be synthesized by humans but need to be ingested in the diet in small quantities to prevent disorders of metabolism. They are divided into water-soluble and fat-soluble vitamins (",
"      <a class=\"graphic graphic_table graphicRef63827 \" href=\"UTD.htm?12/15/12541\">",
"       table 1",
"      </a>",
"      ). This topic review discusses the water-soluble vitamins B1 (thiamine), B2 (riboflavin), B3 (niacin), B5 (pantothenic acid), B6 (pyridoxine),",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"       biotin",
"      </a>",
"      , and vitamin C. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The following tables outline the requirements for each of the water-soluble vitamins (",
"      <a class=\"graphic graphic_table graphicRef69963 \" href=\"UTD.htm?11/20/11585\">",
"       table 2",
"      </a>",
"      ) and typical symptoms of their deficiency (",
"      <a class=\"graphic graphic_table graphicRef78426 \" href=\"UTD.htm?1/19/1341\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Thiamine (vitamin B1) is found in larger quantities in food products such as yeast, legumes, pork, rice, and cereals. Thiamine deficiency causes each of the following disorders:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Beriberi, characterized by peripheral neuropathy, with or without edema and congestive heart failure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Adult beriberi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wernicke&rsquo;s encephalopathy, characterized by nystagmus, ophthalmoplegia, and ataxia, along with confusion, and Wernicke-Korsakoff syndrome, a chronic neurologic condition. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Wernicke-Korsakoff syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infantile beriberi, due to dietary deficiency, or Leigh syndrome due to a sporadic mitochondrial disorder. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Infantile beriberi'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Leigh syndrome'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Riboflavin (vitamin B2) is supplied in meats, fish, eggs and milk, green vegetables, yeast, and enriched foods. Mild deficiency is often undetected due to the mild nature and nonspecific signs and symptoms of deficiency. Riboflavin deficiency is characterized by sore throat, hyperemia of pharyngeal mucous membranes, edema of mucous membranes, cheilitis, stomatitis, glossitis, normocytic-normochromic anemia, and seborrheic dermatitis. Risk factors for riboflavin deficiency include anorexia nervosa, malabsorptive syndromes, and chronic use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      and other barbiturates. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vitamin B2 (riboflavin)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Niacin (vitamin B3) is widely distributed in plant and animal foods.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Niacin deficiency causes pellagra, which is characterized by a photosensitive pigmented dermatitis (typically located in sun-exposed areas (",
"      <a class=\"graphic graphic_picture graphicRef69889 \" href=\"UTD.htm?25/40/26245\">",
"       picture 2",
"      </a>",
"      )), diarrhea, and dementia. In industrialized countries, pellagra tends to occur in alcoholics and has been reported as a complication of bariatric surgery or anorexia nervosa. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In high doses (1 to 3 grams a day) niacin is a well-established antihyperlipidemic agent, decreasing total and LDL cholesterol. Side effects at these doses include flushing, nausea, vomiting, pruritus, hives, constipation, and elevation in serum aminotransferases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link&amp;anchor=H5#H5\">",
"       \"Lipid lowering with drugs other than statins and fibrates\", section on 'Nicotinic acid (Niacin)'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H29\">",
"       'Toxicity'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pantothenic acid (vitamin B5) in the diet is mainly in the form of coenzyme A (CoA) and is supplied in egg yolk, liver, kidney, broccoli, and milk. Pantothenic acid deficiency is rare in humans but has been noted in severely malnourished individuals. Clinical manifestations can include paresthesias and dysesthesias, known as \"burning feet syndrome.\" &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Pyridoxine (vitamin B6) is found in the diet in several forms, including pyridoxine and pyridoxamine (from plants) and pyridoxal (from animal foods). Meats, whole grains, vegetables, and nuts are the best sources. Overt deficiencies of vitamin B6 are probably rare. Marginal deficiencies may be more common, manifested as nonspecific stomatitis, glossitis, cheilosis, irritability, confusion, and depression. Toxicity has been reported with long-term use of megadoses of pyridoxine (over 250",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      characterized by peripheral neuropathy, dermatoses, photosensitivity, dizziness, and nausea. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Vitamin B6 (pyridoxine)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"       Biotin",
"      </a>",
"      deficiency was first noted in patients who were on long-term parenteral nutrition prior to routine biotin supplementation. Symptoms of biotin deficiency are nonspecific and may include changes in mental status, myalgia, dysesthesias, anorexia, and nausea. Chronic deficiency can lead to maculosquamous dermatitis of the extremities. (See",
"      <a class=\"local\" href=\"#H50\">",
"       'Deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple carboxylase deficiency is a congenital disorder of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"       biotin",
"      </a>",
"      metabolism, caused by deficiency of biotinidase or holocarboxylase synthetase, enzymes crucial to the biotin metabolism pathway. These disorders are included in newborn screening programs in the United States and can be treated with pharmacologic doses of biotin. (See",
"      <a class=\"local\" href=\"#H51\">",
"       'Multiple carboxylase deficiency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the hereditary ataxias\", section on 'Disorders of pyruvate and lactate metabolism'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Vitamin C (ascorbic acid) is essential for a variety of processes including collagen synthesis. Vitamin C deficiency, known as scurvy, is characterized by ecchymoses, bleeding gums (",
"      <a class=\"graphic graphic_picture graphicRef76282 \" href=\"UTD.htm?38/51/39728\">",
"       picture 3",
"      </a>",
"      ), petechiae, coiled hairs, hyperkeratosis (",
"      <a class=\"graphic graphic_picture graphicRef64172 \" href=\"UTD.htm?33/17/34067\">",
"       picture 4",
"      </a>",
"      ), Sjogren's syndrome, arthralgias, and impaired wound healing, as well as constitutional symptoms. However, current evidence does not support the use of vitamin C supplementation for disease prevention. (See",
"      <a class=\"local\" href=\"#H54\">",
"       'Vitamin C (ascorbic acid)'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tanphaichitr V. Modern Nutrition in Health and Medicine, 9th, Shils M (Ed), Lippincott, Philadelphia 2000. p.381.",
"    </li>",
"    <li>",
"     Tanphaichitr V, Wood B. Thiamin. In: Present Knowledge in Nutrition, 5th, Olson RE, Broquist CO, et al (Eds), Nutrition Foundation, Washington, DC 1984. p.273.",
"    </li>",
"    <li>",
"     Gubler CJ. Thiamin. In: Handbook of vitamins: Nutritional, biochemical, and clinical aspects, Machlin LJ (Ed), Marcel Dekker, New York 1984. p.245.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/4\">",
"      Davis RE, Icke GC, Thom J, Riley WJ. Intestinal absorption of thiamin in man compared with folate and pyridoxal and its subsequent urinary excretion. J Nutr Sci Vitaminol (Tokyo) 1984; 30:475.",
"     </a>",
"    </li>",
"    <li>",
"     Sauberlich HE, Daude RP, Skala JH. Laboratory Tests for the Assessment of Nutritional Status, CRC Press, Boca Raton, Florida 1974.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/6\">",
"      Talwar D, Davidson H, Cooney J, St JO'Reilly D. Vitamin B(1) status assessed by direct measurement of thiamin pyrophosphate in erythrocytes or whole blood by HPLC: comparison with erythrocyte transketolase activation assay. Clin Chem 2000; 46:704.",
"     </a>",
"    </li>",
"    <li>",
"     Chaitiraphan S, Tanphaichitr V, Cheng TO. Nutritional heart disease. In: The international textbook of cardiology, Cheng TO (Ed), Pergamon Press, New York 1986. p.864.",
"    </li>",
"    <li>",
"     Tanphaichitr V. Epidemiology and clinical assessment of vitamin deficiencies in Thai children. In: Child health in the tropics, Eeckels RE, Ransome-kuti O, Kroonenberg CC (Eds), Martinus Nijhoff, Dordrect 1985. p.157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/9\">",
"      Fattal-Valevski A, Kesler A, Sela BA, et al. Outbreak of life-threatening thiamine deficiency in infants in Israel caused by a defective soy-based formula. Pediatrics 2005; 115:e233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/10\">",
"      Fattal-Valevski A, Bloch-Mimouni A, Kivity S, et al. Epilepsy in children with infantile thiamine deficiency. Neurology 2009; 73:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/11\">",
"      Fattal-Valevski A, Azouri-Fattal I, Greenstein YJ, et al. Delayed language development due to infantile thiamine deficiency. Dev Med Child Neurol 2009; 51:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/12\">",
"      Towbin A, Inge TH, Garcia VF, et al. Beriberi after gastric bypass surgery in adolescence. J Pediatr 2004; 145:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/13\">",
"      Chaves LC, Faintuch J, Kahwage S, Alencar Fde A. A cluster of polyneuropathy and Wernicke-Korsakoff syndrome in a bariatric unit. Obes Surg 2002; 12:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/14\">",
"      Lawson ML, Kirk S, Mitchell T, et al. One-year outcomes of Roux-en-Y gastric bypass for morbidly obese adolescents: a multicenter study from the Pediatric Bariatric Study Group. J Pediatr Surg 2006; 41:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/15\">",
"      Hahn JS, Berquist W, Alcorn DM, et al. Wernicke encephalopathy and beriberi during total parenteral nutrition attributable to multivitamin infusion shortage. Pediatrics 1998; 101:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/16\">",
"      Shimon I, Almog S, Vered Z, et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med 1995; 98:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/17\">",
"      Seligmann H, Halkin H, Rauchfleisch S, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study. Am J Med 1991; 91:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/18\">",
"      Rieck J, Halkin H, Almog S, et al. Urinary loss of thiamine is increased by low doses of furosemide in healthy volunteers. J Lab Clin Med 1999; 134:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/19\">",
"      Leslie D, Gheorghiade M. Is there a role for thiamine supplementation in the management of heart failure? Am Heart J 1996; 131:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/20\">",
"      Singleton CK, Pekovich SR, McCool BA, Martin PR. The thiamine-dependent hysteretic behavior of human transketolase: implications for thiamine deficiency. J Nutr 1995; 125:189.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board, National Research Council Recommended dietary allowances. 10th edition. Washington DC: National Academy Press, 1989. p.125.",
"    </li>",
"    <li>",
"     Food and Nutrition Board-Institute of Medicine. Dietary reference intakes. Thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline, National Academy Press, Washington DC 1998.",
"    </li>",
"    <li>",
"     McCormick DB. Metabolism of riboflavin. In: Riboflavin, Rivlin RS (Ed), Plenum press, New York 1975. p.153.",
"    </li>",
"    <li>",
"     McCormick DB. Riboflavin. In: Present knowledge in nutrition, 6th, Brown ML (Ed), International Life Sciences Institute Nutrition Foundation, 1990. p.146.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/25\">",
"      Merrill AH Jr, Lambeth JD, Edmondson DE, McCormick DB. Formation and mode of action of flavoproteins. Annu Rev Nutr 1981; 1:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/26\">",
"      Said HM, Ma TY. Mechanism of riboflavine uptake by Caco-2 human intestinal epithelial cells. Am J Physiol 1994; 266:G15.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson JA. Vitamin deficiency and excess. In: Harrison's Principles of Internal Medicine, 14th, Fauci AS, Braunwald E, Isselbacher K (Eds), McGraw-Hill, New York 1998. p.481.",
"    </li>",
"    <li>",
"     Nichoalds GE. Riboflavin. Symposium in laboratory medicine. In: Symposium on laboratory assessment of nutritional status. Clinics in laboratory medicine, Labbae RF (Ed), WB Saunders, Philadelphia 1981. Vol 1, p.685.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/29\">",
"      DiDonato S, Gellera C, Peluchetti D, et al. Normalization of short-chain acylcoenzyme A dehydrogenase after riboflavin treatment in a girl with multiple acylcoenzyme A dehydrogenase-deficient myopathy. Ann Neurol 1989; 25:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/30\">",
"      Ohkawa H, Ohishi N, Yagi K. New metabolites of riboflavin appear in human urine. J Biol Chem 1983; 258:5623.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board, National Research Council. Riboflavin. In: Recommended dietary allowances, 10th ed, National Academy Press, Washington, DC 1989. p.132.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/32\">",
"      Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998; 352:291.",
"     </a>",
"    </li>",
"    <li>",
"     Weiner M, Van Eys J. The discovery of nicotinic acid as a nutrient. In: Nicotinic acid: Nutrient-cofactor-drug, Clinical pharmacology, Weiner M (Ed), Marcel Dekker, New York 1983. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/34\">",
"      VILTER RW, MUELLER JF, BEAN WB. The therapeutic effect of tryptophane in human pellagra. J Lab Clin Med 1949; 34:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/35\">",
"      Kim H, Jacobson EL, Jacobson MK. Position of cyclization in cyclic ADP-ribose. Biochem Biophys Res Commun 1993; 194:1143.",
"     </a>",
"    </li>",
"    <li>",
"     Cervantes-Laurean N, McElvaney G, Moss J. Niacin. In: Modern Nutrition in Health and Medicine, Shils M (Ed), Lippincott, Philadelphia 2000. p.401.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/37\">",
"      Ashourian N, Mousdicas N. Images in clinical medicine. Pellagra-like dermatitis. N Engl J Med 2006; 354:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/38\">",
"      Prousky JE. Pellagra may be a rare secondary complication of anorexia nervosa: a systematic review of the literature. Altern Med Rev 2003; 8:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/39\">",
"      Wan P, Moat S, Anstey A. Pellagra: a review with emphasis on photosensitivity. Br J Dermatol 2011; 164:1188.",
"     </a>",
"    </li>",
"    <li>",
"     Elsas LS, Longo N, Rosenberg LE. Inherited defects of membrane transport. In: Harrison's Principles of Internal Medicine, 14th, Fauci AS, Braunwald E, Isselbacher K, et al (Eds), McGraw-Hill, New York 1998. p.2203.",
"    </li>",
"    <li>",
"     Levy HL. Hartnup disorder. In: The Molecular and Metabolic Basis of Inherited Disease, 7th, Scriver S, et al (Eds), McGraw-Hill, New York 1995. p.3629.",
"    </li>",
"    <li>",
"     Bean WB. Some aspects of pharmacologic use and abuse of water soluble vitamins. In: Nutriton and drug interrelations, Hathcock JN, Coon J (Eds), Academic Press, New York 1978. p.667.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/43\">",
"      Hathcock JN. Vitamins and minerals: efficacy and safety. Am J Clin Nutr 1997; 66:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/44\">",
"      DiPalma JR, Thayer WS. Use of niacin as a drug. Annu Rev Nutr 1991; 11:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/45\">",
"      Gharavi AG, Diamond JA, Smith DA, Phillips RA. Niacin-induced myopathy. Am J Cardiol 1994; 74:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/46\">",
"      Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/47\">",
"      McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994; 271:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/48\">",
"      Petley A, Macklin B, Renwick AG, Wilkin TJ. The pharmacokinetics of nicotinamide in humans and rodents. Diabetes 1995; 44:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/49\">",
"      ALTSCHUL R, HOFFER A, STEPHEN JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 1955; 54:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/50\">",
"      Elliott RB, Pilcher CC, Stewart A, et al. The use of nicotinamide in the prevention of type 1 diabetes. Ann N Y Acad Sci 1993; 696:333.",
"     </a>",
"    </li>",
"    <li>",
"     Robinson FA. The vitamin co-factors if enzyme systems, Pergamon Press, Oxford 1966. p.406.",
"    </li>",
"    <li>",
"     Plesofsky-Vig N. Pantothenic acid. In: Modern nutrition in health and disease, Shils ME, Olson JA, Shike M, et al (Eds), Lippincott, Philadelphia 2000. p.423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/53\">",
"      Said HM, Ortiz A, McCloud E, et al. Biotin uptake by human colonic epithelial NCM460 cells: a carrier-mediated process shared with pantothenic acid. Am J Physiol 1998; 275:C1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/54\">",
"      Fenstermacher DK, Rose RC. Absorption of pantothenic acid in rat and chick intestine. Am J Physiol 1986; 250:G155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/55\">",
"      Robishaw JD, Berkich D, Neely JR. Rate-limiting step and control of coenzyme A synthesis in cardiac muscle. J Biol Chem 1982; 257:10967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/56\">",
"      Wittwer CT, Burkhard D, Ririe K, et al. Purification and properties of a pantetheine-hydrolyzing enzyme from pig kidney. J Biol Chem 1983; 258:9733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/57\">",
"      Plesofsky-Vig N, Brambl R. Pantothenic acid and coenzyme A in cellular modification of proteins. Annu Rev Nutr 1988; 8:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/58\">",
"      HODGES RE, BEAN WB, OHLSON MA, BLEILER R. Human pantothenic acid deficiency produced by omega-methyl pantothenic acid. J Clin Invest 1959; 38:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/59\">",
"      Sander JE, Packman S, Townsend JJ. Brain pyruvate carboxylase and the pathophysiology of biotin-dependent diseases. Neurology 1982; 32:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/60\">",
"      Rall LC, Meydani SN. Vitamin B6 and immune competence. Nutr Rev 1993; 51:217.",
"     </a>",
"    </li>",
"    <li>",
"     Leklem JE. Vitamin B6. In: Handbook of Vitamins, 2nd, Machlin LJ (Ed), Marcel Dekker, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/62\">",
"      Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/63\">",
"      Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 1983; 309:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/64\">",
"      Silva CD, D'Cruz DP. Pyridoxine toxicity courtesy of your local health food store. Ann Rheum Dis 2006; 65:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/65\">",
"      Katan MB. [How much vitamin B6 is toxic?]. Ned Tijdschr Geneeskd 2005; 149:2545.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board-Institute of Medicine. Dietary reference intakes. Thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline, National Academy Press, Washington DC 1998. www.nap.edu (Accessed on June 06, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/67\">",
"      Dupuis L, Campeau E, Leclerc D, Gravel RA. Mechanism of biotin responsiveness in biotin-responsive multiple carboxylase deficiency. Mol Genet Metab 1999; 66:80.",
"     </a>",
"    </li>",
"    <li>",
"     Mock D. Biotin. In: Modern Nutrition in Health and Disease, 9th, Shils M (Ed), Lippincott Williams and Wilkins, Philadelphia 2000. p.459.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/69\">",
"      Kopinski JS, Leibholz J, Bryden WL. Biotin studies in pigs. 3. Biotin absorption and synthesis. Br J Nutr 1989; 62:767.",
"     </a>",
"    </li>",
"    <li>",
"     Mock DM. Biotin. In: Present knowledge in nutrition, Ziegler EE, Filer LJ Jr (Eds), International Life Sciences Institutes Nutrition Foundation, Washington DC 1996. p.220.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/71\">",
"      Cole H, Reynolds TR, Lockyer JM, et al. Human serum biotinidase. cDNA cloning, sequence, and characterization. J Biol Chem 1994; 269:6566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/72\">",
"      Mock DM, Mock NI, Dankle JA. Secretory patterns of biotin in human milk. J Nutr 1992; 122:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/73\">",
"      Baumgartner ER, Suormala T. Multiple carboxylase deficiency: inherited and acquired disorders of biotin metabolism. Int J Vitam Nutr Res 1997; 67:377.",
"     </a>",
"    </li>",
"    <li>",
"     Carpenter KJ. The History of scurvy and vitamin C, Cambridge University Press, New York 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/75\">",
"      Szent-Gyorgyi A, The function of hexuronic acid in the respiration of the cabbage leaf. Biochem J 1931; 90:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/76\">",
"      Svirbely JL, Szent-Gy&ouml;rgyi A. The chemical nature of vitamin C. Biochem J 1933; 27:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/77\">",
"      Kallner A, Hornig D, Pellikka R. Formation of carbon dioxide from ascorbate in man. Am J Clin Nutr 1985; 41:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/78\">",
"      Glatthaar BE, Hornig DH, Moser U. The role of ascorbic acid in carcinogenesis. Adv Exp Med Biol 1986; 206:357.",
"     </a>",
"    </li>",
"    <li>",
"     Jacob R. Vitamin C. In: Modern nutrition in health and disease, Shils M, Olson J, Shike M, Ross AC (Eds), Lippincott, Philadelphia 2000. p.467.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/80\">",
"      Bigley RH, Stankova L. Uptake and reduction of oxidized and reduced ascorbate by human leukocytes. J Exp Med 1974; 139:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/81\">",
"      Schorah CJ. The transport of vitamin C and effects of disease. Proc Nutr Soc 1992; 51:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/82\">",
"      Rebouche CJ. Renal handling of carnitine in experimental vitamin C deficiency. Metabolism 1995; 44:1639.",
"     </a>",
"    </li>",
"    <li>",
"     Ronchetti IP, Quaglino D Jr, Bergamini G. Ascorbic acid and connective tissue. In: Subcellular biochemistry Ascobic acid: Biochemistry and biomedial cell biology, Harris JR (Ed), Plenum Press, New York 1996. p.41.",
"    </li>",
"    <li>",
"     Katsuki H. Vitamin C and nervous tissue. In: Subcellular biochemistry Ascobic acid: biochemistry and biomedial cell biology, Harris JR (Ed), Plenum Press, New York 1996. p.293.",
"    </li>",
"    <li>",
"     Horrobin DF. Ascorbic acid and prostaglandin synthesis. In: Subcellular biochemistry Ascorbic acid: biochemistry and biomedial cell biology, Harris JR (Ed), Plenum Press, New York 1996. p.109.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/86\">",
"      Millar J. The nitric oxide/ascorbate cycle: how neurones may control their own oxygen supply. Med Hypotheses 1995; 45:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/87\">",
"      Reuler JB, Broudy VC, Cooney TG. Adult scurvy. JAMA 1985; 253:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/88\">",
"      Smith A, Di Primio G, Humphrey-Murto S. Scurvy in the developed world. CMAJ 2011; 183:E752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/89\">",
"      Monget AL, Galan P, Preziosi P, et al. Micronutrient status in elderly people. Geriatrie/Min. Vit. Aux Network. Int J Vitam Nutr Res 1996; 66:71.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board - Institute of Medicine. Dietary reference intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids, National Academy Press, Washington DC 2000 www.nap.edu (Accessed on April 07, 2009).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Water-soluble vitamins. In: Pediatric Nutrition Handbook, 6th, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village 2009. p.485.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/92\">",
"      Hirschmann JV, Raugi GJ. Adult scurvy. J Am Acad Dermatol 1999; 41:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/93\">",
"      Weinstein M, Babyn P, Zlotkin S. An orange a day keeps the doctor away: scurvy in the year 2000. Pediatrics 2001; 108:E55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/94\">",
"      Jaffe RM, Kasten B, Young DS, MacLowry JD. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med 1975; 83:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/95\">",
"      Urivetzky M, Kessaris D, Smith AD. Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis. J Urol 1992; 147:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/96\">",
"      Block G. Vitamin C and cancer prevention: the epidemiologic evidence. Am J Clin Nutr 1991; 53:270S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/97\">",
"      Hatch GE. Asthma, inhaled oxidants, and dietary antioxidants. Am J Clin Nutr 1995; 61:625S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/98\">",
"      Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994; 272:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/99\">",
"      McLaran CJ, Bett JH, Nye JA, Halliday JW. Congestive cardiomyopathy and haemochromatosis--rapid progression possibly accelerated by excessive ingestion of ascorbic acid. Aust N Z J Med 1982; 12:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/62/28650/abstract/100\">",
"      Smith JL, Hodges RE. Serum levels of vitamin C in relation to dietary and supplemental intake of vitamin C in smokers and nonsmokers. Ann N Y Acad Sci 1987; 498:144.",
"     </a>",
"    </li>",
"    <li>",
"     Cody MM. Substances without vitamin status. In: Handbook of Vitamins, 2nd, Marcel Dekker, New York 1991.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5367 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28650=[""].join("\n");
var outline_f27_62_28650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2997416\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VITAMIN B1 (THIAMINE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Actions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Infantile beriberi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adult beriberi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Wernicke-Korsakoff syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Leigh syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Requirements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      VITAMIN B2 (RIBOFLAVIN)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Actions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Requirements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      VITAMIN B3 (NIACIN)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Chemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Actions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Pellagra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Therapeutic roles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Requirements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      VITAMIN B5 (PANTOTHENIC ACID)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Actions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Requirements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      VITAMIN B6 (PYRIDOXINE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Actions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Deficiency and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Requirements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      BIOTIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Chemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Actions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      - Multiple carboxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Requirements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      VITAMIN C (ASCORBIC ACID)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Chemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Actions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      - Fatty acid transport",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      - Collagen synthesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      - Neurotransmitters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      - Prostaglandin metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      Therapeutic and prophylactic roles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69\">",
"      Requirements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70\">",
"      OTHER VITAMINS AND PSEUDOVITAMINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71\">",
"      VITAMIN B12 AND FOLIC ACID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2997416\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5367\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5367|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/40/1664\" title=\"figure 1\">",
"      Water soluble vitamins A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/9/43165\" title=\"figure 2\">",
"      Water soluble vitamins B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5367|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/39/8821\" title=\"picture 1\">",
"      Atrophic glossitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/40/26245\" title=\"picture 2\">",
"      Pellagra dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/51/39728\" title=\"picture 3\">",
"      Gingival abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/17/34067\" title=\"picture 4\">",
"      Perifollicular abnormality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5367|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/15/12541\" title=\"table 1\">",
"      Clinical symptoms of selected vitamin deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/20/11585\" title=\"table 2\">",
"      Water sol vit DRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/19/1341\" title=\"table 3\">",
"      Signs of nutritional deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28631?source=related_link\">",
"      Dietary history and recommended dietary intake in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39332?source=related_link\">",
"      Electrolyte disturbances with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=related_link\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=related_link\">",
"      Overview of the chronic neurologic complications of alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=related_link\">",
"      Overview of vitamin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=related_link\">",
"      Overview of vitamin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16122?source=related_link\">",
"      Surgical management of severe obesity in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=related_link\">",
"      Wernicke's encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_62_28651="Air embolism differential dx";
var content_f27_62_28651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of air embolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary thromboembolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute bronchospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute pulmonary edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular",
"decompensation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypovolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiogenic shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electromechanical dissociation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurological",
"disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral hypoperfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraparenchymal or",
"subarachnoid hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxic brain injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic",
"disorders (eg, hypoglycemia)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Orebaugh, SL, Crit Care Med 1992; 20:1169.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28651=[""].join("\n");
var outline_f27_62_28651=null;
var title_f27_62_28652="Booster vaccination for HBV";
var content_f27_62_28652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Consensus Group recommendations for hepatitis B booster vaccination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Children and adolescents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To date no evidence supports the use of boosters in children or adolescents. It is important to ensure that the full three-dose primary course is given.*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Healthcare workers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        If post-vaccination antibody testing suggests that adequate immunological priming has not been achieved, the following course of action is recommended:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Screen for markers of present or past infection (HBsAg, anti-HBc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Administer an additional dose of vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Repeat anti-HBs measurement with a different assay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Consider passive immunization with HB immunoglobulin after exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Booster vaccination is not recommended for those who achieve an adequate response after primary vaccination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intravenous drug users",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testing should be considered only if the user has reduced immunocompetence. Currently there is no evidence to support booster vaccinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High-risk sexual behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Public health services should try to identify persons with high-risk sexual behavior and ensure that they receive primary vaccination but boosters are unnecessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunocompromised patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There is some justification for using boosters to maintain the anti-HBs levels above 10 mIU/mL in immunocompromised individuals as recommended for dialysis patients by the US Advisory Committee on Immunization Practices. Additional or double doses are recommended for nonresponders. Attempts should be made to administer the vaccine when the patient's immune system is likely to be functioning maximally (eg, before initiating hemodialysis). Post-vaccination testing every 6 to 12 months is advisable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Residents of mental institutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No booster vaccinations are recommended. However, staff who are in close contact with residents should receive primary vaccination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Close contacts of HBsAg carriers/immigrants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Close contacts of HBsAg carriers should receive primary vaccination in the absence of serologic evidence of HBV infections. No further boosters are necessary.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A two-dose regimen has been approved for Recombivax in adolescents.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from The European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355:561.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28652=[""].join("\n");
var outline_f27_62_28652=null;
var title_f27_62_28653="Contents: Neurology calculators";
var content_f27_62_28653=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Neurology calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Neurology calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13697\">",
"           Calculator: Apgar score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/29/17874\">",
"           Calculator: Epworth Sleepiness Scale (ESS)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/25/10642\">",
"           Calculator: Stroke Risk in Female Patients 55-84 Years Old (Framingham data)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/43/9906\">",
"           Calculator: Stroke Risk in Male Patients 55-84 Years Old (Framingham data)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-AB27A7C25B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_62_28653=[""].join("\n");
var outline_f27_62_28653=null;
var title_f27_62_28654="Progestagenic biological";
var content_f27_62_28654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Progestagenic biological activity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 404px; background-image: url(data:image/gif;base64,R0lGODlhJwKUAeYAAP///wAAAAAz/4CAgMDAwICZ/0BAQMDN/0Bm//Dw8ODg4NDQ0BAQEODm/6CgoNDZ//Dz/zAwMCAgIKCz/zBZ/xBA/2BgYCBN/7CwsP/w8JCQkHBwcP/AwJCm//8QEGCA/7DA//+goP9gYP9AQP+AgFBQUP8wMP8gIP/g4P8AAHCN//9QUP+QkP/Q0FBz//+wsP9wcH9/f+/v719fXw8PD5+fn9/f3y8vL7+/v09PT8/Pzx8fH29vbz8/P6+vr4+Pjz8AAJ8gIFBAQN+wsGAQEO/AwKBwcF8AACAQEK+AgB8AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAnApQBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vPSDQcQ9Pn6+5UTCP8fHswqIODAoQIT+ClcuI8gAhUCKuBrZK+BIQgHDlgcpLHQA4MeBRr6uFEAAoYoU7ojWAAAgoIEDcY8IMAFhZMQBQj4UEinThUAIFDwKSDo0IgCXx4FGrPBUQEFXuoEqbKq1XAsIVwQ0CAmgJkCKCAEIaADABdcCU2AAGIrgA9l/10WhXivAgW5E0BUKBqTJYCPD8Leu0q4sDaCPlt6BdvyK9GCgyAo3StX0MvKlS9Xjvlgr4ALAk0aHk16GsEPHR2bhZsRqqAJcYNOdAyiMlqLl+FavHAB82XO9iCeFF26uPFkfjn63Nu6sdCwL6mSvXAUwPTqnakLSKj5N0yTQxNuRUD1uPnzvA4UKA9APQj1DbqWB1GgQG1C9CdMaKx+AoUKgjTQQQEi7fdaS/BBsB+BAdY3G3oQRnjNARcgsBVQEmaoYTsQDMjghiCGKOKIJJZo4okopqjiiiy26OKLMMYo44w01mjjjTjmqOOOPPbo449ABinkkEQWaeSRSCap5P+SmhBggAODbMBAABEsIIgDEgQgAZSpLDDAlwM4kMAkDhhgpgVWguLAAEy2aYoBAQTAJgAOBFACBloCoICWBGSpQCUBRIKBBDvMEMOhPQRgwZ+QDBCAARsEwMCYhixAQCEEMDqIpZTqSUCacBLCaSKfGpIpIQRc6uaqAAwA55wlBIABABEEsIAGAWwAQKQaAAqJBTTUYIgNMzAw6yOOsgknAY5aIMEACdQqqZXRxhknAAnAGSeUscZpgKNxQqttAFDCKeWnU1I5ppbpzrpAltOy6maygiwLwLL00ktJoI5YcIMMidQQgKqNJJuAn46WMAABkRKQAAMRAGBBAL2GGun/AgdLQICdCSiAgQK1ZnpxxvfmOgDIk26sq5YY4GoArRIksICi8rapr734ytmqzoRY6/PPPzsywL+L1DCp0D6z6aiqoZbstNPjxlmtpOXyG3WgTQPwqCBbb631yz+/XPOS+vIKwJQJ4FkCALEeOwm/izyMQyM5WIC0BafurOrEf0ogAdsB/BnqxGkqYDgBGkz5NOGCCA6333rS7PXWflOq6dhHGpClBC8rwADEuQpSK5wRVwIECSFwkEEiGuTgiA0BdKqIvoIsLcgCDEhQK5R46n4t7o+GTCWcdk8cgQbAG1Dr03RSKQEDVk7+cp0MaC425keC+WXjGgzgdgJrimnJ/xEkjDBCCimMsALqqtcrrCM3uK0IswQDwKymCnSfpv1hRsCAIOD7kpUw8KVjJUB/2FrTAKy0JlENQAOMClPtuJS/B14Oexi8BNwAkAEOhIAEKzhf+hhgg0fwYE6e6JPmQpfBFiJjg4foIAwXEQMUduKAAnShDo0xw0MEAGCOqOEOh3iOHhrCAHNzRA+CMAL2EfGJ3zBiITYwA0fIIABD+OAITpCCEzTxBS2AohirIUVCKIAGQKTh9QbhwfJ5IAUmWB8HUDDGOi6jjISwgOsWoQMa1C+GHGCBCM7ngRHAIHV2TKQw8DiIaFUxETbYgQ0dgYIXlI+LJhABCdqnyE7egv+Rm4pADkpoCB/QwG6X6CAJRGCCLspxdZ6MpStA2ciJzcAHOJABDn5wAwnIbxOBZKUrNwlLWRqTFLQ0owZWaAALcIkUwWzlCVbAAg4c85qeSKYtgolJEYQgjNgM576SocoReKCQJHhBMcXJzkRo0xcoCAEMWpnJb7bznj2bBgfc6AFqWhOf4nynMVogSC428Z8AlaVAkxFPYX5xnQkd40KZkYEXzDN9m4yoRMdRURgYNKMa3eFEp9HQE/STBeAMKfZGag0UsGAFHjiBNyGq0jaxNBv7pCcJUlrTJd10GxUVgUln2tMk/dQbBD2fCVBa1CIdFRwZCIEIYiqCFzQ1SE//HQcHPNrPEND0qjbKajlc2soVhICOYL2RWM8RzxXAkQVoTauM1pqOqLp1qXGVa4voug67vjWvekURX9vhVxN4NbCCjZBfzfpVxGZosPIgqweq6tgQQZYeKPDoCWAA2Mqe57L64MBUDdtYz44GtPuI6vlEgFDTlga1CkEBCU5wAri6ljSwZcgL3LqC1t62KrlFiWxpy4LS/lYfwVXJblMgAp4elx/JrUpmCxmC5yokulaJKm1JYFzrrgO7hOGAW0XQWe+yA7yFQcFUR+Bb86oDvYbJAAk8YFj3nvdHIaBtde2LDvgWJwRb5C5/y+Ff43DAnAIecDgKfJwDeyDBCu4G/4PN42AIRzgbEz5Phbt7YWdkGD0HPsF+OxyJBYgtWxfExYchxAETiJjEj7jVwAiApz+qeFX5NUF7YXxEoKX4k/JiQSHLy+MrTQxMNr6xvOTLXA5fOAFJ3sWKQaTeBxfZENnyWZRrMeUQhXjHJMYV58y0P110WUQhGPKVAYAr2fXizCLKAAxSYOEOe+7HZt5hC7YIZv5uTMtvJmKaV+Dk45rYTGQONBEzMFUWrNkXcEYRB7xIZO9K6Un/U7QY50sCBffOAAkYmKbF2AITmMC51h1ABJyktS3TItIsIkEKHO1eDfjSALjCM5c7WeoRVNqzD7PWGvPsSRh4YMTPXYAFIP/l5lzA+kWTJvRzFWCAWQ1gbaPuZAZg2ufA2rpxoubFs2OU5k7f1lWDCLeUsdnrQvcUTwubWLOBHE5jdxus0mKhuNn5Aiubdk2/JLY42+1YE5c529hk9AlQfdU9uZre9xQyssEKMoV9SdevTigHPAADvf7ZWg+Xxbh1hII4urudUE5VquZti5HraNsm+HVE8+cAxEFapcZmuEY996iZYXwWLudRmice0sShW90CD+nGiR5RVznJ4QiPaAsm29ONlUB3md53UTOQyZ5ObFs3byrXpa1SBTjsF0EHEsxPHksMlIDZYQcrK9muyI9TKe5yNwHd7TgACfypTiGPRdqHNHf/gC6gdFo7uJL1ykqZxxJ3iH6UARS/a8ROVefGtDvI1+3Ywj/aV5X1/OclMfgjiX70jyi96fWOekiofvV7fyLLIW7aQbbTACUIPCxefySui4Cdffda0k3r+1RgZCOQ+Ago7PEgXSg/GAp4prOfm4Fjf8IfPLHOP9rjmkhoxhNeMYSBKDF+Tny/EAiRBQHuFAzeJ2nqTL8EYnajE4qkRhAHeMD58Z9/QtxfEM9HCPZwCPYgEvs3CB/BHu2xEd+HEfeHEc3XfyFxCCQhCMQBC38mARvwc0DnXRuHeZSAGKjhE9xXAEIhETTBEzmxE0ZBFIUgFWHRgiT4HEjhGEdxF16B/xY6gQCI0X2D0IMVYBGf4Rn0kRgAQBRA0Rk+cRJKGBb4oBQ/URlOkRgwqICrkD/S8iRaZ11p5niQcBoV4AJwURQ00RKdgQB2YR1xcRsQYRb7BwIYER1w4YZzURAQkIYEoQIHMBTqURA04QIQ0AAgMIUasSAI0gAPABEt8Rkg0AEmQYgWsRZtURRbERon8R8YIQBA8RJ5QRneYYb5JxjNxwr5Ay9xonut4H5LMk+xdxACoBcFUX9l+Bo6YRE9OBXdURSEABG8URC56Bt8ARl9YYdHUQHcoYsq8A8nMQEVYBeuQRyioRmSERaUAY3DcRJHeBK/eBlNCBrZqH5xwgBoov9slJdx7iUCK7AJfeECR0iG3ecCe2EWsGEWsnEbmIF/mugYB2CPuZEWvKGP+tgU9tABnqiLPXEXs2iNmEEQtXEZFdAb3/iPDcCC21gUDxAconGBr7B+0hd1v8V1HZcJ4deOJegYE8Aaz3ETfvgZ1TEIDdCMUnEA11F/2REeADmMraGSPAEXFECPgzAUaPiM2CgaPNkBM1mHFDAeAAAbSVkBSaGLl+EdCGCT42GFqaAAc5IA0OKRv4UC1ocJ8PGDLSEfEFAAZlGW9Egf9oF/CFF+AGiW9GER/fEfATIgIhGW8BGWankfHfIhkVEf6iETCfEVCdGXApEf47cfZMGOf2H/lhuRmC1hIApSHyLRFSaIgfwSaqg4SwP2gcNAIRaSj7pQADexF/ehDFdjK1x5XCxwAq3YCn3pl7lgmR2AfMqwAaNjJpM0fQqGjnWElYsUYVxnbkSkABijciu3ms81dfc2Nk73M5uZih2WZq95JATgAFipPRwoeCRme09knMHZYVxHa0O0MRIAQWgHY1MHgmOjABaQLiWwnbvHY61ZnUiCK0jHmzC2AiHZCRIICcxnIu6ZLgYgn6+githTfVb1CBDwAXtRAdlnCBqpCOM3krXgltxgnuiJdyTWb+42FB1wAASJgIPxjQBYovxnGQa5CB8xigAoEhRYHhBYCBkhgBJ4/34tigjHZwgP+J+9AJ7tt2YrkI6OoBMTYBH4MI1G+o1Kuh1L6RkV0IP1URBkARQQAYcwOJiC4BA6wROncQEmWIwC0YSi8QBbUYM6aBJS2qQJERZosZQ+kX1DqBO1wYw6QQEuWgvGmXIqN3vmWGQZcAILyggreAEJAREPoBW9IRqIqqh3eAEQAAEqAIle8ZAAQJeN+o8/6KQv0RU1sR50cYd3UYnfmJQQEBgjCIiCCImZuqhRaoKiwZBHeAGNaBIQUBMA4IhamgvPCWhbWGQbV2gHoAJHoX+P8Y0wOBU+uJCQcaX5mKwruhjfARK/qJCPgQA0aIzA6ILEMYsJOZTk8f8YjaEL15mdYGKgnPlovskIl3mpAvAAcFGZ3xivATKRjNmQuugVgUGq9AoAtpmDXBF+ugEA/2ipEQmp9TqQBSkI/SqE2DiRPAEbbQqu9uqSvgCc2LKVvwqoHjCoibCDQ8ETSjiVRVGme0GybxEWQ5GyPRl+W3EXf3GyK7upFBCyABmz2nGoYaGUsFEBFhKuOsmyHTCyK3uBcIGGeGqiRPkZaDiuu7AxAJSfi7dmL+Cai9AACwKjk8kg6RcUWfuW6xEUdhmW7RG2grC1MOoY9TGYZOuvdjkIiomrbuuY1lEffPm2aEuY+IEQE9G1XfsAa5untZCa5Vh5n8efwWCh7Fr/mq/4Drgped/CoVfmlexZC21LEfVRm/FAbX+yAIVruJ/HAiaAPXhiJbmmnCS2VNEQoBfxf59QEaaAEWl7CejGNdHJCgg6RMF6CvJhCoqLj06rFsE7CVqRtA+ggxcgj8oYEH+hjAhAj9gnCCCwfYfQr5hga2MyM5/bga0HACLwe45Qo/5HFbBLCA9wlz64o41wvkGBoqx7or9bkn8hvvc4v4nggIZAEALxkhXwHsnoGA8REZkIpluREPNHsPV3oshXIZqwJ9WTO5L7aNW3Yy+hAhWQf2fqlE+qEwCygl5qEl3ajvUHGyH8hzdBCARxFAWwFzA7hk6asj7RHCU4i0Do/6k6EaYc/JQWLKIuSAgQio+0mqRqKxetcRJ+IYI0UX9TeMO0OLuVMChUsr3c270sMAKHUMEF4BSQiqqPGqkqQBZmcRsEcYwCshP3EKuvSBNisat5OB0ggBYy6RovwRa4yhgz7BoakYhQwap2mIZYPJEX0AAKYr4v7K53KhBZsRX28BkrHISO4aBiWH9+8XwT6ZPakLtP9GIvaJDXOotb+hh9KBMriSB4DBWejMKQgcahHJDCOMp3HJnNOBQt8YuZYZAujCH4WB4nuRUAcouk3IyxwZDMQZOe4Y0WOLyU4CqIJsXc2b2CMGkQ9X28MRHxIbcgMI9nW5aQcRuzCLFwOv8Bp7ypBqHKEpuyZWzAK8mOsLEez4iQcqyLA/uP35d//gEZ+HgfDzCYt9rLZrwRNIEAPWuLMMGONImR2HiryCwJeOKrnOfMANBEmwy3EfGzLDsUKRkdKWyzE5mGR2sXmTi8XqHKJ/gSPHGHPjsVd8jBpuwaQLkXLVGUNcmpnFwhHk0IokkTPlvAQ6wcJ4EWRmzPJOkQNqmGVhkJfXdxR7OxreeVeeWWAkK3jWm2e6m2XVu2acm3/mq2/pfFehuWk3maXWGUXN0VEwC4GhG2ZbkeaP22T10g4wq4WE0IDjoRDzAgmlu25UHWQUGZbVsfXkuZg2AhmuAqZaKZqHtl38v/CfFbDS/JmKYAG6d5CQ4APdbCzPPp0ILA1JtwudlAH04MCmi5CVAGPlp42FdWPvaFyWI0we6l2ptmxebl2lAUqM2JWLINRQCmJMyiPRdn2o92ArXNI+ACnb69ZrmNJGaHnMmp1JgNAMC9JHx6dsyN2ceN3OlyisX928G9Iy7TTAyArtLZ3IZQ3UbiKgOwMpZ9oOJ9CB6w3TmiagTAAA2T3Y+G2kdiYiCjLvS9ZtVXuT4y2hG83qt037KyK0nd0OtNCBmQAl743qVj2NO93oldJKoWtbe7CredSF5pny0yM9/iPwGe4BBdJJECdvv9eZN2JGbnp6Cb4IWgyUBSrrwN/96JcGhmoit0sjkdGQkZrkjk7SO9unmZsDHVAymRozF+Anoubgj9HSR7qtws/ggbs2qMgiu6YjbjtOSHAAPgGyTRnTeYYHe9ki888zZafggokAIcniKap2+W0DH2cy1kPklAU+c+c+aHQE1eAibioyN98iXvGSs0bipWQuQAoDaAE3Cph+eGkARKUCiHEgOJsig5skzptjEXXgjDTS6i8yh3p+SMLjHBMizFougxgisawCwDI7WSEEAL1EjhE+WK0OOJ5C9pZAgCk+kjEmxxUiWBg+BnPjS3fghGI+sqgkN9HuHiLTd0g0o2suLpyeit8zqxYyNfx+kn3kJQJp+Wgv8tYM4KBvA+jRA/NVInFuAqv67sRPJ2u1kJG9PuhxAq714IiAYlhxcnFkApC9AtbLIBiGbkkEBCJgTvLVK7rZbtODIzkmJGpQJA3+4pjJByheC5mFLmtfMqZyMrsdIrnsMANXcp/s5MPA4JQkQjk11zjjLoqkDr8DAxcMIl3bI1dYLvce4/6mJ1EWAA846f10I6caIr8m7xtaMzU6IBkTIrkfIlvUIIWbLji/BDj1DyMzI1NIPwNwIxiG51HYMBofYyjoIBG2M3jlJzVBIm864lCgA+JeMAGKA4Qb+b9PJxYkM6WeLsdfI3kYBEj5ADTv8iAWTqtIck5v5naS8tHj//7++O+HIy73HOJtcO9FaDNYHC+IRgMH6DAbUC+Q5zLYLQ9JJARVaU7jGS3FBu9TVyNSdjdokTODRTJ2TPJrjy+oKA+AvgACHTNKHy9oaQ9FN+6FsTKWKy8GyWJ5JwRsOOCDEwbC+y6UIO7EayJ9g2MxozPDTj8hADZVpCOtg/J2fPOdeP+5Lf+EwPJ99NK1QyJbPS8Z4fbH3PCHrECH2k6xuy2zNu+jPiJQTzJWlTQIMACBgDDgkABAEWAxqFCgMEAACNjwsDg4UOA5CYAJuSkJCVGgqQCZiinwoajpCUGp+vsLGfCREzsp82O5m3vL2+v8DBwsPExcbHyMnAAcrN/87P0NHS04e709fFCxE5NrI+NBbY4uPk5Z8OEgERC+bOzO3w8fLzvp707QkWATM+ODI4P25IwHCvoMF2hyQYYMCg0MFlDyNKnEgxYioD6QwQMVKxo0dgAyKQCvDo46t3JlOqXMnyFgsRLWNK1CBh1CF2K1HK3MmzZzwUKTL4HGpOAYMASEWy1Em0qdOnw0yEgEr12QILBjY4zFm1q1eqLFZ8HUsWEtOyaNNSBCpUrVoHGxYYmDsXp8qzbvPqjSd1b9kBBg4hRVryrt/DiMeFTcy4I97GkCP/YiuZKoYSWbcarsy5s6y+nocKTtrycejTiRej5jmgJieSS1fLbkx5dv9LAkoBwOZqu/deEy98p3QwlwHdAHZTmhbOHCzM5h0HDJ5eWDn0615beMDO/WT3701PBAd/fTn58x5hwEDf3Dz79w9bnIDv2z39+/M8tMAPT4EBggOUUBp/BD4kAgkFlkMTJArstlmCEMbzggkRigPYJw5aV+GG5GSQAgocSoNBAI7oo5lJ9oWoYjErTLXiMxEMtsGAL9bYjGo2KoMJQTTm6CMxQP1YjAILJEDAkUee+FGKQjYpXpPCADYaYbFBaSUv6l35CwEONFJJJaPwpuWYkLwwH5leMYnmih+ueUsCBlBXpZtXrsACnbFoEIBCdc2JZ5M4/gmAnko+KOiPQR7/GgkDYcakpqIJnsCBolNmiCKkQmZ5qFx0GZDcpZj6OGGoOz1K6n0etiXoBsY5wECPp744got/jqhQApYuGauNJDz3Z0gEGKBbdaDuuiIHZ/5JEwYG6Nmohsau6AGIfyZwFFLC+hkth3ZuipVWsG67YaBuGokkAc8WK+6G2glaaQAzGrpuhfr9SYAElVjAQAkBpOvYvCGKcCeeGmQ7bK4VmQoweCGIRXAAGhAg3SHE/rtwhYnSae1g6/Qr78UFSlqtKoSECzKBB1Z7bqEWn5xgCCPgaZScYrpMYMZr6jmXvv56pLDN14nsJmADzIictkDfl/LQERDAwAYIt5w0fjDT/ymXAjFGwHLCU9+cgqBGbs111/ydsN+ah4z0qa5k4yfwmg7oUwnUFfvcNn7kXhnndA0hffd57aK5gJ5Iik3Rz3/bVi+aYVPSs92Jw9ctmiPOnNvHkYP30ppSknh0zZmThyznEUiHa91Sh05em2QugJQErq8NuernzZqzpxoI6Dft2JGw3poLLECkybxjV0QQXw4gu420BPBfAIZLhHjxleUTQA8xZD/DDhI40KQDAWA27O7U97YAA9zEUsMOJUQfoZQGnE5++bKdXwMvMtxgsI2uhmTi/PQ7jbXu14v8WcNGMUJKvEAXwNkMoAfA0IHHclSKAfAIgA3sDAN0EIwZLP/wReZC0uPGlsHZEGAHwvDB5Vb0rg+yrYSy0YAtgiGD6aHnXvna1wTVFTojhclcxiDA8r4ygBgMw4bnKRiGKIY5mxEnHABglrCqsSikGMN5spDYCImxAbpYgB1yiVcX7VKweGkDKRZwCAYSiDpZDIAHR8yRniI2sahNBImhko7H0sEU6VxwAQTQTNi2FEgATGwW6ILFIEkhxFjEyQL6kIAhsAiAOJVEMNk6ymUgFkV1YAADW4QFASAYDB1IknnXUofrQvkQPGJKjxYYzSQdMZgBwGkw3ttTOhjADnXwSzdTTKUesQg+NE4ygYzixLW09gpL6oYZh8iWMxMggRhlEmL/UCNIjHY0DFx1Axg8gCLzSOa+iLgSUtLRVwn0AU0SWU8UUCuSBCSpDiMhQjcMqAQwKwkbDFwFYkXCoh+jSQC54UpAevLeJx7JrxlFExLO3MBAKDmabGHrKAoNhgWM+AsZ0KCNG6rgBRkIND8eRTCzNCRs9jaYfe6TkvsspvMScEgqVsOmJKrUAeO0S0g8lJ9CDF8kCTHPNcLrmZ3c3y8axEFfzECpK2qeMTG4sIkFCKlUPKQ+cDIKLLouHDDFIro2WQnYNCgc4HMATgfQIN1FopkBMOqMXHfKdARvLjF62iFEMiJhxUgBI3JrMBxAg6beIgZ9kyMD1CqdIR7uboc0/0s7M3HI8zkvRvhcCC9dus+FYISX4JNAOPSxEK2tFQCRXMhOSeI62OgjAjES5ySzlTVNdlICDHHsLQZAAwLCQgY52KyPLmQWkN7xblr8hD49kVwAVFB5uomAKsI0COV6LxWKCBM3o2iJSKzCHpTo7jnYyl1XcNeCsGiEQit4ClaA6RgYkMAOfoADG+jABzMARzkhNKJExGm/Bjln12DqGQxgJQBIAAJ5ocTOAGS0iSWsrm1YZyUFFJJ4MBTOCMbTJCbKRMAZ9gsMEAQlaxk3dSEWzgtiBqUFzJMuupVeiq+Dsx9V6sTmnPF1FqdjDPW4OS1qUj4MYMsP/5g5vWoSv/+miuEjn4YDFBISIgoKYnJU2clk8VCTYJM2R2HZNyaY1I+mMxgct/LLvVmaj8hMJZKi2TN5S/GV39wV+Th5znSuCoV1jOc8Q2XDR+6zn50y4kAPGjUrNvShQ1NjOS/6NDyesaAf7RPb9XjSlOaJ736M6UzLhAMs5rOnOaPlS4+aM0KT9KkrMzlVrzoySRb1qyEDZVPPGjJBkfWtGRNmXe8aMWoOcad//ZE4Z3DYxO6InV2d7MPk2tHNPswIxCzsaB+m0NC2tl6qlm1tuyVw1fa2XvZcQmSL+yGADve51UICEmfY3OsuSKLVHW+yOEAI05HABliZOHi7zMIA1os2dlD/g28CAAczOCr9/N2k+KIx4L2ILCw24QzidOquczVA+17BqvA5BB0ByCcojrJYVsSoeybf04N/cT6OxsIGN2Am9Rj+oxE1TTqXW6QhGvmK4C2V53HqecV8/glAnsjifDzSTGNUnXSmEwB0vdfRSrABqPXLWgxwuAKwrvVg2K+AN5At7WjuoxjhhF8Y2CtSkslSkUhnb+FIJ74OuWTnDdOWyGRHnBI4o1siZeXOje1s5QYLZ1rRdVlfyLMs+VDp0FJYjg+GAVyOPxqMVHVkz5EVQZFT51E5ExgwkiWl4704NSJ8jpjYIdoHWKyRRAF0s5ZI4uQADBwFAPGk5ilfwS9m/x7iKCtE7ZQ3f/dXNEiSDcq63JJvYBIB44QyAEYNdj/2ux3FIVCLmPOpCLV5kuSQVt3NxKRa8qDzE6LMMH/QWbr5T0AtmZMsc3qtuSdD7MtVcWVQBIQ7AIZs05D+52DAYAFwFAw0EGMDdjf64ArU1C9rdQgzEn6PwC+nVxITowAWpgG3Z376MArzdH7nt1UM8grFZBfRpCeJBQt6EndHBTWZcD6wo0jp0CgNyG8RgAPCkAPmVX1t0zz7J4BrZRTGQRg4J3iRpXrq8EjCJ10w+H/qxwyWZQCYtVBk9ngAwC/7gxtZwwhHESfJVIVXuBACGIYYFQxqEgMHFDqZ5yOC0P9enuAJrSAIp1cJCtVcySUI6OVcqsAO2IUTFEdxz5UcmJA86FJdNAVdDFIJI4VdJWNIhMgJ2TVe7QURwoCGxbOG6GRHpyEBhvULPJCGmYOJlLJgvlECvvULO2BmSSOK9RYNDnADwYADr3KJregVEuADwNADoIgpCbBkG5cMrFiLz4ABheULPCBzsSI3TweMwtgVvNWJsMADwrUr14crs4gMwdiMFbcPBgcJPhBzCPgnm9d+x5CN2tgMCqAvN9ADPNADNIBy4jKOeMFm9FiP9niP+JiP+riP/NiP/viPABmQAjmQBFmQBnmQCJmQBIkeZuc6wXeOEJkMtpIOlxeRFnn/DOEVjhe5kRzZkR75kSAZkiI5kiQZQA9wACVZPAiwkgjQAe0wAQUwDQggALLQAAWAkinZNQIgAAVAATwpDAeAk7BwkkL5CQfQAJAwk5/QAEEJAZ8AAQfglK9wAA8QC0cpCyeJlAfwkzk5NTsJAFuJAAAgAGI5lmI5kypQAVR5ATtZAVX5CQWwkwJQAUgpABdQATsJAnG5kzcplwIAAgDwAHi5k2IpmDtJAU5pl4MJmErZAD7Jl37ZlUnzlR0gAB9glpBAlgCAlgXgmBcAAQ9gmVPZAA+gAj9plyBQmQjgmAJwlEzZABOgmWxZlZpJARUAlQKgAmN5AampmUoZlzF5/5KV+QFFKZkg45cXUJdl6Zs0mZl+WZaQMAEVUAE+GZOaiZlKGZhsOZNieZ2a6Z3duZxnSZOGaZcnyZXG6TI7GZSfYJcQ0ADM+QkX8JmQgJTtSQFgeZriuZnNOZOJKZYVcAGZKZbzCQDweZngyZ+ByZSmiQBbGZPpqZ7N+QkzOZfxGZ1ziQAXAJ0A4JMIgJfWuZ8fIAAU0AGmSQHbCQAnmqKxiaJuiZnYSZNxiQA+OQHwSZ0RejIFAKFP2QEdYJMTAAAw+QoN0AEF8KOvAAE7egA3CQAFEKROGqQQYKRVaaRMCqUwCQIC4AKQ8ABHap9PCglhOqQQAJMF8JZM6pI5ui5qPfmhf7mmG2mTXwqndFqndnqneJqnerqnfNqnfvqngBqogjqohFqohnqowxAIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28654=[""].join("\n");
var outline_f27_62_28654=null;
var title_f27_62_28655="Thyroid suppression scan";
var content_f27_62_28655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thyroid suppression scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 318px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE+AYQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5XpyliCo6Hkim0qEqwIoAeFJwMihhg9R/vUu4fT2HSkwXbapOc5FACcY9CKdtweev+zzikdCjlGwGpqnGOTz70AbHhsI2rWwJbHnDAx/stX3TpEY/sTSwFGfs69R7mvhnw7NELy1UqNyyhyfUhWr7n0Js6HpbHHNsv8zTEy5tBA+VRiqHiWIHw5qI4wYjn/vlq0M4z3B9ap63zoV+uOTE2c/7rUAfA+rx7L6fP/PR/wD0Nh/SqX4cVo65u+2zBsbhJJn/AL+NVAjEYO7n0zSGNJFNPWl4JOaQ9TQAHGeM496MUoRipYKSo6n0pM0AGD6U+KaSIOI2K71KtjuPSmZPrSUAOzkY5zSHoKXsMZzTaACpxdziza1ErC3Zt5TsW6ZqCigAooooAKKKKAFBwQaeWBOcD6VHRQA9V3ZOQMetIBnNNooAfv8Ak24H1pNx2bc/LnOKbRQA4dKcOMEjimLjcM9M1NI/7tYx90En86AEj27G3dcinTrGHBhJKHpuqI0pORQA/dlsDjIxSdvrxTRkcildGUDdkA80ALkd857U0ngUvBzgjGOM1bsLmGBpPtFuJQwIAx04oAqHt6Uu1uRjOPSlAwFOCe3qKcjbSTz0/E+1ADA2Vwevb2prdeMfhSnAG717Cmn8B7UAFFH44pAT260ALRQKKAPSfAq58PREE/fb+dFQeCJmXQUULkB2/nRTA8970DjoaQjigfSkApPvSgnIOeaSk5oAezFzljk+tCDOece9JnjGeKQEgZHagByMVOQSDg8jr0r6/wBA+LnhCLw5pEU9/Es0dqiyKZMFWyTg/nXx9z6UgOOwoA+0D8YfBoX/AI/oif8ArsKr6l8Y/CR0y6Tz0O+NlXEoOcqRXx1HIYwdoXn1UGnTStKRuxkdOMU7gWdXnjnvpZITmJpHIJ64LsR+hFUXADEA5FJk5z3oNIBKKKKAJFldY3jU/K+Nw9cVHRSnGBgc96AEopQM9KAM9KAAEjpTsZ6dabxg880AZ6UAABJ4oxxmgjHWkoAXPGOKSlOOwxSUAFFFFABRSkYFGeMdqAEpzADpTaKAFxxSUueMdqBjuM0AFOXAPqBTRjnNGTgDsKAHDn/H0pR0I4FR0/8AGgBSc4/lTsnADk49KZShsA+4oAXAdwowAe9STIYndGO8jHzCmcKRkc0jrjHf39aAJ5Y/LCjcGyM4XsajY5AyRnHagEsSAc4HXFRkYJB4xQAsg2kDcG4ycdvamEZ60tFACEHsTzQRjBB5paQ45x+VAC9RnnH9aKe8TrEkjL8h4BplAHZ+ELiVNJKxqCBI39KKpeGp2i09lVsfvCf0FFAHM8DryPSmkknJ607vSAc85xjPFACjsO9AGeB1ppOaU9AP5UAAzxxxQen096DgccHFSR4zggHI70AM4PShfb60d+1Az270AFKQR9aSlJ4PHWgCOlBx0pKKACiiigAooooAKKWkoAXjB45pKKUjBoASiiigAooooAKdt+TNNooAUHGaSiigBcnGO1JRRQAU5R7U2lB/KgBdp5x0oXJBApex+nagNzwPwoAacsfelGcfSnAjZjbz2NJjt1oAQde2acDg4yM9DSfSlPTGc5FADRT1J7DJ7U3PNKm4n5Rk+gFACtjjBzj2pvfNKSQcHt7U9FOC+3K5xQALHlgpGCfWhsZ5+UdsU8Biu4DIA69qidieDzQAhGDimkc9KXANAPsRj2oAMngE9ORQDg5FJxzxgilHJ68ZoA19IlVbZg5Gd/f6CiodPRjC2HC/N3PsKKAM6j+dFHXigCSDyAJfPDnKHy9mOG7Z9utQjmlPp36YpOQfQ0AB4pfQmm06MFmAUZPpQAtPRHcgIpLHoB1pnXr1p0crRsGXII4zQAH5cgj5u+abjIpx5HqSckk03OO1ADQM9KSnfw8HpTaACiilAJOB1oAdgZ/+vTKcTyelNoAWlRSxOO3NNpQSOhoASnOQzZAxSUHk8UAGOM5FJRRQAuOOooxxmkpwbC4A69aAFOFAxg80hH4/SrFnbpcCTzJ0i2DIDfxH0FRyQywhfNRkDDK7hjIoAi7U+KKSUt5SM+0ZOBnAq1mW+WGGOJGeNcKI1wSPU+tR29xPZPMsXyMylGB9KAK1JTm602gBTjtmlHTpknim05e45oAORxikPB4P5Up4FBHuTQApU/w5wP0p2CvJ7djQrYGO1LnefegBJH3EHAGOAAKbTyCDjHP9KawxigBPSlVipypIPtQBkGkxjrQA4fM/zc56mrKq20RgkqeRjofeqyj5iOhqzArONiH5wM59qAEkJjj8pXyO+O5quQcA4PNPlxkbVI45z60hB2AntQBHSkYH9KcAGyTwT+QprDDDd+NADe4pQMnHAocAHg5ooAt2bkRtwTz/AEFFMtiQhwe9FAEB5yRSevOOPSlz1xTSM9TQAmOM0AZpQPalzwTz6fSgBNx4OafEjyMEjBZj0FMzjvmpIppInR42Kuv3SO1ADZVZGKuuGHrTQcEVLPNJcStJM+526k8ZqI9qAHEnnPK9xTTwMH+dJjOcUHOORQAlKQRjPekp2c9RmgBOMdKU52+1NpRweRkUABx2GKSnKu4+lNoAKKKUHFACUUp5NJQAUU4tls+tITk0AKoyQM4zVxbNf7Pe6E4ypxs2nnn1qkTnFaUM0a6LLGG/es33fagDPRirqe4IPSt7xXq39qT2pG0+WhGFGMZrMsLKfUpUgtEaWc/wAfh/hXZ2fgxdOsLqTxKhilKFrfBOCAKAOGs7qaynE1u2yQDg9aikkaSV5HOWclicdzXc+C9K0G+0OSTUwWvPO2gbiPl/CuP1VII9QuEtc+SsjBQewoAl1mOyjeD7ATgxgvk5+bvWdUzsSo35OBxmoaACnAcZptLjjPagBwGRkClBxTQe1KaAEHSnA4OaQc4xQcigCaedpdrt94Dbkd6hJySTTtpxmhSBnoc/pQAEdMcjtT2LO2WXJHpTA2GJz16mnJIwzg4zQBIVYS5l+U9c0iyskzFeuNtRu7OQXpuSOlAEjHr7nmngME3A8DpxUlw9s0MQt4tsq8uc/eqK4dTJ+7XamBx60ARKOpJ5pzqQoLck01jj6+mKaST1oAKXGOvBo6EEUvBGABn1zQBYtQvlnKM3PUNiio4VLKcMRz2ooAhooPtSd6AFBxnj2puCT0607FIc9c0AC5zkUKeO1LSKDnGOfpQAtA7d6Q0o7gUAHc8cdelIemD17UvbPakxk8Ef4UANpxAyBkfnSAc4p7qN2ARnvQAzB+tJTh0pCMUAJRTmIPQY/CkxxmgBKKKKACnMAOn86bRQAUUUo75oAMcUoGRx1p6xyS5CIz7RngE4FMIIbC5zQB03hUXtiq3+khpLw5VUx8uARnNbHiTVvEvieO2gubURxwDYwQ9c+vP6VT+HVx5Wt20ExZUZZMjp6f4Gu3g1TTEuL638/E6qV2scfMRxTAy7LSYbPwdrE0ERS4jMjI+MEYHGK88vrZF0q2uOTNI3zHrnjPX1rufCtprT6Fex3Jco7srLIctjHNVfGXh25s/CVtdExCCOUDaAQemPWgDghFJIuQBj61ERXX6BpUniaCaKwMdsbOJWdn6uTkdj7Vy8yeT5kbgFwxGfoeaQEO07c9qbS5PrRj3FACkDcNp7Z+lKeeMimnrS4wD0NACjj+tKRjgghvel24AJ79KdcNvlLEgk9x3oAbywx6c4ppyB9KVTjPPWkbnp+dAB+lOUgZz0puD1xT40LtgemaABeGXOCAaWUqSdvT2pIz3Y5zTT1NAE8qeXEjjbhuODmo5CGGelDvuRVHAHb+tEcgVGUqCG796AGhu+Mmkbk5459KGOWJwB9KTvQA4jGOvPrTlxtIIy3tTWYkKDg4HFJk54OKAJPlyc5H6UUsWWXJMf/AutFAERGDSd6s34VJygTDr945+8fp2qtQAUY3ZPp+tFIeRQAqozjIyccmjOMHBFPkQxEAng9qZjjBoAu6Npd5rWow2OnQtNcSnAUDp7n0Ar0Lx74Z0bQfh1Zf2bMt5qEepm2vbheiyCNt0ftjjiuZ+HPipPCGvTX8tiL2KW2kt2i37Dhschu3SvR/EvirRr/wCEFxdW+hrDHdXz2kUDThmjk27hOT1JwO469+5YHL/C3QtNGj6v4o1VBeR6UgkW0H8XOOfzpfGms+FPE3hua50+0/svUrNlEMBwDMGYbunXAOfwpvwilg1Cx8ReGZLsW93rECQ2pcZXcGJPsOKTxl4F03wZoN3/AGpqKXerTlBZLECAMN8+QCe3r7UAdF4T8MaLr3w3to7yIQ3hcMsyYVuG9f0qL4q+H9L0fwNpiaZCnmW5WKWYqN7t1yTWbZ6mqfBW7FtcmK8guI1AU4YAsOnPvU/i7VoNR+ElgZbpZb5pIzIOMlscmgR5OMZO2jjvQc5P1zig8j29fSkMRuvYUDHTJpSoC57jqKUEHr+dADcY5NIR1PbNOxzgUEcnPJ70AMopwyGyKMcgDvQA2nAcZNPmheLaXQqGGRTQcpt980APhneDf5TYLrtP0piAmQZzyaltrWW5kdIU3MoLEZ6AV0elpoSalafakJQcOpbjd/8AroANFaHTLaDVHSTzQSCScjk+lep6INHh0dNVvIo1W7i3B2AyTwBmvN/FVvbQ6689vAzaCAmURgByD0x713Phy4S00G2u7zDaQ0WLeMjJQcDB9eaaAyLS3v7xLqDT7xo1kkMYZskrkdajutD1XQ91xrF+2o6dEmXgPIPb7pOK2dJv4Lt5ZbKNgIpSpA9R16VR1fRbvxP4ritxeyW1q0C5BBKk5P4elAFOx8Pvrry/2Pdf2SiIJWKAr5oYbgDgjpz+dcDBcRxaZqNtLEryuy7ZCMlSDzg+9ep6vqS+FnFuLd7ggFN8ZCjgEe1eS30O2QspIV2LAbTxzSApLjvQwI6jGeaDx1pKAF644FKPQ9e1KmARuGR3GaNvfFABShcjjrRgjB6elSbtwA3AY9u1AEZUj196bjHrTmBzz35oAJGaAEzkUoJB4JFLt96ci/MDjgHpQARjdG2Bk9qtrZP/AGc9yGBCttIxyPWt3T9Ej8Q2NxdxSx2X2RSrRkbjIQM5znj9ak8IavGLI6HNEAt7Nu884+QEY6fhQBx5OaK2tY0VLPU5bWG5WVEHDhevT0qnqGozXnlLIsaiIbRtXHTigCou0tzx6Ujrg8D5R39aJdoJ2dKTPybSaAG4/nThjBzSUoI5yKAFC5HANFG4Hlhk0UAW9bTZqtwvTBH8hVKtPxHGV1WVzjEhyPyxWZQAUUCnxIHcKTt9z0oAYcnrRQeCfakPb1oAM8/jmldvlAxjv1plFAC9sUqcuAKbRQBIQFbAJI64oIOMlSFPTPSmZ4xUz3MjwLCxyi9BQBCTk0A4OaSigAp/secUynjkD19hQAD17U+QRg5Uk565FMz27e9AGeDn2wKADsDQM9fSkJ9BRuOKAJZ7mW42idy20YX2qInB44oRcso9elaZ0i4FjLcMnyp1wDQBoeGVtriby448TCPMjE9R3/pVG4sL+K4RiNjPKVjO4dRVGB57dRPAzRnpuHFdRpHh3Vbx/MllQrgPgtk4JzntQBu6X4Q1XWvCTXM04Ly4KhnHI7Z4rsvC+hSQWFvp0zKxgjYEZyM5zWLew39gVv7W52aPbp+8sowMtweg/L8q6rwHC19cwXvmOsdxCXEbjBWmIzPA8S6W+s21xGXMl6zKzLgYIB4rfu7IXV0kSSCAuNvmLj5a09W03y4SyDORnKc1z8Ilawlhw53kgSAcrTA5HxLYNBcy2eGuEjG/zG6Mee9cJq1/PcSRSyQC3+zMSiEY38//AFq9c1S0kGnrAgdyoPQZJrgfEulNevE98z24TITgc8/0xSGcPqV2+o6hNdTAK8hyQo4HGKqHg8cirupWkcF2YrWU3C/3hzUctt5cCSHOTwQR0pAQAlVwO9WF8pbcksfP7DHH51XXqOmOtK3WgCROFIYdfeoz1BByfpT0cDO7k9qZk5yetAAQeppVA3DvntSE5HvUiIXJAIyB3OKAGkl+SOOhrU0TShql/HbmURB1Zs9SMdv1qhcOrvmNVQYwR2z61e06b7Ci3yBWfDKUJ9cUAanh/wANjU5NQSa9aD7K23Kjh+tUhp8V1qNpE0+ElIVjGMhMj1FaPh+WGeOdLiSOP7QpBG7Hzdse9Psre2023kge4XeZdwViAW46Y9KAK02mro2qbbWRrhQPvEVz1yqmRmVsksSeOnNdJ9ruJtXEVlEGG0HAGcGuev7ae2lc3ELRl2OMj3oAXUktElX7DK0qkfNlcYNVMgDpmp1jVVYShg38OO9QYwPQUAA5PHPFFKCAuKSgBTjPBzRRj3FFAGv4nTbeo2c71zWPW94rGWtGA42sM/jWFxj3oASlAyDSUA+hoAUdMAZzSUDilXgjNADW/D1ptSSBQ7BTlR0qOgBQMmkpwOM9c02gBScnPAoIx6UlO6+gwKADHByD7U2l5xntSUAFPQ4Oc4pvGD60EcA0AKxyx5zQCR2NAxj3pcjB+lADeMd80lPOMds00daADJ9elW0v7gW7wmeTYx5GaW7ETWtoYUKuEO8n+I5oR3lszCscflq28sFG/wCmf6UAQjeLYOTmPOAp9a9++GOlHw5a3smqSLf/AGy3Ty+CTF8p968YsPD81/Ym5inijj3FQrkjmvb/AAzcrq8YgRHhNpEhLt0k47U0Bxvw+juJ9QuJbmeYwrPKvkykEHLD0/Gu5lZNTv30O3eaymjxL58Py4A52gn19Kw5fGdv4h1dLDTtJltXQtG0gUBSV4OMfUVraBoP9n+JPt8lxKZfKZCsjE9eaBHe6Ud9obc4JVCpY96zbmxextpo7ZWlJG8d8n0q7o21ZpWkbYpyVY9DVjVL2+tpU/sy0+0RbQWcDO00wObsrK8lbzLm2liBHYY7Vl6ho1peNMNWaSMKreUM43Egj1967Y6tdNahrxFiznII6VzUcd3qV3eLq0I+zRc2boMbifX8aAPCz4J1y3Iubeyl8lCQ7tt+X5jg9fTBrDMiXMzRsWIUliR0+v0r2jVrXx5BZTQBbRbeXcWDRncBnjv6YryO98N6xpds11cW+yBv3W44PXj+tSMzb3TrizhSW4iMcch/dnsao5H4VqW+oGa9sV1R3ltYZPmTPbitP4jfYD4gB0uJYbfyEyqgdefT8KAOYA7Hg+9OI4wRgiiNDI4C9eaRTzjPy+/agAA75pUyc4P50uACcc4/zmjeeMAUASyMshU7QCBggd6kFvJ9nMpV8ehqxoFtbXmowxX0oigJO9ycemOfzrttXsdB0/R3gttQhklQDaPMyeevegDk9D0qOW4gk1Evb27uPLfIAY+gPrXca/4SsJori9V7rzooSy4YbSR061z89x9vFpYRmOW1t5VkQovJUd8n61r+IfEtwJ4LezmtmtJVAmOCWGTzz9KYHFQ3V3YXMNxAhj2oHJI4JI/+vSM17rNwUdmlKZfaDnrzxV7XZbVp2FvLviEQUAZIyOMVjmdoEWS1LxO3ysQeopAV5pWdgWPzcgmojyPajvmjvQAY7Cg+9KPrihjk89uKADj3opKKAOm8UAtaox/hOOO2a5nqemRXWeI+dMmP+0tcm3Oc0APdUCKVbLY5GOlNQ4yOnNHGwf3qQcUAFAYjvij2owcH070AITgUqq8mdoztH6VIkTPnBReM/MwXP0zRGXUHYygMOfmHNAEQPY9KMfN0qXYqq29huxwAQf60zk4A6e1ACYBb0HpQR1wO/WkbihcA80AHHHFPDoETamJAcls9R9KYxBHSm0AKeDzSUpOTzSr0Pp3oAQfWjPzZB5zRxj3pd3+FAAwx1+96VYsJYra8SS6h86Jc7kzjPHrVY04EYwc/WgCWVlaZ2SPajn5Vz0rf8NeHpL+P7b9oRUgmAKEfexz1rnncNEihACvU+tbejRySWVxJHL5flHcY95AY4oA3/E2jPcadPqEMzR+XkmBRwfyrp9Fsx4F09dQTztUk1BVjeKLgx4B5/pWb4a1E3uiszJGCXb5d2a3tQRvD+nLqOmxyajcXBCPb7siMDuB2pgaPwrK6hJPe3FsLWSGTKo68tuKt6e9emS6Pb69rQW4bZvGSqjHt2rhPDMV+bpGntDECVIxnjODXrmmWkdtOt/Cd90g2he3IpiOai02GW/udNutyW9rkRMDjOOlLo0uowRT28kGIS5AJOcr610WpadIzteumJJW5xTtOgiuInGAzrwaAMk6at6CkqF0bjAOOlQw29lZSyjUlKR4xFznmuxsbS2jUCRBvyfwrnNftdl1PJMoNtj92M9DzQByevJqEk8Ukb/6Gikyr7f8A6q5bxlp9tf8AhN5LVf3JlVhk+hBH8q6B11F0m82YsoyAPUelcn4yunh8IXEMBfdn5URdxxx0oA8h1vw3cadZW11uVllIXgg44qtbR/2xqFvaABJ5Pk80ngbRnpVrQo7rWXkt7m6cRQRhgrnp+dY15bta3BG7ox2lT27GpGSaxYtpepTWjSCRo8fOowDkA/1ql3pSSxySST1p/kt5QchhkjGR1+lADF78VNbTPbSM0WOR3GRTPLPmKqAux6ADOau3NjHDZxuGc3W4rJAy42Ad6AK9uA86oWwkhwSOO9bGsaHJa3EiwRSMoC+Xls5BHPasWFWSUOh+dCGHsa6rS9Vu9Uvo5NSZTpwGJAAMZxgZ/HFAEPg5LmfWntSgJjgc7emOR/jUul6VeahfSukQa2trgrOSwGMdQK0/Dc1lo3jC81DUf3emNG0aNjPzHBAx+BqbxJMNHvLW8sFEOnXcwkn2c+YpxnI/PpQBV1mfw/a6feWcdr/p8sf7ogdCehriLuKW3cQyrtYKDtzntXQeLLyy1TUPtuloEt1hWMDGCHBz0+lc5ISxCkhvQk0ARUDj60oGDjPenyptIy2SetADMg59aSnMTxnsOKTGegoADx0OaKSigDsdcVZNOnVSRnBP4elccOldzehJIpVx/Acj3xXCjpQA8kFMAfNSJ0Iz2pKVeDzQAmOB05p4/wBW3Xmmn7o4FTW0XnP5ZYICDgt0zQB7d+zl4Q0bxML8a/ZR3axlvLEi52gL/jXtS/CrwScZ0O06f88q8s/ZVl232owE4YK5IH0NfQqNwBTEcYfhZ4HAOdCtD/2yrxT9pLwnofhsaVJoFhFZiVmD+WuN3X/CvqDIAPANeFftXhTp+ht5efnk4x/syUAfMDEnrTalkADnbnbnjNMwOxpDEAJOAMk0EYOD1pysUwVIBByCOtJyxJJ5J70AJng0EY7ikpce1ACUueMUD36UrLj8aAG0opKco3MBnFACZ5yBVs4hVBH+8Mq8j0J7VVI+bA5rsvA/h+w1SG4uru6eKa2bcqKQM45Gf/rUASeA7GOSWGGaVobl58LEThmG3rg/j+Veu6VpZt3YW5keQ/eBFcN4b0u41P4haNqUUUklipCSTRkFVbDZHXPB9q9VmNxba3OmmjzJePlPJxnrTQjQsLq/YMJowvACj1rrvC8jFVFxhX6EA0mgaTc3ccrXkL7lAK7foM11+kaPbCyDXCuk3fPWmBVB8+4aCTBhXkfWoRYxQMDbKFDN8+K6CC3sUbCyKXx680+5s1ZE8lRknn6UgMJljeYBF/Gs/UrVZnKFVOOua6hLAohO1c9qybqM2+oz+aoZccAdutAHn/iHTw7R/ZVWJUU7wP4q8z8R3sOlXq3d1HvtYoS7REdcd69V1KFnvd+5lXeOD061xHxN8Lw6zdLKbgW6i3aLarEA5K89famB4342tIrjT7fUdMh2JdzeZsiHO1hxn8q5jUtL/su5tyZBMrjLf7PHevRbWeHRZfs7us4jjCAHnAH8X6ivNr64Jmugq5M0rufYE5AFSMpHbPeEDbEpP4D1qzfXhmhitCqsluNqOOprOYFSQRg+9SwgL8zhh3U+9AElnLLZ3kM2CrRuHG7irWrXxurtrpWxK/Bx0xVaSZJ1dpy5mHC46Yp+lWMl/ceVGjt67aAHWggLhEeTzH2qeBjJIHH513l5okfhlN94g+w4BdVBOSQMZz9K8+jAhm/jDxP83tgj/Cu41vxLb67rVls86TT4lxNFIPvnbxx3xQBHpmt6Rdas0clu8lqyE4ZM/N9KoeLL9dQQLbyyeVC+VVxtCgAdKfYxQ2fiWa+EAFk+RHGg5BOO351BrWr27SzwpBG2ecgdOnX34oA5lm4IXJHWozyeMmpxCDbNL5iAg42E80wOBEVAGT3/ABoAYBxnH1pCPpTi2OAOB69/rTSMY5oASnLkHcDgjoabSgHFAD0PB/eFTmio6KAO9uMMZMLn92f5VwRGOPSu6uWIdyDnAwPxri7xCl3OhHKkg0AQ0UmeKUkccY4oAcRzinRvtIJ5x2oUYDj6UpQggDnvQB9A/srSq3iHUlO3LQu4B64+b/CvoxAdmePzFfDPg3xTqXg+Vr/RrlI7p0MR3KSAhzkcEc8muoj+OPjHcQ15b7R0PlHn/wAfFMR9fcY6j8xXh37WCf8AEm8PksFzJLzn/Zkry0/G/wAZhmxeQFe37s//ABVc3438f694zgtYtbnSWK1JaIKpXGevc+tAHKMScknvmmgZFKeec80Hgc/WkMbRSr1+tB+vNAAOtPxnGDx39qjpSSTk9aABhg4zmlZsqBgUgwSMnA9aUgbiAcjsaAEAyetFBpKAJIgpYbuneuq8CyIl9cxMwEUo2KT/ABden5Vy8MfnPsXqQcD+ldNodtAt7YrYTbrpWD3CEdAM55oA9b8FldGMNlEfLiMxlwxz1z/jXr3hLw+L/VpL+7hmWFwFWVGwpx2rxq3mi81Zt/75PuV7p8MvEM1/YW+nvEAFZmMufX2zTEdiscmmxhdPSSZm+8C2cf5xVlt0ts8t0rIVGcZ7Vi6jq2o6YzyTWpFtn5JN33vw/CjT9dn1KCUgfux8rZ96AFhVZ8SWvUjO41qLqD7Qg27lGD9ayIJ4g/lw8EDNPkjfCsrck5oA2V1KKJlju5kSZugAplxNBeK8VuUecj0zWTuAiZnUMV9eTTtBm8zVpGVdoIxzQBwvjfzYLmJERmZmw2ztk9a5TXbBPtiW0t2W3rn73uK9O8YQjRkn1EFbg3DYMZH3c14r4jtIdQ1uzv7mSSKS2TaiiQgN05Pr0pgeaeJ/Dr2viCb7M0skRTO7dnJyBtrOufD1pZW8ksbszleCx4B6112uavJJqktnaxiYovmEZAxn3/OuevdUaCCT+1I/KznyT13nByP1pDOAcmabzJuATyRU9vZ3F/cPBYxtMUUvgH+EdTUZmc25h427sgY561JZ3k1hcGeykMTFSoPX5T1pARRWk7pJIImaKI/vCP4afDcyW1wJLEyRMRxzzQbmVVkWNyEkyZPQnvVY5H4j9KALd8FiKoD85+ZyTkkmp4UfS7yGaYb0xkgDGRXR+HfE2m6SJDd2DytKqrwQcYGO5qt49uorueyMMYiwjE8g5B57UANt2XXpEs4GNru+cM3IAHGKxNQQQTzW2VkeFivmgfexUo1MDRktUj2SIc+Ypweufr1qtLGBCknnBpGb7hHI980AVxlskkYHFNI2t0yPepF6kMSB1JpGZVctEe3GRQBFnPOaUnK+9Jnj2qaBIpHYSyiFQpIO0tk9h+NADG2nleOOc00ZPU8Ck9Kkh2lxu6dzQAw4PPSilc/OccUUAdxcfNJwemMVx+rDGp3HH8ddhMfmYe45H9K5TXY9t8SB94ZoAoAd8Y5o7mmgd8ilzxwDQBIvy8EVKuQoyfp7VBuJOe9G88jse1ADmPyYPY8VGeO9OGD+VDdunTtQA0evv6UBTxkHBpy9ecH60SSMyBSflXO0elADMHAPY0lFKOooASilwS2AOSelBBB5BH1oASlGO5xSUUAFLzj2pKezFwowAFGOKAGnrQKKBnqKALEbJFFujdhOO2OMVZ0e7ubfUBNbuRIfv+49KzuTxVqymS3n3TLvG0jA7UAen6d4h06a6gijlZnY4I2mvcvhAzyaxE0Lf6OTgKfXvXzF4d0+7ju4Ltmj+zh/NILjdtPtX1N8GNFviLTW0kibTmdk2hstkDnimB3fi27tzZiJnDuDgp3HJrO0pRCjqihQzAkZrD11JF8ZajuY7QVIB7VZt7w6hKGtyYxEQrj1piOm8sLKZAeMd+KdDJ87lumOAaydWv8A7NYyYVpX7KBk06O/+2WFuNgRwoYjuKQE95f/AGVlh2hvNOM56Vn3eoyIDbxSC3cEHzAfmx9KjkZJGEsziJ4zlQT96ua8Q3W/WZZotsnQcHIPWmB2kyWnjHTntHmeJ7RcuwXO4jn3rwLxokq6gTCvmQW6EO24gg8HtXtfw7uPNOoLJx8h4H0ryfXLmxhj1mCabZNKzLGpIBYkCgDznRmgXVJr7UFVLOaNVVy2c9c/0rm9VvUu7qRdQf8AcCVvszAdBu/XitGPfY2MNvrGDYqq5Veecc5/Guailt4jcC/jkeIgm2GOBz/hipGV9YNt9rP2P/VkcjpzUth9kjRJb+AvEVI4bkt2P5VRUobaTIy+RgmrWmssUqyXUazW+CNjE4z60AU3IWVio2q33RntUbc5Papn2tLJhQE7D0pFVXiIz+8z+lADrtJImEUu3OAw2kEYNNkwyoQxZiPmB7UwI3AAJ9hSqzIpAx836UAORSy7s96tafBbXFw8d1cNBEFLKwGcn0oIgj04FZHM5bBTtjvVOUAN8vSgCS7ZWlKq25V4BI6+9QAEgntR/OjGQSDge9AAaTPNLQRx1FAC8Y6UlFFAATk0UUUAdzcn94cdcdK53xMcz27dCY/610lzk8YGAO3X8657xLGALOQSK4ZPmAH3DnoaAMKlBwKD14pKAHZH/wCqjIoAyMYpDxQA5SQTkdR3opAfWl//AF0AGKQ84xSj8qTPp1oAbSikpccZoAUHadwJBByKRmLHLHJpKcMEYxzQA2ilHB+aigBKcDgUAcj1zjFK+chcAGgBtLxzjOKTGKftwuc8ntQA1sg5IA9qs2DQxzq9ym9AD8o7ntURjYjJzt7GkTHmL9RQB9KfCfRU8YJaanp1vDHY2cmJ47hcFwAc4wele23U9tZMfD+jvDZ6lKN0EXRFJ5Jxz2r5Y+CHjHU9DujZw3lpDpCymS5Dqd+0g8g9OtfVnh/UNK8R2sWt6Ube4XJRLlcM2V4ODTEeeeIUvNM1S5l1C5Wa64DmI5Xv/hUvgq48uHUTI+4s4IJ7DFdp4ktbXxEs2ix+XBeAgtOw579/xrjvE3hmbwxbRvaubv7QpLiP+H3pgWl1PybtJVPmKF5z0q9JfRw5ut6AycEHoK5HSfskVhKLq4CPv43HqKj1O+EltGkLqyK2QQKANnV71L9laN0k8vltnb61jT3EEUJPmosuQNp+tZ3h2dU+1K7gK/ByOvNd54Z8KaLremR3t4s7SMedj4HGP8aALKtF4V8LQ61aJJcSXiYdXGVGcDI614Nrz6fN4gt7zUYC0huRswuduR/9avp3ULLSF0SOw1GVotPhGIyWwc5GMmvknxtYytrWqvb3KmytrvzIuMnCqP65pAUfiXqlj58lpbrIC8W4emSR/ga89MjMAsjMwXAAPY1Y1W7a9u/NlO5iBzjtUCgSqAMKy/rSGTahYTWDRxyujeaMjac4FLaWv22ZLdJUjbaWLSNgCoMyOjSM7Nt4O45qLf3XIPegBZl8qcplW2nGV5BpFYq24cHqMUuAccjn1pzqAQqsG56igCS3u3t3LxqpJ6lhST+VGV8hyQRznsagYYHPX0plAEm7DZGM00tkkmkHUY60Hqc9aAHE5H6Uinjt+NIRjrR2oAdQRg4yD9KQ54I4pR156UAKwxjgjjvSVLOIwyiIkrjnJ71GOTQAlFKRzRQB3U/+sI7r29/rWJ4jBe1EvH38HH0rduGxIwX/AFhxkntWPr0bf2WWxxvB+lAHMA46UlFFAC5OAOwpKKKAHZJFNpQcUlABSjk8nApKKACiiigBwUnkUfwgE8UmRkcUE547UABGKKSigB+eM44/rR1560ylBxQAp7E8/pUsPlq2ZBu46DsaiB65704Yz6igB7yZXA6HqKjB6GlI6DHNJ0oA0dEfbd7zMY1Qbjj+L2r2z4UfEV9LnsVupY4NEhldpoc46456jqc9q8Bzzjr2rQ0W5ktb6KaEkyq3ypk/NxQB90+FvG+k+KLsW+mJEGbnzdwz275966mdvMtJ1VEcmJgMgHk+lfG2h+INUWwgvIy1tl1Jdc9AwyOvcV7HpPxw02K3gsmt4muYgEIZ8Fm/769qYjmfGWj3MVwkM0ckckkWUAYjPv0p+lz2ttCkWqMUVFHGM4Nem2kuk+OVGp659mtJbU/Z0haQDcv97n6Vafw14I8wvObN/wDtstAHnuiaNcarJI+hW5nVDuk5xhT07V6h4QtpdC8PBdYX7MYz85POM4/wNch4q8R6X4Es4JfB8MNxJduyXKJKvyqOh6j0rzrU/jjd6or6VcW4jguOHbzFIGM+jGgDrfij4yN9cXmj2r77NJQ0cinGQPxrw/VvFdrbTzQtC8j7trjcOvfvU174jtr7UJbO1PlsfmEpbg98ZJrhb8ma9nfKqYSf+BY//VQMXVryO+u/tVvB5MYUKE9x3/lWcxBORVwwpPYvdGUCQMR5fr71R7470gAHHXkelKRxkdT7Uw9wMYoAJ6UAO3bcgfSgHnI60gGDyOaUfmelACsC3JphGOtP3fKR1GaNoA579/SgBp56DFIRilB4xT5IwsasGzntQBFRRTmGPcHvQABeM/lS96aeOtOoAKBRQDgHHegBzEsc+tFOSQKuCgPvmigDtrjIkHOOOPaqV8jT2MyKQCAX+bgcVo3uBM2MY7VQuRm2uB1zEaAOO4pKKXFACUpxnjOPekooAKKUY75pKAClzwaSl7UAHGDnOe1JRRQAvHbPvQce/vmgdaDzQAlFFFABSjqKSlH0oAfkbQu0DBznuakjztLDqO+Kix0NPLFFKjIz1oAaOT2FByctkZPWk7U/aPLyc7ieKAIznJPvUtrMYp0kU7SvIIprbe3Wm96ANpfEV7HZfY0k/wBGHQdx3qT+2ImxNK0slzkPk9Aw6EVz+ec9afGVDHf0x2oA6VPEOo30ime43v8A6sZJAOfoRVS+1K7judrSvgLj77cH25rEVyuACQM54pWdiwYkk46k0AdRoWtWtrJev9nUGRFGcsSx98n1rmxM7Ejcepwc9M02KLeGPmKpAzyetPu5Fd8qqqMfwigCMnDnJyfWmsSfc+tAbBzgH60meTnjjtQAA5IpwUtyDjHemjGeM5x+tPGcEYPPTFAEZGKAcEU8Ru4YqCQvX2qOgB2eScn8Kch5BPI6YqOloAe/Dfw/0pvHG7p7UE+lCjBzx+NAAB3P15pD1peq96APXpQALk8AZJoxhunHvSqSvK5B9aTGccigAIz3FSSKgSPYxJK/MD2NMPU8n8aKACge9FFAAevHSijBooA7++x9of2/KqMoysij+JSMfWr+o589woJHU4qnyWQEcH9eaAOLlXbIy+hxTc1PfjF9cD/po386r0AFKOtJRQAp4NKwAxgg5GaQkkc0A4B96AEpe1ABJwOtJQAUU4gEZH5U2gAooooAKKKKAClX8aSigCYcnjoOOe1NJJ6mmgZ4HU9qM880AObBIwDSE46k0hJBptAC555NLkZ7/hSxoXOF600jBIPagAAJpwznDDPemjg0Z4xQAHg4pKKKAJBGMZ3CmjjrSZ4xS7vUZoACuBShcjpz1/CmU4HtmgBcD6c9aDnGKBgEHHNB5NACgsCdjEZ60wDOaVugpD9P1oAM8Y4oHXmkpwbnk9sUAKCOcAflRnGM5/rSMQfxoIwB0zQAmTjGaUZ756U2nbeODQAdAcUucEHA/pTopGjV9uMMNpyM0mOD+ooAT/P1oFCg9qsQW0kvCqSM84oArj2pwX8q37fQJZSoAwzHjI7VqWnh1jHsdec88d/yoA4/yz3yPYCivQovD3yDOD/wH/61FAFyazMszseQcYpj6V8yMBnBGeK2IlXzSG46detbMVorINvJ7UwPFte02a31CbCYU5fjpzWQ8ZU4IIPoe1e3ajpCO+4IjcYz71yureGUcM6jaSvzf7X60gPODSVr6jpE9m5zgjqMEVlFSDigBtFFFABS8Y6c0lFACg4oPtSUUAFFFFABS4OCewo7UlACjg5oPJzSUUALg4zikp2RtxTaAFIx1pRnb7UHHGOlAHXkDigBM0lFFABRSg4OaDyaAEooooAKKKKACnDgdKQcGlzx260ASL90/LyeM05VXyjz83cVFS7+DkAk0AISNuO46+9NPWg4pd2SKAEHJxRg5x3peueDmgDIxz60AHqQMY60hpeG9qVSAPf3oAaoyeO3NBHftmnyMGwQu0D0pu3jPGKAF9DzkChRkgDqaULnGK6bw7ojXHlyMCrg5O4duOlAFXRtFluJQzgqndsdOn+NdzpWhwxIuI8nHUj/AOtWvpGkqsKo2cD/AOtXQQWiIAOTgYzTsBiQ6Yp27gOmRxVuGzToUGQcgetawhHAxjmniAZ9c0CM2OyQrkqKK1lhBHzYzRTA8+stUuA00MtvC+xlAcZLYPeuntbtGCIiuDjkmuX02DdeTScnJAz68Cuos7YKAR06ZpDNAR7lG0cHniq81sr7gy5GOAa0YYyQFB5A7UskZU8jFMRympaVHLGcqCOcA/jXn/iDw5JE4lhRipBP+ea9jmhDDpkGsjUrFSmOTn36UgPBnQxsQwx9airt/FOhlXM8WAAD8uK4txt4IwaQxlLQOtO4AH60ANIxQDjNBNA60ADDB65pKcRxTaAF7UlFFABRS44z2pKACiilGM80AHoaXJz6Zobqcjn2o9M0ADetJ2pSOM0meDQAlFTWsBuLmGFSA0rhAT2JOK9WudF8C+Hrx/DevWOo3Ot2+EuNSinxbIzgMrbQc7QDzQB5IPfpS8ZFdp4T8LWV/wCN7rT/AO0IbyysUe482IYW6CEfKuemc/pXWeM4tAvPDt00/h288OtCjPZTTY/0iX/nngD05/woA8gZAEVgynP8OeRSxx71Y7lG3nBr1Twt4WHib4XtHZJCNVjeRoUZAXnIOSqkng4Fc94qjSD4d+CD9mjjuN1+JW2YZiJlADeuORQBxfBOcUKQMnAP1pO3XmkGOc0AOznJ6U09euaUHjHJOelAxnpmgBtOWm0tADqCMY5FIPXnNA64PNACg4PPT2pAemf5Uvf1PvQvbpx7UAJ9aXr0FIOe/OelXdLgE1ygIOM9aANrw1pYmkRpYyyN3Hb8a9M0mwRUUBcBegPXtWd4e01YlxtbaTk812dpAAqgDgUwFtoQqgD8zVgIO/6VPDFz8v41NHDz060xFcRE4zyP1qZICOMe9XVh4Awc9eO9W4bbOM5oAzPs+O1FbyWny80UAeRaRGHv5TxjI49OBXXQ224ZwOnXFcjpQEPiS/hxgqydOnK139igIUYoQFeOBo+vNSyxblB7+taEkClRjvzUYj25zyDxigDFni257rVK4QFSDW1cqBkDpWbMoOcAA9vagDl9btIvsskkxCov3s14vqEqTXcjRDCZO36V6n8T7qS20URROwEjhWx37/0ryMdakYo4HTmnsADwdwpg9KcCcEdjQAwjFKMfjQzEgA9qRetACt2pAM9KD1pUGWAoAQAml288UueOKTHOaAD73U9BxSGnsNoB9aYepoASlHB5GRSUUAO/hPvRkAdaTPGKAMkCgBKUAnpSvjPAxjigj5QaAHQKjzRrK/lxlgGfGdozycV9C6KPEMdhCNN1nTb/AMHRoWF5PAvnSwj/AFgbdyCOV554r55kXa3JyabxjvmgDuNKbw7L8RLt7SR7TTGctpzkN8kmRsyPTOeDxXeeM9RuNK8NaqniXW7bXDfwtb2kEdqsZt5c58wH0rwqloA7/T/ENna/DRrCG/kt9VWRmRY9ysPnB4Ye1M+IHi1fE/hnws008cmrWy3CXaJFsCjcojPoSQCTjvXCoDkEYqzNZOkxQFegPWgCpxjpzQMdxmtK10iWaTaXQDGep/wq1BoSuxV7gqR6Jn+tAGGvWlJwemCK6dPDMJwTdSdf+eY/xp7+HIFk2eYzEHrjGaAOUPJ4GBRXYtollEqEw7gR/fNPTSbJBkW4zwcls/56UAcYDjigckcE13KWkCNtWFAc4FTbQcAqp4z90ev0oA4VLeV0G2JjzjNWF0u+YDFuxHboK7IJhdx2nr/CKe0ZAfGPfigDkYdCv5W2mEoOuSc12PhfwvJDNvmkG702/XnpTVTCdfm7H8P/AK9dn4exNCJOnqPzoA19LsPKQDeGP0xWxDagHO7IplsvA9KvQjcQO1UIkht1I55+lXIrRCCR17GiBAQvvWjDDlGwcDBNAFaCA8ZOT64q5DCQfUnjNSwQgBc+lX4oPmUZByaAIoofkHymitERAcdcUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    123-I thyroid scan of the indeterminate thyroid nodule shown in the previous radiograph, after four weeks of T4 therapy. The nodule (outlined in white) overlies an area of relatively increased isotope concentration, indicating autonomy, since uptake is suppressed in the rest of the gland.",
"    <div class=\"footnotes\">",
"     SSN: suprasternal notch.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_62_28655=[""].join("\n");
var outline_f27_62_28655=null;
